IE45950B1 - Novel 7-halo-3,20-dioxo-1,4-pregnadienes and-4-pregnenes and their preparation - Google Patents

Novel 7-halo-3,20-dioxo-1,4-pregnadienes and-4-pregnenes and their preparation

Info

Publication number
IE45950B1
IE45950B1 IE2576/77A IE257677A IE45950B1 IE 45950 B1 IE45950 B1 IE 45950B1 IE 2576/77 A IE2576/77 A IE 2576/77A IE 257677 A IE257677 A IE 257677A IE 45950 B1 IE45950 B1 IE 45950B1
Authority
IE
Ireland
Prior art keywords
group
dione
pregnadiene
methyl
hydrogen
Prior art date
Application number
IE2576/77A
Other versions
IE45950L (en
Original Assignee
Scherico Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US05/753,257 external-priority patent/US4076708A/en
Application filed by Scherico Ltd filed Critical Scherico Ltd
Publication of IE45950L publication Critical patent/IE45950L/en
Publication of IE45950B1 publication Critical patent/IE45950B1/en

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04G—SCAFFOLDING; FORMS; SHUTTERING; BUILDING IMPLEMENTS OR AIDS, OR THEIR USE; HANDLING BUILDING MATERIALS ON THE SITE; REPAIRING, BREAKING-UP OR OTHER WORK ON EXISTING BUILDINGS
    • E04G11/00—Forms, shutterings, or falsework for making walls, floors, ceilings, or roofs
    • E04G11/06—Forms, shutterings, or falsework for making walls, floors, ceilings, or roofs for walls, e.g. curved end panels for wall shutterings; filler elements for wall shutterings; shutterings for vertical ducts
    • E04G11/20—Movable forms; Movable forms for moulding cylindrical, conical or hyperbolical structures; Templates serving as forms for positioning blocks or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001—Lactones
    • C07J21/003—Lactones at position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0084—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkylene group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • E—FIXED CONSTRUCTIONS
    • E04—BUILDING
    • E04G—SCAFFOLDING; FORMS; SHUTTERING; BUILDING IMPLEMENTS OR AIDS, OR THEIR USE; HANDLING BUILDING MATERIALS ON THE SITE; REPAIRING, BREAKING-UP OR OTHER WORK ON EXISTING BUILDINGS
    • E04G17/00—Connecting or other auxiliary members for forms, falsework structures, or shutterings
    • E04G17/14—Bracing or strutting arrangements for formwalls; Devices for aligning forms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Architecture (AREA)
  • Engineering & Computer Science (AREA)
  • Civil Engineering (AREA)
  • Mechanical Engineering (AREA)
  • Structural Engineering (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to novel 3.20-Dioxo-7 alpha - halo-4-pregnenes and-1.4-pregnadienes. [FR2384793A1]

Description

This invention relates to novel steroids of the pregnane series having valuable pharmacological properties to processes for their preparation and to pharmaceutical compositions containing them.
According to the invention, we provide 3,20-dioxo-7cxhalo-4-pregnenes and -1,4-pregnadienes of the formula M wherein the dotted line at the 1,2-positions indicates a 1,2-single bond or a 1,2-double bond; W is a group (H,H), (H, lower alkyl), (H,d-0V^) or =CHT, wherein is a hydrogen atom or an acyl radical of retinoic acid or of a carboxylic acid having up to 12 carbon atoms, and T is a hydrogen, fluorine or chlorine atom or a lower alkyl group; Q is a chlorine or bromine atom or a group 0V wherein V is a hydrogen atom or an acyl radical of a carboxylic acid having up to 12 carbon atoms, or , provided that W 4595 is a group (H,H) or (H, lower alkyl), Q can also be a hydrogen atom; or Q and W taken together are a l6a,17a-lower-alkylidenedioxy, -cyeloalkylidenedioxy or -aralkylidenedioxy group together with a Ιββ-hydrogen atom or a grouping ---S or ---N.
C-R wherein R is a lower alkyl group and R3 is a lower alkyl or phenyl group; B is a hydrogen atom or, together with Q, is a 14a,17a10 lower alkylidenedioxy group; M is a group -CHO or such a group in the form of a acetal, hemiacetal or acylal, -CH^, -COOR3, -CE^Hal or 3 -CH20V , wherein R is a hydrocarbyl group having up to 12 carbon atoms, Hal is a halogen atom having an 2 atomic weight of less than 100, and V is a hydrogen atom or an acyl radical of retinoic acid, of a carboxylic acid having up to 12 carbon atoms or of phosphoric acid, which may be in the form of a mono- or di-alkali or 2 alkaline earth metal salt; or OV together with Q is an alkylidenedioxy, cyeloalkylidenedioxy, aralkylidene dioxy, alkylorthoalkanoate or alkylorthoarylcarboxylate group; or, provided that Q is an Ο-Acyl group, 48980 2 M can also be a group -OR wherein R is a lower alkyl or halolower alkyl group; X is a hydrogen atom or a halogen atom having an atomic weight of less than 100; Y is an oxygen atom or a group (Η,β-ΟΗ) or (H,β-OCOH), or, provided that X is chlorine or bromine, Y can also be a group (H,β-halogen), said halogen having an atomic weight of less than 100 and being at least as electronegative as X, or, provided that X is hydrogen, Y can also be a group (H,H); Ά, which is in the α-position in the 4-pregnenes, is a hydrogen atom or, provided that Y is (Η,β-ΟΗ), A can also be a chlorine or fluorine atom or a methyl group; and Z is a fluorine, chlorine, bromine or iodine atom; and, when W is (H,H), the D-homo analogs thereof.
Hydrocarbon groups in the substituent E. may for example be aliphatic groups having up to 12 carbon atoms including straight and branched chain alkyl groups , especially lower alkyl groups, and cycloaliphatic groups which can be saturated or unsaturated or substituted or unsubstituted, and aryl, aralkyl, and alkaryl groups. However, alkyl groups having - 4 45950 up to four carbon atoms are preferred. Typical unsaturated aliphatic groups are vinyl, propenyl, propynyl and butenyl; typical cycloalkyl groups are cyclopropyl, cyclopentyl, cyclohexyl, cyclopentenyl, and _p-dicyclohexyl; typical aryl groups are phenyl, α-naphthyl, and_g-diphenyl; typical alkaryl groups are tolyl, xylyl, and symdiethyl phenyl; and typical aralkyl groups are benzyl and phenethyl.
The lower alkyl groups included within the definitions of 1 ο -J W, T, R, R , R and R have up to six carbon atoms, and thus include pentyl and hexyl groups, but preferably have up to four carbon atoms, e.g. they are methyl, ethyl, ji-propyl, isopropyl, n-butyl, .sec-butyl, ort-butyl. Similarly, lower alkylidened ioxy groups referred to herein have up to six and preferably 1 to 4 carbon atoms.
The acyl radicals of the carboxylic acids having up to 12 carbon atoms included in V, V and V6 may be saturated, unsaturated, straight-chained or branched-chained, aliphatic, cyclic, cyclicaliphatic, aromatic, aromatic-heterocyclic, aryl-aliphatic, or alkyl-aromatic, and may be substituted by one or more hydroxy groups or by alkoxy groups containing from 1 to 5 carbon atoms or by halogen atoms. Typical ester groups of the 7-ha1o-3,20-dioxo-l,4-pregnadienes of our invention are thus derived from hydrocarboncarboxylic acids such as alkanoic acids exemplified by formic, trimethylacetic, isobutyric, isovaleric, enanthic, capric, cyclopentyl propionic, unuacylic, lauric and adamantanecarboxylic acids; substituted alkanoic acids such as phenoxyacetic, trifluoroacetic and β-chloropropionic acids; aromatic and substituted aromatic acids, especially benzoic acids substituted by a halogen atom or a methoxy group, such as 45850 benzoic, toluic, p-chlorobenzoic, p-fluorobenzoic, pmethoxybenzoic, and 3,5-dimethylbenzoic acids; aromaticheterocyclic acids, in particular isonieotinic acid; aryl-alkanoic acids such as phenylacetic, phenylpropionic, and p-benzoylaminoisobutyric acids; unsaturated acids such as acrylic and sorbic acids; and dibasic acids such as succinic, tartaric and phthalic acids.
The preferred acyl groups are those derived from lower alkanoic acids having up^'to 8 carbon atoms, in particular from acetic, propionic, butyric, valeric, caprylic, caproic and .t-butylacetic—-r—.------acids, and from benzoicTacid or the substituted benzoic acids mentionedabove, and ip particular those derived from propionic, n-butyric and benzoic acid.
X is preferably a fluorine or especially a hydrogen atom, and, 2 is preferably a chlorine or bromine atom.
The alkylidene or alkylidenedioxy groups represented by =CHT, by W and Q together, by B and Q together or by 2 OV and Q together preferably have up to 4 carbon atoms and thus include methylene, ethylidene, n-propylidene, isopropylidene, n-butylidene, and sec-butvlidene and their corresponding dioxy derivatives. W is most preferably a methylene group or the group (H,CH3), especially (H,a-CH3).
Y is most preferably an oxygen atom or the group (H, p-OH), Ά particularly preferred group of 1,4-pregnadienes according to the invention has the formula (II) wherein Z is a chlorine or bromine atom, W is a methylene group or the group (Η,ΟΗ^), Y is an oxygen atom or the group (Η,β-ΟΗ), and V and V , which may be the same or different, are hydrogen atoms or acyl radicals of hydrocarbon carboxylic acids having up to 12, especially up to 8, carbon atoms.
The dotted line at the 1,2-positions preferably represents a 1,2-double bond since the 1,4-pregnadienes are in general much more stable and more convenient to prepare than the 4-pregnenes.
A preferred group of 3,20-dioxo-7cc-halo-4-pregnenes according to the invention can be represented by the formula wherein Z is an iodine or (preferably) a chlorine or bromine atom, Y is an oxygen atom or the group (H, p-OH), W is a methylene group or the group (Η,ΟΗ^) or (H,H), and V and V , which may be the same or different, are hydrogen atoms or acyl radicals of hydrocarbon carboxylic acids having up to 12 (preferably up to 8) carbon atoms. In particular, V and V in Formulae Ii and III cart be’ any of the acyl groups hereinbefore defined A particular preferred compound of this group is 7a-chloro-4-pregnene-lip,17a,21-triol-3,20-dione 17,21dipropionate.
The 7a-halo-3,20-dioxo-4~pregnenes and -1,415 pregnadienes of formula I are usually white to off-white crystalline solids, which are insoluble in water (with the exception of alkali metal salts of their esters such as the hemisuccinate and phosphate esters). and soluble in most organic solvents, particularly in acetone, dioxan, dimethylformamide and dimethylsulfoxide, although of limited solubility in non-polar solvents such as dialkyl ethers and alkanes.
The 7a-halo-l,4-pregnadienes are preferably kept below room-temperature (e.g. at 0° to 5°c.) when stored for long periods of time to minimize decomposition to the correspondingly,6-pregnatrienes (from which they are usually preparable). For short term storage, the 7achloro derivatives are relatively stable up to 100°C,{ - 8 45950 however, the 7a-bromo derivatives should be stored below 55°C. The 7tx-halo-3,20-dioxo-4-pregnenes are preferably stored in an open vessel placed in a chamber under reduced pressures and at moderate temperatures (e.g. 0° to 40°C.) to minimise decomposition to the corresponding 4,6-pregnadienes (from which they are usually preparable) with release of hydrogen halide.
In general, the 3,20--dioxo~7a-halo-l,4-pregnadienes of formula I, particularly those wherein V is a hydrogen 2 atom or an acyl group or wherein OV and Q together are a 17a,21-alkylidenedioxy group, exhibit corticoid activity. Those that have halogens at both C-9 and C-ll or an oxygen function at C-ll and a halogen or hydrogen at C-9 possess glucocorticoid activity and are particularly valuable as anti-inflammatory agents. Preferred antiinflammatory agents, particularly for topical administration, are 3,20-dioxo-7a-halo-l,4-pregnadiene-17a,21-diols and especially -llp,17a,21-triols of formula II above and their esters. 7a-Bromo and 7a-chloro compounds of formula I having a cortical side chain at C-17 (i.e. compounds of 2 formula I wherein M is CI^OV and Q is OV) and ester derivatives thereof, particularly compounds unsubstituted at C-2, C-9 and C-14, are especially useful as topical antiinflammatory agents; and in particular, compounds that are substituted at C-16 by a lower alkyl group (preferably a 16-methyl and especially a 16a-methyl group) or by a 16methylene group exhibit excellent topical anti-inflammatory activity that is in general superior to the topical antiinflammatory activity of the corresponding 7-unsubstituted analogs. Thus particularly valuable compounds of this invention include 7a-halo-3,20-dioxo-l,4-pregnadienes of formula II defined above, wherein Y is the group (H,p-OH).
The compounds of formula II wherein Y is the group (H,p-0H) and V is a hydrogen atom and in particular wherein 2 V is also a hydrogen atom are valuable mainly as intermediates in preparing the preferred 17-mono- and 17,21diester derivatives.
The 17,21-desoxy-, 17-hydroxy-21-desoxy- and 17acyloxy-21-desoxy- derivatives of formula I exhibit antiinflammatory activity but are more valuable as progestational agents.
Particularly useful topical anti-inflammatory agents 2 of formula II are those wherein V and V are acyl radicals of hydrocarboncarboxylic acids having up to 8 carbon atoms, particularly the 17-propionate, 17-n-butyrate and 17-benzoate derivatives which exhibit high topical anti-inflammatory activity with very low systemic corticoid effects. We have discovered that, when the compounds of formula II are administered topically or systemically, the topical antiinflammatory effect of the compounds is dependent much more upon the nature of the ester group at C-17 than upon the ester group at C-21, and in particular that the topical anti-inflammatory activity of a 17-propionate 21-ester of formula II is to a large extent independent of the nature of the C-21 ester group. The 16a-methyl~17-mono- and 17,21-diacyl—derivatives of formula II are most valuable since their topical activity is greatly enhanced over that of the corresponding 7-unsubstituted compounds.
The superior topical activity of the preferred 3,20-dioxo“7a-halo-l,4-pregnadienes of formula II, particularly of the 16a-methyl derivatives, may be demonstrated by pharmacological tests in animals. Thus, for example, when tested topically in mice by a modification of the croton oil induced ear edema test (G. Tonelli et al., Endocrinology 77: 625-634 (1965)), 7a-bromo-16txmethyl-l,4-pregnadiene -lip,17a,21-triol-3,20-dione 17-benzoate 21-acetate exhibits about twice the topical activity but only a fraction of the systemic effect of betamethasone dipropionate (9a-fluoro~16p-methyl-l,4~pregnadiene-lip, 17a,21-triol-3,20-dione 17,21-dipropionate). Additionally, when tested in mice by a modification of the skin atrophy test (E.G. Weirich and J. Longauer, Res. Exp. Med. 163, 229 (1974)), this 7a-bromo-compound of our invention shows markedly lower skin atrophy potency than betamethasone dipropionate. Moreover, 7a-bromo-16a-methyl-l,4— pregnadiene — lip,17a,21-triol-3,20-dione 17-benzoate 21-acetate shows great separation of local from systemic effects when injected locally in the rat and has very low glucocorticoid activity when administered orally to both mice and rats.
In similar manner, when tested by the above described tests in animals, other 7a-halo-l,4-pregnadienes of formula II, e.g. 7a-chloro- and 7a~bromo - 16a-methyl-l,4~ 43950 pregnadiene-lip,17α,21-triol-3,20-dione 17,21-dipropionate, exhibit high topical anti-inflammatory activity coupled with low systemic effects following topical application, and low skin atrophy as well as low parenteral and oral glucocorticoid activity.
Preferred compounds of formula ΪΙ include: the 21-acetate, 21-propionate, 21-ii-butyrate, 21-isobutyrate and 21-valerate of 7a-chloro- and 7a-bromo16a-methyl-l,4-pregnadiene-lip,17a,21-triol-3,20-dione 17-propibnate; the 21-acetate, 21-propionate and 21-n-butyrate of 7a-chloro- and 7a-brOmo-16a-methyl-l,4-pregnadienelip,17a,21-triol-3,20-dione 17-n-butyrate; and the 21-acetate, 21-propionate, 21-n-butyrate and 21-benzoate of 7a-fluoro-, 7a-chloro- and 7a-bromo-16a-methyl1,4-pregnadiene-lip,17a,21-triol-3,20-dione 17-benzoate.
In particular, 7a-chloro- and 7a-bromo-16a-methyl1,4-pregnadiene-lip,17a,21-triol-3,20-dione 17,21-dipropionate and 7a-bromo-16a-methyl-l,4-pregnadiene-lip,17a, 21-triol-3,20-dione 17-benzoate 21-acetate are especially valuable since they have high topical anti-inflammatory activity coupled with low systemic effects following topical application, and low skin atrophy activity as well as low parenteral and oral glucocorticoid activity.
Other valuable compounds of formula II include: 7a-chloro and 7a-bromo-16a-methyl-l,4-pregnadienelip,17a,21-triol-3,20-dione 17-valerate 21-acetate; 7a-chloro- and 7a-bromo-16a-methyl-l,4-pregnadiene11P,17a,21-triol-3,20-dione 17-isobutyrate 21-acetate; 7a-chloro- and 7a-bromo-16a-methyl-l,4-pregnadienelip,17a,21-triol-3,20-dione andthei.r21-acetate, 21-benzoate, 21-pivalate, 17-propionate and 17-valerate; the Ιδβ-methyl epimers of these 16a-methyl derivatives such as the 21-acetate, the 17,21-dipropionate, the 17-propionate 21-n-butyrate, the 17-propionate 21acetate and the 17-benzoate 21-acetate of 7a-chloro- and 10 7a-bromo-16p-methyl-l,4-pregnadiene-llp,17a,21-triol-3,20dione; and 16-methylene derivatives such as 7a-chloro16-methylene-l,4-pregnadiene-lip,17a,21-triol-3,20-dione 17,21-dipropionate.
The invention also includes 7a-halo-3,20-dioxo1.4- pregnadienes of formula I such as: 9a-halo derivatives of the compounds of formula II, particularly their 9a-fluoro and 9a-chloro derivatives; 9a,Ιΐβ-dihalo-pregnadienes of formula I such as 20 7α,9a,lip-trichloro-l,4-pregnadiene-17a,21-diol-3,20-dione 21-acetate and in particular 7α,9a,llp-trichloro-16a-methyl1.4- pregnadiene-17a,21-diol-3,20-dione 17,21-dipropionate; 21-halo-21-desoxy-pregnadienes such as 7a,2125 dichloro-16a- and 16p-methyl-l,4-pregnadiene-lip,17adiol-3,20-dione 17-propionate, and 7a,21-dichloro-l,4pregnadiene-lip,17a-diol-3,20-dione 17-propionate and its - 13 45950 7a-bromo analog; 21-desoxy-pregnadienes such as 7a-chloro- and 7a-bromo-l,4-pregnadiene-lip,17a-diol-3,20-dione 17propionate, and 7a-chloro~, 7a-bromo- and 7a-iodo-l,4-pre5 gnadien—17a-ol-3,20-dione and its 17-acetate and 17-propionate 16a-hydroxy-pregnadienes and their ester derivatives such as 7a-chloro- and 7a-bromo-l,4-pregnadienelip,16a,17a,21-tetrol-3,20-dione and their 17-prooionates, 16,21-diaeetate 17-propionates, 17-benzoates, and 17-benzoate 21-acetates. 16a,17a-lower alkylidenedioxy compounds, especially 7a-bromo-16a,17a-isopropylidenedioxy-l,4-pregnadiene-lip, 21-diol-3,20-dione 21-acetate; compounds wherein Q and W together represent the grouping --S 'H or —N. i.e. pregnadieno[17,16a-d]-1',3'-oxathiolanes and 5'PH-pregnadieno[17,16-d]oxazoles respectively, R and R1 preferably being methyl groups as in 7a-chloro- and 7a-bromo-liphydroxy-2',2'-dimethyl-1,4-pregnadieno[17,16a-d]-l',3'oxathiolane-3,20-dione and their 9a-chloro derivatives, and 7a-chloro- and 7a-bromo-lip,21-dihydroxy-2'-methyls' PH-1,4-pregnadieno[17,16a-d]oxazole-3,20 dione 21-acetate; - 14 4593ο -carboxylate-pregnadienes such as n-butyl 7a-chloro-lip-hydroxy-3,20~dioxo-16a-methyl-l,4pregnadien-21-oate, propyl 2,7a-dichloro-llp-hydroxy3.20- dioxo-16a-methyl-l,4-pregnadien-21-oate, and their 5 7a-bromo analogs; -alkoxy- and 20-haloalkoxy-21~nor-pregnadienes (which also may be termed alkyl androstadiene-17p-carboxylates) such as 7a-chloro-16p-methyl-20-chloromethoxy-21-nor-l,4pregnadiene-llp,17a-diol-3,20-dione 17 propionate, 7a10 chloro-l6-methylene-20-fluoromethoxy-21-nor-l,4-pregnadiene-ΙΙβ,17a-diol-3,20-dione 17 propionate, 7a-chloro16p-methyl-20-methoxy-21-nor-l,4-pregnadiene-lip,17a-diol3.20- dione 17-propionate, and their corresponding 7a-bromo derivatives; 21-oxo pregnadienes and derivatives, e.g, acetals, hemiacetals and acylals thereof, such as 2,7a-dichloro9a-fluoro-16a-methyl-l,4-pregnadiene-lip,17a-diol-3,20,21trione and its 21-methylhemiacetal, 7a-chloro-9a-fluoro16a-methyl-21,21-diacetoxy-l,4-pregnadiene-lip,17a-diol20 3,20-dione 17-propionate, 7a-chloro-9a-fluoro-16amethyl-l,4-pregnadiene-lip,17a-diol-3,20,21-trione and its 21-ethylene ketal and 21,21-dimethylacetal, and their corresponding 7a-bromo derivatives; D-homo-pregnadienes such as 7a-chloro- and 7a25 bromo-D-homo-l,4-pregnadiene-lip,17a,21-triol-3,20-dione 17a ,21-di-ri-butyrate; and 7a-fluoro and 7a-iodo derivatives such as 7a,9a-di£luoro-16a-methyl-l,4-pregnadiene-llp,17a,21triol-3,20-dione 21-acetate and its 17-benzoate, 7afluoro-l,4-pregnadiepe-llp,17a,21-triol-3,20-dione 215 acetate and its 17-n-butyrate and 17-benzoate, and their 16a-methyl derivatives; 7a-iodo-16a-methyl-l,4-pregnadienellp,17a,21-triol-3,20-dione, its 21-acetate and its 17,21dipropionate, their 16p-methyl epimers, and all their 9afluoro derivatives. .
Another preferred group of compounds of this invention comprises the 11-oxo derivatives of formula I which possess anti-inflammatory activity but are more frequently used as intermediates in the preparation of the corresponding lip-hydroxy derivatives according to procedures disclosed hereinbelow. Particularly valuable 11-oxo derivatives are the compounds of formula II defined above wherein Y is an oxygen atom.
Preferred compounds of formula III include the 21-acetate, 2l-propionate, 21-ti-butyrate, 21-isobutyrate and 21-valerate of 7a-chloro-16a-methyl-4-pregnene-lip, 17a,21-triol-3,20-dione 17-propionate, and the 21-acetate, 21-propionate, 21-n-butyrate and 21-isobutyrate of 7a-bromo 16a-methyl-4-pregnene-lip,17a,21-triol-3,20-dione 17-propionate; the 21-acetate, 21-propionate, and 21-n-butyrate of 7a-chloro- and 7a-bromo-16a-methyl~4-pregnene-lip,17a, 21-triol-3,20-dione 17-n-butyrate; and the 21-acetate, 21-propionate, 21-n-butyrate - 16 459 50 and 21-benzoate of 7a-chloro- and 7a-bromo-16a-methyl4-pregnene-llp,17a,21-triol~3,20-dione 17-benzoate.
Other compounds of formula III include: 7a-chloro- and 7a-bromo-16a-methyl-4-pregnene11β,17a,21-triol-3,20-dione, their 17-valerate 21-acetate, 17-isobutyrate 21-acetate, 21-acetate, 21-benzoate, 21pivalate, 17-propionate and 17-valerate; their 16B~methyl epimers such as the 21-acetate, the 17,21-dipropionate, the 17-propionate 21-n-butyrate, the 17-propionate 21-acetate and the 17-benzoate 21-acetate of 7a-chloro- and 7a-bromo-16p-inethyl-4-pregnene~llp,17a, 21-triol-3,20-dione; 16-methylene derivatives such as 7a-chloro-16methylene-4-pregnene-110,17a,21-triol-3,20-dione 17,21dipropionate; and 16-unsubstituted analogs of the aforenamed 16-substituted derivatives, e.g. 7a-chloro-4-pregnene-llB, 17a,21-triol-3,20-dione 17,21-dipropionate.
The 7a-halo-3,20-dioxo-4-pregnenes of formula III also exhibit topical anti-inflammatory activity and thus are useful in the treatment of corticosteroid-responsive dermatoses such as contact and allergic dermatitis and psoriasis. They may be applied topically or locally in any conventional pharmaceutical form provided that it is free of acids and bases. 43950 P.A. Diassi et. al., J. Med. Chem.. Vol. 10, 551 (1967), describe 7a-chloro-A-nor-progesterone and disclose that the introduction of the 7-chlorine atom greatly diminishes the progestational activity of the 7-unsubstituted precursor. Additionaly, P.A. Diassi et al. teach that no 7a-chloro-4dehydro-3-one has ever been reported as obtained either by oxidation of a 4-dehydro-3-one with 2,3-dichloro-5,6dicyanobenzoquinone in the presence of hydrogen chloride (the quinone being simultaneously reduced to the corresponding quinol) or by addition of hydrogen chloride to 4,6-bis-c!ehydro-3-ones; they postulate that steroids having a 7a-chloro-4-dehydro-3-one structure may exist in the reaction mixture but are unstable and revert to 4,6bis-dehvdro-3-ones when attempts are made to isolate said 7a-chloro-4-dehydro-3-ones and free them from the quinone and quinol.
However, we have now discovered that 7a-chloro-4dehydro-3-ones can be isolated substantially pure and in particular free or substantially free of the corresponding 6,7-dehydrohalogenated compounds, quinone and quinol. We have also surprisingly discovered that 7ahalo-4-pregnene-3,20-diones and in particular 7a-halol,4-pregnadiene-3,20-diones are in general valuable steroids having valuable activity such as corticoid activity.
According to the invention, therefore^ we provide a process for the preparation of a compound of the formula I defined above wherein Z is a chlorine, bromine or iodine atom, with the proviso that Z is not a chlorine atom when X is a halogen atom, which comprises, as main reaction step, the addition of a hydrogen halide selected from hydrogen chloride, hydrogen bromide and hydrogen iodide to the 6,7-double bond of a compound of the formula wherein the dotted line, A, B, X and Y are as defined above and W1, Q' and M' are W, Q and M are defined above, or W and Q' taken together are a 16a,17a-alkylorthoalkanoate or 16a,171 together with the oxygen atom of the Cjq carbonyl group are a 17a.20;20.21-bis-methvlenedioxy group, in the presence of an inert solvent; with the provisos that (i) when the hydrogen halide is hydrogen chloride, then X is a hydrogen atom; fix) when Y is the group (Η,β-ΟΗ) and the hydrogen halide is hydrogen bromide, then X is a hydrogen atom; and (iii) when Y is the group (Η,β-ΟΗ) and the hydrogen halide is hydrogen iodide, then X is a hydrogen, chlorine or fluorine atom.
The hydrogen halide should be used in an amount at least equimolar tothe steroid and preferably in at least a 5 molar excess, e.g. 10 to 50 molar excess.
In order to obtain a compound of the formula I, this main step may then be followed by at least one of the following steps: when W' and Q' taken together are a 16a,17a-alkylorthoalkanoate or 16a,17a-alkylorthoarylcarboxylate group together with a 16p-hydrogen atom, the product is hydrolysed to yield a compound wherein Q is a hydroxy group and W is the group (H,a-0H); or, when OV and Q‘ together with the oxygen atom at the C2o carbonyl group are a 17a.20;20.21-bis-methvlenedioxy group, the product is hydrolysed to yield a compound wherein OV and Q are hydroxy groups; and/or when Y is an oxygen atom and either (i) Z is a bromine atom and X is a halogen atom, or (ii) Z is an iodine atom and X is a bromine atom, and a compound wherein Y is the group (Η,β-ΟΗ) is required, this compound is prepared by reduction of a corresponding product wherein Y is an oxygen atom; and/or, when X is a hydrogen atom, Y is the group or bronrine (Η,β-ΟΗ), and Z is a chlorine/atom, a 9(11)-double bond is introduced by dehydration and the product is subjected to addition of halogen to the 9 (11)-double bond or of a 9a-chlorine or bromine atom and of an Ιΐβ-hydroxy group to the 9 (11)-double bond; and finally a compound of the formula X is isolated.
The immediate product of this main step and/or the compound of the formula I may if desired be subjected to a number of finishing steps in any appropriate order, which may be more generally defined as follows: a) Hydrolysis of an esterifying group or groups at the 16α-, 17α- and/or 21-position to hydroxy; b) Hydrolysis of a 17a,2O;2O,21-bis-methylenedioxy group to 20-oxo-17a,21-dihydroxy groups, or of a 21-ethylene ketal to 21-oxo, or of a 17a,21-alkylidenedioxy.-cycloalkylidenedioxy or aralkyl idenedio/y. c) Esterification of a hydroxy group at the 16α-, 17α- and/or 21-position; d) Reduction of an 11-oxo group to an llp-hydroxy group; e) 9 (11)-Dehydration of a 9-unsubstituted-lip-ol to a 4,9(ll)-pregnadiene or to a 1,4,9 (11)-pregnatriene, except when Z is an iodine atom, followed by addition of halogen to the 9(11)-double bond, or followed by addition of a chlorine or bromine atom and a hydroxy group to the 9(11)-double bond with the formation of a 9a-chloro- or 9a-bromo-lip-hydroxy steroid; £) 17a-Chlorination or bromination; whereafter a compound of the formula I is isolated. 45SS0 The main step is preferably carried out under anhydrous conditions, especially when the starting material has a 1,2-double bond, to minimize side reactions such as hydrolysis of any ester groups present. Saturated 5 solutions of hydrogen halide in an anhydrous solvent are preferably employed to minimize reaction time.
Non-reactive organic solvents suitable for use in this process are those in which the starting material of the formula IV and the hydrogen halide are soluble. By “non-reactive is meant any organic solvent which will not react with the steroid substrate or the hydrogen halide so as to cause competing side reactions. Thus, in this process, solvents that are usually better avoided include water (which will cause hydrolysis of esters), alcohols (which might cause ester exchange under acid conditions), and nitriles, e.g. acetonitrile (which would form iminoethers with steroidal alcohols).
Particularly useful solvents for use in this pro20 cess are ethers such as dioxan, tetrahydrofuran and diethylether; chlorinated hydrocarbons such as chloroform, methylene chloride and ethylenedichloride; organic acids such as acetic and propionic acids; tertiary amides such as dimethylformamide, diethylformamide, and hexamethyl25 phosphortriamide; and dimethylsulfoxide. Dioxan, acetic acid and tetrahydrofuran are particularly suitable solvents, tetrahydrofuran being preferred for reactions with hydrogen chloride, and acetic acid for reactions - 22 45950 with hydrogen bromide or hydrogen iodide.
This reaction is preferably carried out at temperatures in the range of from about 0°C. to about 30°C. or preferably up to ambient temperature (e.g. 2o°C.) although lower temperatures (e.g. -2O°C.) and temperatures as high as about 6O°C. may be employed. (Temperatures above 30°C. are preferably not employed except when a 7a-chlorol,4-pregnadiene-17a,21-diol-3,20-dione or ester thereof is being prepared.) The reaction time depends upon the hydrogen halide, solvent, and concentration being employed. Thus, for example, in acetic acid, the addition of hydrogen iodide is usually complete within one or two minutes, whereas the addition of hydrogen bromide at room temperature may be completed in from 20 to 60 minutes. The addition of hydrogen chloride in tetrahydrofuran is preferably carried out at 0°C. rather than at room temperature, since the greater concentrations of hydrogen chloride thereby obtainable enable the reaction to be completed within an hour rather than in about 24 hours.
Substituents present in the 3,2o-dioxo-l,4,6-pregnatriene and 3,2O-dioxo-4,S-pregnadiene starting steroids usually remain unchanged under the conditions of this process, so that it is usually preferable for the starting steroids to have all the substituents desired in the 7ahalo-3,20-dioxo-l,4-pregnadiene and -4-pregnene products.
This process is preferably carried out by adding the starting 3,20-dioxo-l,4,6-pregnatriene or -4,6-pregna23 diene, either in the solid state or in solution, to a saturated solution of dry hydrogen halide in an anhydrous solvent, usually at 0°C. to 20°C., the molar ratio of hydrogen halide to steroid being about 40 to 1. After the reaction is complete, as determined by thin layer chromatography, the reaction mixture is poured into ice water and the resultant precipitate of 7ct-halo-3,20-dioxo1,4-pregnadiene or -4-pregnene is separated by filtration Or extraction and isolated in a pure state, usually by chromatography. In particular, the product especially when it is a 7a-halo-3,20-dioxo-4-pregnene, is preferably separated at temperatures no higher than about 25°c. in a state substantially free of acid and base by freeing it of excess acid and solvent without subjecting it to a substantially basic medium.
In the starting material of formula IV, X is preferably a hydrogen atom, since the 9-unsubstituted compounds of formula IV generally tend to undergo addition of hydrogen halide more readily than their 9a-halo-derivatives. It is indeed advantageous also for X in the final product of formula I to be a hydrogen atom, since the 9a-unsubstituted compounds of formula I generally have better topical anti-inflammatory activity than their 9ahalo derivatives.
When the starting compound is a 1,2-dihydro-3,20dioxo-4,6-pregnadiene, its conversion into a 3,20-dioxo7a-eh1oro-4-preijnene proceeds faster than the conversion of a 3,20-dioxo-l,4,6-pregnatriene into a 3,2o-dioxo-7occhloro-1,4-pregnadiene, and can therefore if desired be carried out in the presence of water without causing significant hydrolysis of ester groups that may be pre5 sent. Moreover, the l,2-dihydro-4~pregnenes of the formula I, being much less stable than the 1,4-pregnadienes, must be isolated from the excess acid as quickly as possible without using a basic medium and should be stored in vacuo in an open vessel at temperatures no higher than about 25°C.
When a 7a-halo-llp-hydroxy-3,20-dioxo-l,4-pregnadiene or -4-pregnene of formula I is prepared from a steroid of the formula XV, rather low yields of pure product are obtained if the steroid of formula IV contains an Ιΐβ-hydroxy group. Better overall yields of pure product are obtained if the steroid of the formula IV has an 11-oxo group, and the resulting 7a-halo-3,11,20-trioxo1,4-pregnadiene or -4-pregnene is then reduced at the 11-position. Suitable reducing agents include sodium, potassium or lithium borohydride, tetra-n-butylammonium borohydride, or lithium tri-t-butoxy-aluminium hydride, in an inert organic solvent, preferably sodium borohydride in an inert organic solvent comprising methanol or di25 methylformamide. When the starting material of the formula IV is a 3,ll,20-trioxo-17a-hydroxy-l,4,6-pregnatriene 17-acylate wherein any 21-hydroxy group is esterified, reduction occurs very specifically at the 11-oxo group. However, when a 3-oxo-7a-halo-lip-hydroxy-l,225 45980 dihydro-4-pregnene is being prepared by reduction of the corresponding 11-oxo derivative (e.g·. with sodium borohydride) , concomitant reduction at the 3-keto group tends to occur ’ so that better yields of the desired product are obtained when the resultant 7a-halo-lip-hydroxy product is oxidised with an oxidising agent capable of oxidising an allylic hydroxy group to an oxo group under substantially ποη-basic conditions. The oxidising agent may for example be pyridinium chlorochromate in an inert organic solvent e.g. methylene chloride, preferably in the presence of a weak base e.g. sodium acetate, or a carbodiimide e.g. dicyclohexylcarbodiimide together with dimethylsulfoxide and a weak acid e.g. pyridinium trifluoroacetate, but is preferably neutral active manganese dioxide in an inert organic solvent at room temperature.
The 3,20-dioxo-l,4,6-pregnatriene and 3,20-dioxo4.6- pregnadiene starting compounds of formula IV either are known compounds or are conveniently prepared from their 6.7- dihydro derivatives by standard techniques for effecting dehydrogenation between C-6 and C-7, e.g. by means of chloranil or 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) or by bromination at C-6 followed by dehydrobromination. Since ester groups are usually present in the 6,7-dihydro derivatives, anhydrous conditions are preferably employed to minimize hydrolysis.
•I'he invention further provides a process for the preparation of a compound of the formula I defined above wherein Z is a fluorine, chlorine or bromine atom, with the proviso that Z is a fluorine atom when a 1,2-single bond is present, which comprises, as reacting a compound of the formula M main reaction step, (V) are as defined above, defined above with M and W are respectively M' and iv' the proviso that M is not a hydroxymethyl group and W is not the group (H, α-OH), and the grouping ;n represents \<,r II wherein Y and X are as defined above, with a halogenating agent capable of replacing the 7B-hydroxy group with a 7a-halogen atom selected from fluorine, chlorine and bromine, in the presence of an inert organic solvent, with the proviso that a 7a-ehlorine or 7a-bromine atom is introduced only when a 1,2-double bond is present.
In order to obtain a compound of the formula I, this main step may then be followed by at least one of the following steps: when W and Q' taken together are a 1δα,17αalkylorthoalkanoate or l6a,17a-alkylorthoarylcarboxylate group together with a l6)3-hydrogen atom, the product is hydrolysed to yield a compound wherein Q is a hydroxy group and W is the group (H, a-OH); or, when 0V^ and Q’ together with the oxygen atom of the C20 carbonyl group are a 17a,2O;2O,21-bismethylenedioxy group, the product is hydrolysed to yield a compound wherein OV3 and Q are hydroxy groups; v \z and/or, when the grouping ill represents C· halogen is added to the 9,11-double bond or a chlorine or bromine atom and a hydroxy group are added to the 9,11double bond with the formation of a 9ot-chloro- or 9a-bromo-ΙΙβ-hydroxy steroid.
The immediate product of this main step and/or the compound of the formula I may if desired be subjected to a number of finishing steps in any appropriate order, which may be more generally defined as follows: a) Hydrolysis of an esterifying group or groups at the 16α-, 17α- and/or 21-position to hydroxy; b) Hydrolysis of a 17a,20;20,21-bis-methylenedioxy group to 20-oxo-17a,21-dihydroxy groups, or of a 21-ethylene ketal to 21-oxo, or of a 17a,21-alkylidenedioxy, - cycloalkylidenedioxy, or aralkyidenedioxy group to 17a,21-dihydroxy groups; c) Esterification of a hydroxy group at the 16α-, 17αand/or 21-position; - 28 45950 d) Reduction of an 11-oxo group to an HB-hydroxy group; e) Addition to the 9,11-double bond of halogen or of a 9«-chlorine or bromine atom and of an Ιΐβ-hydroxy group, H\ either when the grouping |11 is C or after such a 9(11)-double bond has been introduced by 9(11)-dehydration of a 9-unsubatituted-llB-ol; f) 17a-Chlorination or bromination.
Preferably the halogenating agent is either a tertiary amine having an N-(2-chloro-l,l,2-trifluoroethyl) group, said amine being used alone for the preparation of a 7«-fluoro steroid but in the presence of a metal chloride or bromide that is soluble in the reaction mixture for the preparation of a 7«-chloro or 7a-bromo steroid respectively, or a tertiary amine having an N-trichlorovinyl group for the preparation of a 7«-chloro steroid.
A particularly preferred halogenating agent is N-(2-chlorol,l,2-trlfluoroethyl)diethylamine, also known as fluoramine; the reaction between the steroid and fluoramine is preferably effected at moderately low temperatures (e.g. at about 0°C.), under an inert atmosphere (e.g. under argon, neon or nitrogen) and under anhydrous conditions.
All primary and unhindered secondary alcohol groups (i.e. at the 21- and Ιδα-positions, but not at the Imposition) should be protected, e.g. by esterification.
The preferred molar ratio of fluoramine to steroid is about 6:1. - 29 When fluoramine alone (i.e. without metal chloride and bromide) is used as fluorinating agent, the solvent is preferably a halohydrocarbon, especially methylene chloride, and the product is a 7a-fluoro steroid. The preferred metal chloride and bromide are lithium chloride and bromide. When fluoramine is used together with lithium bromide as brominating agent, the solvent is preferably a halohydrocarbon, especially methylene chloride, and the product is a 7a-bromo-steroid. When fluoramine is used together with lithiumchloride as chlorinating agent, the solvent is preferably an ether, especially tetrahydrofuran, and the product is a 7a-chloro steroid. The molar ratio of lithium chloride or lithium bromide to steroid is preferably about 12 to 1.
The reaction of the steroid of the formula V with fluoramine (if desired in the presence of lithium chloride or bromide) is preferably allowed to proceed to completion, e.g. until thin layer chromatography shows that the starting steroid is no longer present. The product may then be isolated by evaporation of the reaction mixture and purified by chromatography to obtain the desired 7«-halo derivative, sometimes in admixture with the corresponding 7~unsubstituted-6-dehydro derivative (especially when fluoramine alone is the halogenating agent). Such a mixture may be separated by converting this 6-dehydro derivative into a derivative that is easily separable from the 7a-halo product by chromatography, in particular into a 6,7-disubstituted derivative, e.g. - 30 45950 into the corresponding 6p,7(3-diol by reaction with osmium tetroxide in dioxan in the presence of pyridine. 7a-Chloro compounds of the formula X can also be prepared from a steroid of the formula V by reaction with N,N-diethyl-l,2,2-trichlorovinylamine in a halohydrocarbon, e.g. methylene chloride, as solvent and preferably at moderately low temperatures, e.g. at about 0°C., and under an inert atmosphere, e.g. nitrogen. The molar ratio of N,N-diethyl-l,2,2-trichlorovinylamine to steroid is preferably about 6 to 1.
The compound of the formula V, which in these processes reacts with the halogenating agent, preferably has a 1,2-double bond, since the resulting 1,4-pregnadienes are in general more stable, more readily isolated arid more active as topical anti-inflammatory agents than the corresponding 1,2-dihydro-4-pregnenes.
The steroids of the formula V, required as starting materials for this process, are novel compounds and can be prepared by conversion of the corresponding 6β,7βdihydroxy derivatives into 6p,7B-alkylorthoalkanoate esters, hydrolysis at the 7-position with weak acid and then reduction of the resulting 6B-acyloxy~7B-hydroxyderivative, preferably with chromous acetate, sodium acetate and aqueous acetic acid in acetone.
The product of either of the two main reaction steps described above (starting from a steroid of the formula IV or V) may then be subjected to one or more of - 51 4&&S0 the finishing steps (a) to (f) mentioned above. Whether or not it is convenient or even essential to carry out such a finishing step will normally be clear to a skilled steroid chemist; it will often be more convenient to carry out the corresponding chemical changes during the preparation of the steroid of the formula IV or V. 7a-Halo-3,20-dioxo-l,il-pregnadienes and -4-pregnenes having ester functions at C-16, C-17 and/or C-21 can be converted into 7a-halo-3,20-dioxo-l,il-pregnadienes and -4-pregnenes having free hydroxyl groups at C-16, C-17 and/or C-21, for example by the action of acidic saponification agents, e.g. a strong mineral acid and preferably 70% perchloric acid in methanol. By regulating the reaction time and quantity of acid, a 17,21-dihydrocarbon15 carboxylate can be converted into the corresponding 17-monoester or 17,21-diol. The compounds of this invention have a halogen atom at C-7 so, basic hydrolyzing agents are usually not desirable since unwanted side reactions will often take place, such as elimination of the 7a-halogen atom; however, mild basic saponification agents such as aqueous sodium bicarbonate in methanol can often be employed successfully.
The hydrolysis of an esterifying group at C-21 or at C-l6 is preferably effected by means of diastase enzyme of malt in aqueous ethanol. Malt diastase hydrolyses 7a~halo-3,20-dioxo-pregnadiene 17,21-dihydrocarboncarboxylates only at C-21 producing 17-monohydrocarboncarboxylates which, if desired, can be re-esterified at - 32 45950 C-21 in known manner with an acylating agent introducing a different acyl function from that present at C-17 so as to produce mixed 17,21-diacyl derivatives. 16a,17a-0rthoesters and 17a,21-orthoesters can be hydrolysed at the l6a- and 21-positions to yield a 17ester. This hydrolysis is preferably effected under mildly acidic conditions, e.g. in the presence of a lower alkanoic acid (e.g. acetic or propionic acid) or a strong mineral acid (e.g. hydrochloric or sulfuric acid). When no substituent is present at C-16 the hydrolysis is preferably carried out under buffered conditions at a pH in the range of 4 to 6.
The hydrolysis of a 17a,21-alkylidenedioxy, -cycloalkylidenedioxy or -aralkylidenedioxy group to 17a,21-dihydroxy groups is normally effected under mildly acidic conditions (e.g. 50% aqueous acetic acid), preferably under an inert atmosphere (e.g. nitrogen). 21Ethylene ketals and 17ot,20;20,21-bis-methylenedioxy groups can also be hydrolysed under mildly acidic conditions; 17a,20;20,21-bis,-methylenedioxy groups can be hydrolysed under substantially neutral conditions by means of triphenylcarbenium tetrafluoroborate.
The preferred compounds of the present invention have ester groups at C-17 and include 17-mono- and 17,21diesters, in particular 17-propionates, 17-n-butyrates and 17-benzoates. It is usually advantageous to have these ester groups already present in the starting materials of the formulae IV and V. However, it may sometimes - 33 45050 be convenient to introduce these ester groups after one of the above-described main reaction steps according to the invention has been carried out, Thus the 17a,21-diesters can be prepared by acylation of the corresponding 17a,21-diols or 17a-hydroxy-21-acyloxy compounds, preferably by means of a carboxylic acid having up to 12 carbon atoms or retinoic acid together with an esterifying agent or by means of a reactive derivative of said acid. In particular, the steroid may be reacted with an appropriate acid anhydride, in the presence of a strong acid catalyst, e.g. toluene2~sulfonic acid, perchloric acid or a strongly acidic cation exchange resin, or with trifluoroacetie anhydride and the appropriate acid, e.g. a lower alkanoic acid, and a strong acid catalyst.
Before a 17a-hydroxyl group is esterified, any lip-hydroxyl function should be protected, e.g. as the lip-trifluoroacetate, which, after esterification at C-17, may be hydrolyzed with mild base (e.g. dilute aqueous sodium benzoate) without hydrolyzing other ester groups at C-17 and/or C-21. Alternatively, the 17a-esterification may be carried out on an 11-oxo compound, and the 11-oxo group may then be reduced (as described above after the discussion of the first main reaction step) to the required lip,17 a-diol 17-acylat e. 17,21-Diesters may also be prepared by acylation of the corresponding 21-hydroxy-17a-monoesters with the - 34 43950 appropriate acid anhydride or acid chloride under basic conditions, preferably in the presence of a tertiary organic base, e.g. pyridine, quinoline, N-methylpiperidine, N-methylmorpholine, p-dimethylaminopyridine or N,N-dimethylaniline.
The 17a-monoesters of our invention may be prepared by hydrolysis of a corresponding 17,21-orthoester or 17a,21-diester as described above; the 17,21-orthoester grouping may be introduced by reaction of a 17a,21diol with an alkylorthoester either before or after a main process step according to the invention.
A 21-dihydrogenphosphate ester is preferably prepared in a finishing step by reaction of the corresponding 21-hydroxy compound with pyrophosphoryl chloride. The mono- and di-alkali metal salts and alkaline earth metal salts of the dihydrogen phosphate ester may be obtained by partial or complete neutralization with an alkali metal methoxide or alkaline earth metal methoxide.
The reduction of an 11-oxo group to an IIP-hydroxy group has already been described.
When 7a,9a,llf3-trihalo compounds and 7a,9a-dihalo110-hydroxy compounds of formula I are being prepared, the 9a,110-dihalogen or 9a-halogen atoms may be present in the molecule before introduction of the 7a-halogen atom. However, the 9a,110-dihalogen or 9a-halogen atoms may be introduced into a 7a-halo-9(ll)-dehydro compound (especially a 7a-halo-3,20-dioxo-l,4,9(ll)-pregnatriene), which may have been derived from a 7a-halo-110-hydroxy-3,20- 35 45950 dioxo compound by dehydration with methanesulfonyl chloride and a tertiary amine (e.g. collidine) in a dialkylamide (e.g. dimethylformamide) in the presence of sulfur dioxide. For example, reaction of a resulting 7a-halo9(ll)-dehydro compound with chlorine in a halogenated solvent (e.g. chloroform) in the presence of a tertiary amine (e.g. pyridine) yields the corresponding 7a~halo-ga, ΙΙ.β-diehloro derivative. Alternatively, reaction of the resulting 7a-halo-9(11)-dehydro compound with hydrogen fluoride and an N-chloro-amide or N-bromo-amide or with hydrogen chloride and an N-bromo-amide in an inert organic solvent yields 7« ,9a,H3-trihalo derivatives wherein the more electronegative halogen substitutes the Ιΐβ-position, Furthermore, reaction of the resulting 7«-halo-9(ll)-dehydro compound with an N-chloro-amide or N-bromo-amide (preferably N-chloro-succinimide or N-bromo-succinimide) and a strong mineral acid (preferably perchloric acid) in an inert organic solvent (e.g. moist dioxan or tetrahydrofuran) yields an Ιΐβ-ol having a 9a-chloro or 9abromo substituent. 17a-Chlorination or bromination may be effected by means of an N-chloro-amide or N-bromo-amide, especially N-chloro-succinimide or N-bromo-succinimide, in an inert organic solvent such as tetramethylene sulfone at reduced temperature and preferably in the presence of a mineral acid such as hydrofluoric acid.
The following Preparations show how the starting materials of the Formulae IV and V may be obtained: - 56 45950 PREPARATION 1 I6a-METHYL-1, 4,6-PREGNATRIENE-110, 17«,21TRIOL-5,20-DIONE AND 21-ESTERS THEREOF A. l6a-Methyl-l,4,6-pregnatriene-110,17a,21-triol-3,2O-di5 one 21-aaetate To a solution of dry hydrogen chloride gas (22 gins.) in dioxan (660 ml.), add I6a-methyl-l,4-pregnadiene-110, 17a,21-triol-3,20-dione 21-acetate (10 gms.) followed by 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) (6.55 gms.) and stir at room temperature for 24 hours. Filter the reaction mixture and evaporate the filtrate at 40°C. in vacuo. Dissolve the resultant residue in chloroform: ethyl acetate (1:1) and filter the solution through a column of neutral alumina, washing the column with the same solvent system. Evaporate the eluates and recrystallize the resultant residue from methanol:hexane to give l6a-methyl-1,4,6-pregnatriene-110,17a,21-triol-3,20-dione 21-acetate.
B. 16 q-Methyl-1,4,6-pregnatriene-llg,17 a,21-triol~3,2020 dione To a solution of l6a-methyl-l,4,6-pregnatriene-110,17a, 21-triol-3,20-dione 21-acetate (1.5 gms.) in methanol (360 ml.) add saturated aqueous sodium bicarbonate solution (40 ml.). Stir at room temperature for 2 hours; 43030 then filter and evaporate in vacuo. Dissolve the resultant residue in ethyl acetate, wash the ethyl acetate solution with water, dry it over magnesium sulfate and evaporate It in vacuo to obtain l6a-methyl-l,4,6-pregna5 triene-110,17 a,21-triol-3,20-dione.
C. l6a-Methyl-l,4,6-pregnatriene-110,17a,21-triol-3,20-dione 21-benzoate (1) To l6a-methyl-l,4,6-pregnatriene-110,17a,21-triol-3,2O dione (0.68 gms.) in pyridine (6.12 ml.) add benzoyl chlo10 ride (1.36 ml.). Stir at room temperature for 30 minutes then pour into 0.1 N hydrochloric acid solution (550 ml.). Extract the aqueous mixture with ethyl acetate, wash the organic extracts with aqueous saturated sodium bicarbonate solution, then with water, then dry them over magnesium ]_5 sulfate and evaporate them in vacuo to a residue of 16amethyl-1,4,6-pregnatriene-llf3,17a,21-triol~3,20-dione 21benzoate. (2) In the above procedure, by substituting for benzoyl chloride equivalent quantities of a substituted benzoyl chloride, e.g. j>-toluyl chloride, p-fluorobenzoyl chloride and 3',5'-dimethylbenzoyl chloride, there is obtained the corresponding 21-suhstituted benzoate ester, e.g. the 21-p-toluate, 21-g-fluorobenzoate and 21-(3’, 5’-dimethylbenzoate) of l6a-methyl-l,4,6-pregnatriene25 11(3,17a,21-triol-3,20-dione, - 38 45950 S->·’ D. I6a-Methyl-1, A ^-pregnatriene-HB ,17«,21-triol-3,20dione 21-hydrocarboncarboxylates (1) l6a-Methyl-l,4,6-pregnatriene-lip,17a,2I-triol-3,20dione 21-trimethylacetate To l6a-methyl-l,4,6-pregnatriene-ll(3,17a,21-triol-3,20dione (0.4 gms.) in pyridine (3 ml.) at 0°C. add dropwise a solution of trimethylacetyl chloride (0.4 ml.) in pyridine (1 ml.). Allow the reaction mixture to warm to room temperature, then leave it at room temperature for 30 minutes. Pour the reaction mixture into water (250 ml.), extract the aqueous mixture with ethyl acetate, then wash the organic extracts successively with IN hydrochloric acid, aqueous saturated sodium bicarbonate, and water. Dry the organic phase over magnesium sulfate and evaporate it in vacuo to a residue of I6a-methyl-1,4,6-pregnatriene-UP,17a,21-triol~3,20-dione 21trimethylaoetate. (2) In the above procedure, by substituting for trimethylacetyl chloride equivalent quantities of other hydrocarbon20 carboxylic acid chlorides, e.g. propionyl chloride, dodecanoyl chloride, valeryl chloride, n-butyryl chloride, cyclopentylpropionyl chloride, cyclohexylcarbonyl chloride, 1-adamantylacetyl chloride, and 1-adamantylcarboxylic acid chloride, there is obtained the corresponding 21-hydrocarboncarboxylate ester, e.g. the 21-propionate, 21-dodecanoate, 21-valerate, 21-n-butyrate, 21-cyelo- 39 'is990 pentylpropionate, 21-cyclohexanecarboxylate, 21-(1’adamantylacetate) and 21-(l'adamantylcarboxylate) of l6a-methyl-l,4,6-pregnatriene-110,17a,21-triol-3,20-dione.
PREPARATION 2 l6a-METHYL-l,4,6-PREGNATRIENE-llg,17a,21TRIOL-3,20-DIONE 17-LOWER ALKANOATES AND 17,21-ALKYLORTHOALKANOATES A. l6a-Methyl-l,4,6-pregnatriene-llg,17a,21-triol-3,20dione 17-propionate (1) l6a-Methyl-l,4,6-pregnatriene-llg,17a,21-triol~3,20dione 17,21-ethylorthopropionate To l6a-methyl-l,4,6-pregnatriene-110,17a,21-triol~3,20dione (1.9 gms.) in dimethylsulfoxide (9-5 ml.) add triethylorthopropionate (3-8 ml.) and toluene-p-sulfonic acid monohydrate (0.142 gm.). Stir for 2 hours at room temperature, then pour into water (250 ml.), add saturated aqueous sodium bicarbonate (150 ml.) and extract with ethyl acetate. Combine the ethyl acetate extracts and wash them with water, dry them over magnesium sulfate and evaporate them in vacuo to a residue comprising l6a-methyl-1,4,6-pregnatriene-llg,17a,21-triol-3,20-dione 17,21ethylorthopropionate. - 40 45950 (2) Dissolve the product of Preparation 2A(1) in glacial acetic acid (15 ml.) and water (0.3 ml.). Allow to stand for one hour at room temperature, then pour into water (300 ml.) and add 8? aqueous sodium hydroxide solu5 tion (50 ml.). Separate the resultant precipitate by filtration, wash it with water and dry it at room temperature to give l6a-methyl-l,4,6-pregnatriene-lip,17a, 21-triol-3,20-dione 17-propionate. Further purify by recrystallization from acetone/hexane.
B. l6a-Methyl-l,4,6-pregnatriene-llg,17a,21-triol-3,20dione 17-lower alkanoates (1) l6a-Methyl-l,4,6-pregnatriene-llg,17a,21-triol-3,20dione 17,21-alkylorthoalkanoates In the procedure of Preparation 2A(1), substitute for tri15 ethylorthopropionate the following trialkylorthoalkanoates: triethylorthoacetate, triethylortho-n-butyrate, triethylorthoisobutyrate and tri-n-butylorthovalerate, to obtain the corresponding 17,21-alkylorthoalkanoate: the 17,21-ethylorthoacetate, the 17,21-ethylortho-n-butyrate, the 17,21-ethylorthoisobutyrate, and the 17,21-n-butylorthovalerate, respectively, of l6a-methyl-l,4,6-pregnatriene-HP, 17a, 21-triol-3,20-dione. - 41 (2) l6ct-Methyl-l,4,6-pregnatriene-lip, 17«,21-triol-3,20dione 17-Iower alkanoates Treat each of the 17,21-alkylorthoalkanoates prepared in Preparation 2B(1) with aqueous acetic acid in the manner of Preparation 2A(2) to obtain, respectively, the 17-acetate, 17-n-butyrate, 17-isobutyrate, and 17-valerate of l6a-methyl-l,4,6-pregnatriene-110,17 a,21-triol-3,20-dione C. l6ot-Methyl-l,4,6-pregnatriene-lip,17«,21-triol-g,20dione 17-benzoate (1) l6g-Methyl-l,4,6-pregnatriene-liP,17«,21-triol~5,20dione 17,21-methylorthobenzoate To a solution of l6a-methyl-l,4,6-pregnatriene-lip,17a,21triol-3,20-dione (1 gm.) in dioxan (56 ml.) and benzene (84 ml.) add pyridinium toluene-p-sulfonate (0.25 gm.) and trimethylorthobenzoate (1.5 ml.). Heat the reaction mixture at reflux temperature for 2 days, then add additional pyridinium toluene-p-sulfonate (0.1 gm.) and trimethylorthobenzoate (1. ml.). Heat at reflux temperature an additional 3 days, then again add additional py20 ridinium toluene-p-sulfonate (0.1 gm.) and trimethylortho· benzoate (1 ml.). Heat at reflux temperature another 3 days, cool, add pyridine (0.45 ml.) and evaporate in vacuo. Dissolve the resultant residue in ethyl acetate, wash the ethyl acetate solution with water, dry it over - 42 459 50 magnesium sulfate and evaporate it to a residue comprising l6 α-methyl-l,4,S-pregnatriene-ΙΙβ,17 a,21-triol3,20-dione 17,21-methylorthobenzoate.
In the above procedure by substituting for trimethylortho5 benzoate an equivalent quantity of trimethylortho-(£-fluorobenzoate) there is obtained l6a-methyl-l,4,6-pregnatriene-ΙΙβ,17 a,21-triol-3,20-dione 17 , 21-methylortho-(pfluorobenzoate). (2) l6a-Methyl-l,4,6-pregnatriene-110,17a,21-triol-3,2010 dione 17-benzoate and l6a-methyl-l,4,6-pregnatriene-llB, 17a,21-triol-3,20-dione 17-j>-fluorobensoate are obtained by hydrolysis of iSa-methyl-ljMjfi-pregnatriene-llB,17a,21tr iol-3, 20-dione 17a,21-methylorthobenzoate and l6a-methyl1,4,6-pregnatriene-llB,17a,21-triol-3,20-dione 17a,2115 methylortho-(g-fluorobenzoate) respectively with aqueous acetic acid by the method of Preparation 2A (2).
PREPARATION 3 Ιβα-ΜΕΤΗΥΙ-1,4,6-PREGNATRIENE-11B , 17a, 21TRIOL-3,20-DIONE 17,21-DIHYDROCARBONCARBQ20 XYLIC ACID ESTERS A. l6a-Methyl-l,4,6-pregnatrisne-HB,17a ,21-triol-3,20dione 17~propionate 21-alkanoates - 43 (1) l6g-Methyl-l,4,6-pregnatriene-ll)3,17a,21-triol-3,20dione 17,21-dipropionate To l6a-methyl-l,4,6-pregnatriene-110,17 a,21-triol-3,20dione 17-propionate (2.8 gms.) in pyridine (23 ml.), add propionic anhydride (4.6 ml.) and allow to stand at room temperature for 3.5 hours. Pour into water (250 ml.) containing IN hydrochloric acid (50 ml.). Extract with ethyl acetate (100 ml.), wash the combined organic extracts with water, dry over magnesium sulfate and evaporate-in vacuo. Chromatograph the resultant residue on a silica gel column, eluting with chloroform: ethyl acetate (4:1). Evaporate the combined eluates to a residue comprising l6a-methyl-l,4,6-pregnatriene-110, a,21-triol-3,20-dione 17,21-dipropionate. (2) In the procedure of Preparation 3A(1) by substituting for propionic anhydride equivalent quantities of other alkanoic anhydrides, e.g. acetic anhydride, n-butyric anhydride, isobutyric anhydride, caprylic acid anhydride and valeric anhydride, there is obtained the corres ponding 17-propionate 21-alkanoate ester, e.g. the 17propionate 21-acetate, 17-propionate 21-n-butyrate, 17propionate 21-isohutyrate, 17-propionate 21-caprylate, and 17-propionate 21-valerate of l6a-methyl-l,4,6-pregna- 44 45850 triene-llg,17α,21-triol-3,20-dione. (3) l6a-Methyl-l,4,6-pregnatriene-llg,17a,21-triol~3,20dione 17-propionate 21-benzoate is prepared from l6a-methyl-1,4,6-pregnatriene-llg,17a,21-triol-3,20-dione 17-pro5 pionate and benzoyl chloride by the method of Preparation 1C(1). 17-Propionate 21-substituted-benzoate esters, e.g. the 17-propionate 21-p-toluate, 17-propionate 21-p-fluorobenzoate, and the 17-propionate 21-(3',5'-dimethylbenzoate) of l6a-methyl-l,4,6-pregnatriene-llg,17a,21-triol-3,2010 dione, may be prepared similarly by using the corresponding substituted benzoyl chloride.
B. I6a-Methyl-1,4,6-pregnatriene-llg,17a,21-triol-3,20dione 17,21-dihydrocarboncarboxylates (1) In a manner similar to that described in Preparation 15 3A(1), treat each of the 17-acetate, the 17-n-butyrate, the 17-isobutyrate, the 17-valerate, and the 17-benzoate esters of l6a-methyl-l,4,6-pregnatriene-llg,17a,21-triol3,20-dione in pyridine with each of the following alkanoic acid anhydrides: acetic anhydride, propionic anhydride, n-butyric anhydride, isobutyric anhydride and valeric anhydride. Isolate and purify each of the resultant products in a manner similar to that described to obtain the corresponding 17-hydrocarboncarboxylate 21-alkanoates, respectively, of I6a-methyl-l,4,6-pregnatriene-llg,17a, - 45 21-triol-3,20-dione; i.e. its 17,21-diacetate, 17-acetate 21-propionate, 17-aeetate 21-n-butyrate, 17-acetate 21-iso butyrate, 17-acetate 21-valerate; 17-n-butyrate 21-acetate, 17-n-butyrate 21-propionate, 17,21-di-n-butyrate, 17-n-butyrate 21-isobutyrate, 17-n-butyrate 21-valerate; 17-isobutyrate 21-acetate, 17-isobutyrate 21-propionate, 17-isobutyrate 21-n-butyrate, 17,21- di-isobutyrate, 17-isobutyrate 21-valerate; 17-benzoate 21-acetate, 17benzoate 21-propionate, 17-benzoate 21-n-butyrate, 17-benzoate 21-isobutyrate, 17-benzoate 21-valerate; 17-valerate 21-acetate, 17-valerate 21-propionate, 17-vale rate 21-n-butyrate, 17-valerate 21-isobutyrate, and 17, 21-divalerate. (2) In a manner similar to that described in Preparation 1C treat each of the l6a-methyl-l,4,6-pregnatriene-lip, 17a,21-triol~3,20-dione 17-monoester starting compounds of Preparation 3B(1) in pyridine with each of benzoyl chloride, ja-toluyl chloride, p-fluorobenzoyl chloride and 3',5'-dimethylbenzoyl chloride to obtain the corre20 sponding 21-benzoate or substituted benzoate ester, i.e. the 21-benzoate, 21-p-toluate, 21-p-fluorobenzoate, and 21-(31,5'-dimethylbenzoate) of each of the l6a-methyl1,4,6-pregnatriene-llB,17a,21-triol-3,20-dione 17-monoester starting compounds. - 46 45950 PREPARATION 4 THE 17-ESTERS, 21-ESTERS, AND 17,21-DIESTERS OF 16g-METHYL-1,4,6-PREGNATRIENE110,17a,21-TRIOL-5,20-DIONE AND OF l6a5 METHYL-1,4,6-PREGNATRIENE-17a,21-DIOL3,11,20-TRIQNE AND THE l6g-METHYL EPIMERS THEREOF l6g-Methyl-l,4,6-pregnatriene-llg,17a>21-triol-3,20dione 21-acetate is prepared from l6g-methyl-l,4-pregna10 diene-110,17a,21-triol-3,20-dione 21-acetate by the procedure of Preparation 1A and is put through the sequence of reactions of Preparations 1-3 to produce the l6g-methyl epimers of the l6a-methyl products described therein. (2) Similarly, l6a-methyl-l,4,6-pregnatriene-17a,21-diol15 3,11,20-trione 21-acetate is prepared from l6a-methyl-l,4pregnadiene-17a,21-diol-3,H,20-trione 21-acetate by the procedure of Preparation 1A and is put through the sequence of reactions described in Preparations 1-3 to produce ll-oxo-l6a-methyl pregnatriene derivatives corresponding to the llg-hydroxy-l6a-methyl pregnatriene products named therein. (3) l6g-Methyl-1,4,6-pregnatriene-17a,21-diol-3,11,20trione 21-acetate is prepared from l6g-methyl-l,4-pregnadiene-17a,21- diol-3,11,20-trione 21-acetate by the pro- 47 45950 eedure of Preparation 1A and is put through the sequence of reactions of Preparations 1-3 to produce the 11-oxol6g-methyl pregnatriene derivatives corresponding to the HiS-hydroxy-l6a-methyl-pregnatriene products named there in.
PREPARATION 5 ALTERNATIVE PROCEDURE FOR PREPARING 1.4.6-FREGNATHIENE-17a,21-DI0L-3,11,20TRIONES and 17,21-DIESTERS THEREOF A. 6g-Bromo-l6ot-Methyl-l.4-pregnadiene-17a.21-diol-3.11. -trione 21-acetate To a solution of l6a-methyl-l,4-pregnadiene-17aj21-diol3,11,20-trione 21-acetate (11 gms.) in carbon tetrachloride (110 ml.) and chlorobenzene (110 ml.) at reflux temperature, add N-bromosuccinimide (7 gms.) followed by azobisisobutyronitrile (530 mg.). Heat at reflux temperature for 30 minutes, cool, and add with stirring 300 ml. of a 10% aqueous sodium bisulfite solution.
Add chloroform (150 ml.), separate the organic layer, wash it with water and dry it over anhydrous magnesium sulfate. Evaporate in vacuo to a residue comprising 6p-bromo-l6a-methyl-l,4-pregnadiene-17 a,21-diol-3,11,20trione 21-acetate. - 48 4sg so B. l6a-Methyl-l,4,6-pregnatriene-17a,21-diol-3,11,20trione 21-acetate To a solution of 6|3-bromo-l6a-methyl-l,4-pregnadiene~ 17a,21-diol-3,ll,20-trione 21-acetate (from Preparation 5A) in dimethylacetamide (125 ml.) add lithium bromide (4.4 gms.) and calcium carbonate (7.75 gms.). Heat the reaction mixture at 120°C. under an atmosphere of nitrogen for 1 hour. Cool, filter and dilute the filtrate with chloroform (500 ml.). Wash the chloroform solution with water, dry it over magnesium sulfate and evaporate it to a residue comprising l6a-methyl-l,4,6pregnatriene-17a,21-diol-3,ll,20-trione 21-acetate.
C. l6a-Methyl-l,4,6-pregnatriene-17a,21-diol-3,11,20trione is prepared from l6a-methyl-l,4,6-pregnatriene15 17a,21-diol-3,ll,20-trione 21-acetate by hydrolysis with aqueous sodium bicarbonate in methanol by the method of Preparation IB.
D. l6a-Methyl-l,4,6-pregnatriene-17 a,21-diol-3 >11»20trione 17,21-dialkanoates (1) Stir at room temperature for 1 hour a solution of trifluoroacetic anhydride (8 ml.), propionic acid (200 ml.) and toluene-g-sulfonic acid monohydrate (200 mg.), then add l6a-methy1-1,4,6-pregnatriene-17 a,21-diol-3,11,20trione (2 gms.). Stir the reaction mixture for 17 - 49 45980 hours, then add an additional 6 ml. of trifluoroacetic anhydride. Continue stirring for 5 hours, then pour into 400 ml. 0.5N sodium hydroxide. Extract the aqueous mixture with chloroform, wash the combined chloroform extracts with water, dry over magnesium sulfate and evaporate in vacuo. Dissolve the resultant residue in methanol and steam distil to remove volatile impurities.
Decant the water from the residue of the distillation and dry the residue to obtain l6a-methyl-l,4,6-pregnatriene10 17a,21-diol-3,ll,20-trione 17,21-dipropionate. (2) In the above procedure, by substituting for propionic acid equivalent quantities of other alkanoic acids, e.g. acetic acid, valeric acid and n-butyric acid there is obtained the corresponding 17,21-dialkanoate, e.g. the 17,21-diacetate, 17,21-divalerate, and 17,21-dibutyrate of l6a-mefchyl-l,4,6-pregnatriene-17a,21-diol-3,11,20trione.
PREPARATION 6 l6ot, 17«-IS0PR0PYLIDENEDI0XY-l,4,6-PREG20 NATRIENE-ΤΙβ,21-DIOL-3,20-DIONE 21 ACETATE (1) l6a,17a-Isopropylidenedioxy-1,4-pregnadiene-ll(3,21diol-3,20-dione 21-acetate is prepared from Ι6α,17αisopropylidenedioxy-1,4-pregnadiene-110,21-diol-3,20dione and acetic anhydride in pyridine by the method of Preparation 3A. - 50 4885ο (2) l6 PREPARATION 7 21-HALO-l,4,6-PREGNATRIENE-llg,17«-DIOL3,20-DIONE 17-HYDROCARBONGARBOXYLATES A, 21-Halo-l,4-pregnadiene-llg-17«-diol-3,20-dione 17-hydrocarboncarboxylates (1) l6«-Methyl-21-chloro-l,4-pregnadiene-llg,17a-diol3,20-dione 17-propionate To a solution of l6a-methyl-l,4-pregnadiene-llg,17«>21triol-3,20-dione 17,21-n-butylorthopropionate (Ο.87 gm.) in chlorofrom (87 ml.) add trimethylsilyl chloride (I.15 ml.) and reflux for 24 hours. Evaporate the reaction mixture in vacuo and place the resultant residue on a silica gel column (80 gms.), eluting with chloroform: ethyl acetate (2:1). Evaporate the combined eluates to a residue comprising l6a-methyl-21-chloro-l,4-pregnadiene110 ,17a-diol~3,20-dione 17-propionate. - 51 4 58 50 (2) l6g-Methy1-21-bromo-l,4-pregnadiene-llg,17α-diol5,20-dione 17-propionate In the above procedure, by using trimethylsilyl bromide as reagent, the corresponding 21-bromo derivative, 16a5 methyl-21-bromo-l,4-pregnadiene-llg,17 a-diol-3,20-dione 17-propionate, is obtained. (3) Treat each of the following with trimethylsilyl chloride in the manner described in Preparation 7A(1): l6a-methyl-l,4-pregnadiene-llg,17a,21-triol-3,20-dione 17,21-ethylorthoacetate, l6a-methyl-l,4-pregnadiene-llg, 17a,21-triol~3,20-dione 17,21-ethylortho-n-butyrate, l6a-methy1-1,4-pregnadiene-llg,17 a,21-triol-3,20-dione 17,21-n-butylorthovalerate, and l6a-methyl-l,4-pregnadiene-llg,17a,21-triol-3,20-dione 17, 21-methylorthobenzoate. Isolate and purify each of the resultant products in a manner similar to that described to obtain, respect ively, l6a-methyl-21-chloro-l,4-pregnadiene-llg,17 a-diol3,20-dione 17-acetate, l6a-methyl-21-chlor0-1,4-pregnadiene-llg, 17 a-diol-3» 20-dione 17-n-butyrate, l6a-methyl2o 21-chloro-l,4-pregnadiene-llg,17a-diol-3,20-dione 17“ valerate, and l6a-methyl-21-chloro-l,4-pregnadiene-llg, 17a-diol-3,20-dione 17“benzoate.
In the above procedure, by using trimethylsilyl bromide as reagent, the 21-bromo derivatives corresponding to ye, each of the 21-ehloro derivatives are obtained. - 52 45950 (4) In the procedures of Preparations 7A(1) - 7A(3), by using as starting steroids the 160-methyl epimers of the l6n-methyl compounds named therein, the corresponding l6B-methyl epimers of the 21-halo-pregna5 diene products named therein are obtained. Similarly, by starting with derivatives having an 11-oxo function instead of an llfS-hydroxyl function, there are obtained the corresponding 21-halo derivatives containing an 11-oxo function.
B. l6a-Methyl-21-halo-l,4,6-pregnatriene-ll(3,17a-diol3,20-dione 17-alkanoate (1) l6a-Methyl-21-halo-l,4,6-pregnatriene-110,17a-diol3,20-dione 17-propionate l6a~Methyl-21-chloro-l,4,6-pregnatriene-llB,17 a-diol-3,2015 dione 17-propionate and l6a-methyl-21-bromo-l,4,6-pregnatriene-llB,17a-diol-3,20-dione 17-propionate are prepared from l6a-methyl-21-chloro-l,4-pregnadiene-llP,17a-diol3,20-dione 17-propionate and l6a-methyl-21-brorao- 1,4-PregnadieneΠβ-17α - diol-3,20-dione 17-pr*opionate respectively, DDQ and dry hydrogen chloride in dioxan by the method of Preparation 1A. (2) Similarly treat the 21-halo-l,4-pregnadienes of Preparation 7A(3) and 7A(4) with DDQ and dry hydrogen chloride in dioxan to obtain the corresponding 21-halo-l,4,6- 53 4S950 pregnatrienes. (3) l6a-Methyl-21-fluoro-1,4,6-pregnatriene-llj3,17a-diol 3,20-dione 17-propionate l6a-Methyl-l, 4,6-pregnatriene-110, 17 a, 21 -triol -3,20-dione 5 17-propionate 21-methanesulfonate is prepared from 16amethyl-1,4,6-pregnatriene-llp,17a,21-triol-3,20-dione 17-propionate and methanesulfonyl chloride in pyridine by the method of Preparation 1C, and is then allowed to react with silver fluoride in acetonitrile according to known procedures to yield l6a-methyl-21-fluoro-l,4,6pregnatriene-110,17 a-diol-3,20-dione 17-propionate.
PREPARATION 8 1,4,6-PREGNATRIENE-11P,17 a-DIOL3,20-DTQNE 17-HYDROCARBONCARBOXYLATES A. l,4-Pregnadiene-lH1,17a-diol-3,20-dione 17-hydrocarboncarboxylates (1) To 1,4-pregnadiene-llB,17a,21-triol-3,20-dione 17,21 ethylorthopropionate (4 gms.) in methylene chloride (100 ml.), under an atmosphere of nitrogen at 0°C. add trimethylsilyl iodide (3.68 ml.) and, after 1 minute, pour the reaction mixture into IN sodium thiosulfate solution (300 ml.) with efficient stirring. Extract the - 54 45950 reaction mixture with methylene chloride, wash it with water, dry it over magnesium sulfate and evaporate it to a residue, which is then purified on a column of silica gel (300 gms.) by elution with chloroform:ethyl acetate (4:1) to yield 1,4-pregnadiene-llg,17a-diol-3,20-dione 17-propionate. (2) In similar manner, treat each of 1,4-pregnadiene110,17a,21-triol-3,20-dione 17,21-ethylortho-n-butyrate, 1,4-pregnadiene-llg,17 a,21-triol-3,20-dione 17,21-n-butyl10 orthovalerate, l,4~pregnadiene-110,17a,21-triol-3,20dione 17,21-ethylorthoacetate, and 1,4-pregnadiene-llg, 17a,21-triol-3,20-dione 17,21-methylorthobenzoate with trimethylsilyl iodide followed by the immediate isolation of the resultant product to obtain, respectively, the 17-n-butyrate, the 17-valerate, the 17-acetate, and the 17-benzoate of l,4-pregnadiene-llg,17a-diol-3,20dione.
B. 1,4,6-Pregnatriene-llg,17a-diol-3,20-dione 17-hydrocarboncarboxylates In a manner similar to that described in Preparation 1A, treat each of the 1,4-pregnadiene 17-ester products of Preparation 8A with DDQ and hydrogen chloride in dioxan to obtain, respectively, 1,4,6-pregnatriene-llg,17adiol-3,20-dione 17 propionate, 1,4,6-pregnatriene-llg, - 55 45950 17a-diol-3,20-dione 17-n-butyrate, 1,4,6-pregnatriene11β,17α-άϊο1-3,20-dione 17-valerate, 1,4,6-pregnatriene11β,17a-diol-3,20-dione 17-acetate and 1,4,6-pregnatriene11(3,17 a-diol-3,20-dione 17-benzoate.
PREPARATION 9 16-METHYLENE-1.4,6-PREGNATRIENE-llB.17a.21-TRI0L3,20-DIONE 21-HYDROCARBONCARBOXYLATES AND 17,21DIHYDROCARBONOARBOXYLATES A. 16-Methylene-l,4-pregnadiene-110,17a,21-triol-3,2010 dione 21-hydrocarboncarboxylates (1) l6-Methylene-l,4-pregnadiene-110,17a,21-triol-3,20dione 21-propionate is prepared from l6-methylene-l,4pregnadiene-ΙΙβ,17a,21-triol-3,20-dione (5 gms.) and propionic anhydride (10 ml.) in pyridine (100 ml.) by the method of Preparation 3A(1). (2) In the above procedure, by using other alkanoic anhydrides in place of propionic anhydride, e.g. acetic anhydride, n-butyric anhydride, and valeric anhydride, there is obtained the corresponding 21-lower alkanoate 20 ester, e.g. the 21-acetate, 21-n-butyrate, and 21-valerate of l6-methylene-l,4-pregnadiene-llB,17a,21-triol3,20-dione. (3) 16-Methylene-l,4-pregnadiene-llB,17a,21-triol-3,20- 56 45050 dione 21-benzoate is prepared from l6-methylene-l,4pregnadiene-110,17a,21-triol-3,20-dione and benzoyl chloride in pyridine by the method of Preparation 1C.
B. l6-Methylene-l,4-pregnadiene-llg,17a> 21-triol-3,205 dione 11-trifluoroacetate 21-propionate (1) To a solution of l6-methylene-l,4-pregnadiene-HB, 17a,21-triol-3,20-dione 21-propionate (1 gm.) in pyridine (10 ml.) at -23°C., add trifluoroacetic anhydride (1 ml.) precooled to -23°C. Allow the reaction mixture to stand at -23°C. for 40 minutes, then pour it into ice water (200 ml.) containing concentrated hydrochloric acid (8.8 ml.). Separate the resultant precipitate by filtration, wash it with water and dry it to give l6-methylene-l,4-pregnadiene-110,17a,21-triol-3,20-dione 11-trifluoroacetate 21-propionate. (2) The 21-hydrocarboncarboxylates prepared in Preparation 9A(2) and (3) may be similarly converted into their ll-trifluoroacetates.
C. 16-Methylene-l,4-pregnadiene-ΙΙβ,17a,21-triol~3,2020 dione 11-trifluoroacetate 17,21-dihydrocarboncarboxylates To a solution of 16-methylene-l,4-pregnadiene-lip,17a,21- 57 triol-3,20-dione 11-trifluoroacetate 21-propionate (1.07 gm.) in propionic acid (10 ml.) containing toluene-psulfonic acid monohydrate (0.1 gm.) at 0°C. add trifluoroacetic anhydride (4 ml.) dropwise. Allow the re5 action mixture to stand at 0°C. for 5 minutes, then to warm to room temperature and to remain at room temperature for 3 hours. Pour the reaction mixture into water, extract the aqueous mixture with ethyl acetate, wash the combined organic extracts with 5/ sodium hydroxide and then with water, dry them over magnesium sulfate and evaporate them to a residue comprising l6-methylene-l,4-pregnadiene-110,17a,21-triol~3,20-dione 11-trifluoroacetate 17,21-dipropionate. (2) In similar manner, treat each of the 11-trifl'uoro15 acetate esters prepared in Preparation 9B(2) in the manner described above to obtain the corresponding 17-propionate ester, i.e. the 17-propionate 21-acetate, the 17-propionate 21-n-butyrate, the 17-propionate 21-valerate and the 17-propionate 21-benzoate of l6-methylene-l,4-pregnadiene20 110,17a,21-triol-3,20-dione 11-trifluoroacetate. (3) In the procedure of Preparation 9C(1), by substituting for propionic acid other hydrocarboncarboxylic acids, e.g. n-butyric acid and acetic acid, l6-methylene-l,4-pregnadiene-110,17a,21-triol-3,20-dione 11-trifluoroacetate 17-n-butyrate 21-propionate and 16-methylene-l,4-pregnadiene-110,17 a,21-triol-3,20-dione 11-trifluoroacetate - 58 4saso 17-aeetate 21-propionate respectively are obtained. (4) The products of Preparation 9B(2) may be converted into their 17-n-butyrates and 17-acetates by the method of Preparation 9C(3).
D· 16-Methylene-l,4,6-pregnatriene-llg,17a,21-triol-3,20dione 11-trifluoroacetate 17,21-dihydrocarbonearboxylates (1) 16-Methylene-l,4,6-pregnatriene-110,17a,21-triol3,20-dione 11-trifluoroacetate 17,21-dipropionate is pre10 pared from l6-methylene-l,4-pregnadiene-llf3,17a,21-triol3,20-dione 11-trifluoroacetate 17,21-dipropionate, dry hydrogen chloride and DDQ in dioxan by the method of Preparation 1A. (2) In similar manner, treat the products of Preparations 90(2)-(4) with DDQ and dry hydrogen chloride in dioxan to obtain their corresponding 6-dehydro derivatives.
E. 16-Methylene-l,4,6-pregnatriene-llg,17 a,21-triol~3,20dione 17,21-dipropionate (1) To a solution of l6-methylene-l,4,6-pregnatriene-110, 17a,21-triol-3,20-dione 11-trifluoroacetate 17,21-dipropionate (Ο.52 gm.) in methanol (26 ml.) add sodium benzoate - 59 45990 (1.5 gm.) and stir at room temperature for 2 1/2 hours. Evaporate the solution in vacuo at room temperature and wash the resultant residue thoroughly with water. Separate the solids by filtration and dry to obtain 16-methylene-l,4,6-pregnatriene-llB,17a, 21-triol-3,20-dione 17,21dipropionate. Additional product is obtained by extracting the combined water washes and filtrate with ethyl acetate, washing the organic extract with water, drying it over magnesium sulfate and evaporating it to obtain a residue of 16-methylene-l,4,6-pregnatriene-llB, 17a,21-triol-3,20-dione 17,21-dipropionate. (2) Similarly treat the 11-trifluoroacetate products of Preparation 9D(2) in methanol with sodium benzoate to obtain the corresponding 11β-hydroxy derivatives.
PREPARATION 10 16-METHYLENE-1,4,6-PREGNATRIENE-17 a,21-DIOL3,11,20-TRI0NE 17,21-DIHYDROCARBONCARBOXYLATES A. 16-Methylene-l,4-pregnadiene-17 a > 21-diol-3,11,20-trione 17,21-alkylorthohydrocarboncarboxylates (1) l6-Methylene-l,4-pregnadiene-17a,21-diol-3,11,20trione 17,21-methylorthobenzoate is prepared from l6-methylene-l,4-pregnadiene-17a,21-diol-3,11,20-trione and tri· methylorthobenzoate with pyridinium toluene-p-sulfonate - 60 45950 in dioxan and benzene by the method of Preparation 2C(1). (2) In a manner similar to that described in Preparation 2A(2), treat l6-methylene-l,4-pregnadiene-17a,21-diol-3, 11,20-trione in dimethylsulfoxide in the presence of toluene-£-sulfonic acid with each of triethylorthopropionate, triethylortho-n-butyrate, and tri-n-butylorthovalerate, to obtain the corresponding 17,21-alkylorthoalkanoate, i.e. the 17,21-ethylorthopropionate, 17,21-ethylorthon-butyrate and 17,21-n-butylorthovalerate, respectively, of 16-methylene-l,4-pregnadiene-17 a,21-diol-3,11,20-trione.
B. 16-Methylene-l,4-pregnadiene-17a,21-diol-3,11,20-trione 17-hydrocarboncarboxylates (1) Dissolve l6-methylene-l,4-pregnadiene-17a,21-diol3,11,20-trione 17,21-methylorthobenzoate (2 gms.) in glacial acetic acid (15 ml.) and water (0.3 ml.). Allow to stand at room temperature for 20 minutes, then pour into water (300 ml.) and add an 8% sodium hydroxide solution (50 ml.). Separate the resultant precipitate by filtration, wash it with water and dry it at room temperature. Isolate the desired compound by preparative thin layer chromatography on silica gel using ethyl acetate: chloroform (1:1) as developing solvent. Remove the most polar band as visualized by ultraviolet light and elute with ethyl acetate. Evaporate to a residue comprising l6-methylene-l,4-pregnadiene-17 a,21-diol-3,11,20- 61 45950 trione 17-benzoate. (2) Treat each of the 17,21-alkylorthoalkanoates of Preparation 10A(2) with aqueous acetic acid in the manner described above to obtain, respectively, the 17-pro5 pionate, 17-n-butyrate, and the 17-valerate of 16-methylene-1,4-pregnadiene-17a,21-diol-3,11,20-trione.
C. 16-Methvlene-l.4-pregnadiene-17 a,21-diol-3.11.20-trione 17,21-dihydrocarboncarboxylates (1) Treat each of the l6-methylene-l,4-pregnadiene-17a,2110 diol-3,11,20-trione 17-hydrocarboncarboxylates of Preparation 10B with benzoyl chloride in pyridine by the procedure of Preparation 1C to obtain, respectively, the 17a,21-dibenzoate, the 17-propionate 21-benzoate, the 17-n-butyrate 21-benzoate and the 17-valerate 21-benzoate of l6-methylene-l,4-pregnadiene-17a,21-diol-3,11,20-trione. (2) In a manner similar to that described in Preparation 3A(1), treat each of the 17-hydrocarboncarboxylates of 16-methylene-l,4-pregnadiene-17 a,21-diol-3,11,20-trione of Preparation 10B in pyridine with propionic anhydride to obtain, respectively, the 17-benzoate 21-propionate, the 17,21-dipropionate, the 17-n-butyrate 21-propionate, and the 17-valerate 21-propionate of 16-methylene-l,4pregnadiene-17a,21-diol-3,ll,20-trione. - 62 45050 D. l6-Methylene-1,4,6-pregnatriene-17a,21-diol-3,11,20trione 17,21-dihydroearbonearboxylates In a manner similar to that described in Preparation 1A, treat each of the l6-methylene-l,4-pregnadienes prepared in Example 10C with dry hydrogen chloride and DDQ in dioxan, and isolate and purify each of the respective products to obtain the corresponding 1,4,6-pregnatrienes, i.e. the 17-benzoate 21-propionate, 17-benzoate 21-n-butyrate, 17-benzoate 21-valerate, 17-propionate 21-butyrate, 17,21-dipropionate, 17-n-butyrate 21-propionate, and 17valerate 21-propionate.
PREPARATION 11 70-HYDROXY-l,4-PRESNADIENE-5,20-DI0NES A. 9a-Fluoro-l6a-methyl-l,4-pregnadiene-70,llB,17a>21tetrol-5,20-dione 21-acetate (1) 9a-Fluoro-l6a-methyl-l,4-pregnadiene-6p,70,11β,17α, 21-pentol-3,20-dione 21-acetate To 9«-fluoro-l6a-methy1-1,4,6-pregnatriene-110,17a,21-triol -3,20 dione 21-acetate (8.3 gms.) in dioxan (350 ml.) and pyridine (5 ml.) add osmium tetroxide (4.9 gms.). Stir the reaction mixture at room temperature for 5 days, then saturate the solution with hydrogen sulfide and filter the reaction solution through*Celite. Evaporate the filtrate *Celite is a Trade Mark - 63 45060 in vacuo at room temperature, triturate the resultant residue with chloroform:methanol and separate the resultant precipitate by filtration to obtain 9a-fluoro-l6a-methyl1,4-pregnadiene-60,70,110,17a,21-pentol-3,20-dione 215 acetate. (2) 9 a-Fluoro-16 a-methyl-1,4-pregnadiene-60,70,IIP,17a,21pentol-3,20-dione 6,7-n-butylorthopropionate 21-acetate To 9a-fluoro-l6a-methyl-l,4-pregnadiene-60,70,110,17a,21pentol-3,20-dione 21-acetate (3 gms.) in dimethylsulfoxide (15 ml.) add tri-n-butylorthopropionate (5.4 ml.) and toluene-£-sulfonic acid monohydrate (0.225 gm.) and stir at room temperature for 3-5 hours. Pour the reaction mixture into water (500 ml.) and saturated aqueous sodium bicarbonate (100 ml.). Extract the aqueous mixture with ethyl acetate, wash the combined extracts with water, dry over magnesium sulfate and evaporate to a residue comprising 9a-fluoro-l6a-methyl-l,4-pregnadiene-60,70,110,17a, 21-pentol-3,20-dione 6,7-n-butylorthopropionate 21-acetate. (3) 9a-Fluoro-l6a-methyl-l34-pregnadiene-60,70,110,17a,2120 pentol-3,20-dione 6-propionate 21-acetate Dissolve the product of Preparation 11A(2) in glacial acetic acid (50 ml.) and water (1 ml.). Allow the reaction mixture to stand at room temperature for 1 hour, then pour it into ice water (500 ml.) and separate the 4S950 resultant precipitate by filtration. Wash the precipitate with water and dry at room temperature to give 9a-fluoro-l6a-methyl-l,4-pregnadiene-60,78,110,17a,21pentol — 3,20-dione 6-propionate 21-acetate. (4) 9a-Fluoro-l6a-methyl-l,4-pregnadiene-70,110,17a,21tetrol-3,20-dione 21-acetate To 9a-fluoro-l6a-methyl-l,4-pregnadiene-60,70,110,17a,21pentol-3,20-dione 6-propionate 21-acetate (3 gms.) in acetone (750 ml.) add a solution of sodium acetate (21 gms.), water (60 ml.) and acetic acid (15 ml.) followed by chromous acetate sludge (freshly prepared from 70 gms. of chromic chloride reduced by zinc amalgam followed by treatment with sodium acetate according to known procedures). Stir the reaction mixture at room temperature for 2 1/2 hours, filter and evaporate. Add water to the resultant residue, extract with ethyl acetate, wash the combined organic extracts with water, dry and evaporate in vacuo to a residue comprising 9a-fluorol6a-methyl-l,4-pregnadiene-70,110,17a,21-tetrol-3,20-dione 21 acetate. Purify by recrystallization from acetone:he26 xane; m.p. 181-185°C·; [α]β +48.7° (dimethylformamide).
B. Treat each of 9a-chloro-l6a-methyl-l,4,6-pregnatriene~ 110,17a,21-triol-3,20-dione 21-acetate, 9a-bromo-l6amethyl-1,4,6-pregnatriene-110,17 a,21-triol-3,20-dione 21-acetate and l6a-methyl-l,4,6-pregnatriene-110,17a,21- 65 459S0 triol-3,20-dione 21-acetate in a manner similar to that of Preparation 11A to obtain, respectively, 9a-chloroΙδα-methyl-l,4-pregnadiene-7 β,11β,17«,21-tetrol-J,20dione 21-acetate, 9a-bromo-l6a-methyl-l,4-pregnadiene5 7β,11β,17«,21-tetrol-3,20-dione 21-acetate and l6a-methyl l,4-pregnadiene-7B,11β,17a,21-tetrol-3,20-dione 21-acetate.
C. (1) Similarly, by treating according to the procedures of Preparation 11A the pregnatrienes prepared in Pre10 parations 1-8, the corresponding 7B-hydroxy-1,4-pregnadienes are obtained. (2) Similarly, by treating according to the procedure of Preparation 11A the corresponding 9a-fluoro-, 9a-chloro-, and 9a-bromo-derivatives of the 9-unsubstituted-l,4,615 pregnatrienes prepared in Preparations 1-8, the corresponding 7B-hydroxy-9a-fluoro-l,4-pregnadienes are obtained.
D. 7β-Hydroxy-16-methylene-1,4-pregnadienes (1) l6B-Methyl-l6a,17a- epoxy -1,4-pregnadiene-6B,7β,11β,21 tetrol-g,20-dione 21-acetate is prepared from l6B-methyl16a,17a·- epoxy-1,4,6-pregnatriene-llB,21-diol-3,20-dione 21-acetate and osmium tetroxide in dioxan and - 66 45850 pyridine by the method of Preparation 11A. (2) l6-Methylene-l,4-pregnadiene-6g ,7P .HP ,17a.21-pentol5,20-dione 21-acetate To a solution of l6g-methyl-l6ajl7a-epoxy -1,4-pregnadi5 ene-6gj7g,llgj21-tetrol 21-acetate (100 mg.) and toluene£-sulfonic acid (10 mg.) in acetic acid (1 ml.) at 5°C. add trifluoroacetie anhydride (0.1 ml.). Allow the reaction mixture to stand at room temperature for 25 minutes, then pour into water and collect by filtration 16-methylene-l,4-pregnadiene-6g, 7(3,11(3,17 a,21-pentol3,20-dione 21-acetate. (3) l6-Methylene-l,4-pregnadiene-7g,llg,17«,21-tetrol3,20-dione 21-acetate is prepared from l6-methylene-l,4pregnadiene-6g,7P,Hg,17a,21-pentol-3,20-dione 21-acetate by procedures similar to those of Preparations 11A(2), (3) and (4). (4) In similar manner, treat each of l6g-methyl-l6a,17aepoxy -1,4,6-pregnatrien —21-ol-3,11,20-trione 21-acetate, its 9a-fluoro and 9a-chloro derivatives, 9a-fluoro-l6g20 methyl-l6a,17a- epbxy -1,4,6-pregnatriene-llfi ,21-diol-3,20dione 21-acetate and l6(3-methyl-l6a,17a-epoxy -9a-chloro1,4,6-pregnatriene-llB,21-diol-3,20-dione 21-acetate in a manner similar to that of Preparations 110(1)-(3) to obtain, - 67 4SSS0 respectively, 16-methylene-l,4-pregnadiene-7(3,17a,21-triol 3,11,20-trione 21-acetate, its 9a-fluoro- and 9«-chloroderivatives, 9a-fluoro-l6-methylene-l,4-pregnadiene-7P,HP 17a,21-tetrol-3,20-dione 21-acetate and 9a-chloro-l6-me5 thylene-l,4-pregnadiene-73,11β,17«,21-tetrol-3,20-dione 21-acetate.
PREPARATION 12 ll-OXYGENATED-4,6-PREGNADIENE-17a,21DIOL-3,2O-DIONES AND ESTERS THEREOF In the procedures of Preparations 1 and 4, by using as starting compounds the 1,2-dihydro derivatives of the 1,4-pregnadienes named therein, there are obtained 1,2dihydro-4,6-pregnadienes corresponding to the 1,4,6-pregna trienes of Preparations 1 and 4 which, when put through the procedures of Preparations 2, 3, and 9, will produce 4,6-pregnadienes corresponding to the 1,4,6-pregnatrienes named therein.
The following Examples illustrate the invention but do not limit it: - 68 45950 EXAMPLE 1 7a-CHL0R0-l6a-METK7L-l,4-PREGNADIENE110,17a,21-TRI0L-3,20-DIONE 17,21-DIPROPIONATE A. Add l6a-methyl-l,4,6-pregnatriene-110,17a,21-triol3,20-dione 17,21-dipropionate (2.0 gms.) to dioxan (24 ml.) whioh has been saturated with dry hydrogen chloride gas. Stir at room temperature for 16 hours, pour into ice water (600 ml.), separate the resultant precipitate by filtration, wash the precipitate with water and dry it in air. Separate the components in this precipitate on silica gel by thin layer chromatography using as developing solvent ether:hexane (2:1), and elute with ethyl acetate the band containing 7a-chloro-l6a-methyl1.4- pregnadiene-lig,17a,21-triol-3,20-dione 17,21-dipropionate as shown by ultraviolet light. Evaporate the combined ethyl acetate eluates and triturate the resultant residue with acetone:ether, then filter off and dry the triturated precipitate to obtain 7a-chloro-l6a-methyl1.4- pregnadiene-110,17a,21-triol-3,20-dione 17,21-dipropionate.
Alternatively, the compound of this Example is prepared according to following procedures IB and 1C.
B. 7«-Chloro-l6a-methyl-l,4-pregnadiene-17a,21-diol-3, 11,20-trione 17,21-dipropionate - 69 46980 Saturate dry tetrahydrofuran (137 ml.) at 0°C. with dry hydrogen chloride gas. Add l6a-methyl-l,4,6-pregnatriene-17 a,21-diol-3,11,20-trione 17,21-dipropionate (6.85 gms.) and stir the reaction mixture at 0°C. for 1 hour. Pour into ice water (1 liter) and stir for 1/2 hour. Separate the resultant precipitate by filtration, wash it with water, and dry it in air to give 7a-chloroI6a-methyl-l,4-pregnadiene-17a,21-diol-3,11,20-trione 17,21-dipropionate. Purify by recrystallisation from methanol:acetone containing a trace of propylene oxide; [a] + 76.2° (dimethylformamide); [M]+ 520, 518; m.p.
. MeOH 18O-183°C.; 238 nm (C =15,800). max C. To a solution of 7a-chloro-l6a-methyl-l,4-pregnadiene17a,21-diol-3,11,20-trione 17,21-dipropionate (3.2 gms.) in tetrahydrofuran (24 ml.) and methanol (8 ml.) at 0°C. under an atmosphere of nitrogen add sodium borohydride (Ο.697 gm.) and stir the reaction mixture for 15 minutes at 0°C. Pour into ice water (1.8 liters) and 250 ml. of IN hydrochloric acid. Filter off the resultant pre20 cipitate and dry it in air to give 7a-chloro-l6a-methyl-l ,4-pregna diene 110,17a,21-triol-3,20-dione 17,21-dipropionate. Purify it by recrystallization twice from acetoneimethanol:iso26 propyl ether; m.p. 212-216 C.; [α]^ + 42.6° (dimethylformamide); [M]+522, 520; λ m®*hano1 242 nm(£ 15,600); 1743, 1730, 1720, 1652, 1610, 1595 cm1; nmr ΤΠ2.Χ (dmso-dg) £ 0.84 (C.g-CHj, d J7Hz), 1.02 (C^-CHj, s), 1.42 (C10-CH3, s), 4.38 (lla-H, mult.), 4.67 (70-H, mult), *Nujol is a trade nark - 70 45950 4.80 (C21-H, s), 5-95 (Cjj-Hj s), 6.20 (C2-H, dd J10,2Hz), 7.35 (^-H, d JlOHz).
EXAMPLE 2 g-BROMO-l6«-METHYL-l,4-PREGNADIENE5 110,17a,21-TRIOL-3,20-DIONE 17,21-DIPROPIONATE A. Add l6a-methyl-l,4,6-pregnatriene-110,17a,21-triol3,20-dione 17,21-dipropionate (0.29 gm.) to a solution of 30& (w/v) dry hydrogen bromide in acetic acid (4 ml.) precooled to 0°C. Stir the reaction mixture at 0°C. for 1 hour, pour into ice water, separate the resultant solids by filtration, and wash the precipitate with water and dry it. Purify it by trituration with acetone:ether; dry the triturated precipitate to obtain 7a-bromo-l6«-methyl1,4-pregnadiene-llfi ,17 a,21-triol~3,20-dione 17,21-dipro15 pionate (0.19 gm.).
Alternatively, the compound of this example is prepared according to following procedures 2B and 2C.
B. 7 a-Bromo-l6a-i.iethyl-l, 4-pregnadiene-17 a, 21-diol-3,11, -trione 17,21-dipropionate To a solution of l6a-methyl-l,4,6-pregnatriene-17a,21diol-3,11,20-trione 17,21-dipropionate (0.5 gm.) in glacial acetic acid (2 ml.), at 0°C. add a freshly prepared 4S980 solution of dry hydrogen bromide gas (3 gms.) in glacial acetic acid (8 ml.) at 0°C. Stir the reaction mixture for 1 hour at 0°C., pour it into ice water (400 ml.), stir for 30 minutes, filter off the resultant precipitate and wash it with water until the water washings are neutral.
Dry it in air to obtain 7a-bromo-l6a-methyl-l,4-pregnadiene-17 a,21-diol-3,11,20-trione 17,21-dipropionate 26 (0.51 gms.); [a]_ + 105.1 (dimethylformamide), . MeOH U A 238 nm (C = 15,400).
C. To a mixture of 7a-bromo-l6a-methyl-l,4-pregnadi'ene17a,21-diol-3,11,20-trione 17,21-dipropionate (2.84 gms.) and sodium borohydride (0.573 gm.) under an atmosphere of nitrogen at 0°C. add methanol (8 ml.) precooled to 0°C. and stir the reaction mixture for 5 minutes at 0°C. Pour the reaction mixture into ice water (2 liters) and IN hydrochloric acid (300 ml.), filter off the resultant precipitate and wash it with water. Dry it in air to obtain 7 a-bromo-l6a-methyl-l,4-pregnadiene-HP,17 a,21-triol3,20-dione 17,21-dipropionate (2.6 gms.). Purify by recrystallization from acetone:ether:hexane; 1.44 gm.; m.p. ^295°C.; [aL· +37-3° (dimethylformamide); . methanol c Nujol λ max 242 ™ 15,350); Vmax 1745’ 1735’ 1660, 1612, 1600 cm. *; nmr (dmso-dg) S' 0.85 (C^g-CH^, d J7Hz), 1.03 (C13-CH3, s), 1.43 (C1q-CH3, s), 4.38 (lla-H, mult.), 4.75 (7f3-H, mult.), 4.81 (C^-H, s), .86 (C4-H, s), 6.19 (Cg-H, dd J10, 2Hz), 7-31 (0χ-Η, d J10 Hz). - 72 45950 EXAMPLE 3 7«-BR0M0-16a-METHYL-l,4-PREGNAPlENE11β,17α,21-TRI0L-3,20-DIONE 17-BENZOATE 21-ACETATE A. To l6a-methyl-l,4,6-pregnatriene-113,17a,21-triol5 3,20-dione 17-benzoate 21-acetate (0.31 gm.) add a solution of 30% dry hydrogen bromide in glacial acetic acid (6.2 ml.) at 0°C. After 1 hour at 0°C., pour the mixture into ice water, filter off the resultant precipitate, wash it with water and dry it in air. Purify it by thin layer chromatography on silica gel using as developing solvent ether:hexane (2:1) and eluting with ethyl acetate the band containing the desired product as shown by ultraviolet light. Evaporate the combined ethyl acetate eluates to a residue comprising 7a-bromo-l6a-methyl15 l,4-pregnadiene-110,17a,21-triol-3,20-dione 17 benzoate 21-acetate. Further purify the residue by trituration with isopropyl ether (yield 0.125 gm.).
Alternatively, the compound of this example is prepared according to following procedures 3B and 3C.
B. 7a-Bromo-l6a-methyl-l,4-pregnadiene-17a,21-diol3,11,20-trione 17-benzoate 21-acetate To a freshly prepared solution of dry hydrogen bromide gas (9.3 gms.) in glacial acetic acid (16 ml.) at 0°C. - 73 45980 add dropwise a solution of l6a-methyl-l,4,6-pregnatriene17a,21-diol-3,ll,20-trione 17-benzoate 21-acetate (1.56 gm. in glacial acetic acid (5 ml.). Stir the mixture for 1 hour at 0°C., pour into ice water, stir the aqueous mixture for 30 minutes, filter off the resultant precipitate, wash it with water and dry it in air to give 7abromo-l6a-methyl-l,4-pregnadiene-17a,21-diol-3,11,20trione 17-benzoate 21-acetate (1.6 gm.). Further purify by recrystallization from acetone:hexane; m.p. 19026 . methanol 192.5°C.; [a] +77-3° (dimethylformamide); A , max 232 run (C 27,600).
C. 7a~Bromo-l6a-methyl-l,4-pregnadiene-lip,17a,21-triol3,20-dione 17-benzoate 21-acetate (1) To a mixture of 7a-bromo-l6a-methyl-l,4-pregnadiene17a,21-diol-3,ll,20-trione 17-benzoate 21-acetate (1.05 gm.) and sodium borohydride (0.1 gm.) under an atmosphere of nitrogen at 0°C. add a precooled solution of tetrahydrofuran (7·5 ml.) and methanol (2.5 ml.) and stir the reaction mixture for 25 minutes at 0°C. Pour into ice water (500 ml.) and IN hydrochloric acid (100 ml.) Filter off the resultant precipitate, wash it with water and dry it in air to obtain 7a-bromo-l6a-methyl-l,4-pregnadiene-ΙΙβ,17a,21-triol-3,20-dione 17-benzoate 21-acetate (0.53 gm.). Further purify by recrystallization from acetone:hexane:ether; m.p. 156-159°C.; [a]D +21 ^o - 74 45850 methanol „ (dimethylformamide); ,λ ,. 233 nm (C 26,800); nmr Πΐα,Χ (dmso-dg) ? 0.89 (Cl6-CH3, d J7Hz), 1.12 s), 1.48 (Cin-CH,, s) 2.13 (OAc, s), 4.46 (lla-H, mult.), 4.96 (C21-H, quart.), 4.90 (7P-H, mult.), 6.00 (C^-H, s), 6.28 (C2-H, d,d J10,2Hz), 7-39 (C^-H, d, JlOHz), 7.50-8.00 (phenyl, mult.). (2) Alternatively, the compound of this example is prepared as follows. To a mixture of 7a-bromo-l6a-methyl~ 1,4-pregnadiene-17a,21-diol-3,11,20-trione 17-benzoate 21-acetate (Ο.65 gm.) and sodium borohydride (61.7 mg.) under an atmosphere of nitrogen at room temperature add dimethylformamide (6.2 ml.) and water (0.3 ml.). Stir at room temperature under· an atmosphere of nitrogen for 1 hour and pour into a mixture of water (200 ml.) and IN hydrochloric acid (50 ml.). Filter off the resultant precipitate, wash it with water and dry it in air to give 7a-bromo-l6a-methyl-l,4-pregnadiene-llg, 17a,21-triol-3,20-dione 17-benzoate 21-acetate. Further purify by recrystallization from ether:acetone.
EXAMPLE 4 7a-CHL0R0- AND 7a-BR0M0-ll-0X0-l,4PREGNADIENE-17a,21-DIQL-3,20-DI0NES AND ESTERS THEREOF A, 7 a-Chloro-Derivat ives In a manner similar to that described in Example IB treat each of the following ll-oxo-l,4,6-pregnatrienes with dry hydrogen chloride in tetrahydrofuran: the 21-acetate, 21-n-butyrate, 21-isobutyrate, 215 valerate, 21-caprylate, 21-(1'-adamantyl)-carboxylate, 21-(l'-adamantyl)-acetate, 21-benzoate, and 21-g-methoxy benzoate esters of l6a-methyl-l,4,6-pregnatriene-17a,21diol-3,11,20-trione 17-propionate; the 21-acetate, 21-n-butyrate, 21-isobutyrate, 2l-vale10 rate, 21-caprylate, 21-(11-adamantyl)-carboxylate, 21-(1 adamantyl)-acetate, 21-benzoate and 21-p-methoxybenzoate esters of l6a-methyl-l,4,6-pregnatriene-17a,21-diol-3,ll 20-trione 17-n-buyrate; the 21-acetate, 21-n-butyrate, 21-isobutyrate, 21-vale15 rate, 21-caprylate, 21-(11-adamantyl)-carboxylate, 21-(1 adamantyl)-acetate, 21-benzoate and 21-p-methoxybenzoate esters of l6a-methyl-l,4,6-pregnatriene-17a,21-diol-3,ll 20-trione 17-benzoate; l6a-methyl-l,4,6-pregnatriene-17 a,21-diol-3,11,20-trione 20 17,21-diacetate; the 21-acetate, 21-propionate and 21-valerate esters of l6a-methyl-l,4,6-pregnatriene-17a,21-diol-3,11,20-trione 17-valerate; l6a-methyl-l,4,6-pregnatriene-17 a,21-diol~3,11,20-trione 25 17-isobutyrate 21-acetate; - 76 45950 and l6a-methyl-l,4,6-pregnatriene-17a, 21-diol-3,11,20trione 17-dodecanoate 21-propionate; and the Ιόβ-epimers and 16-unsubstitufced analogs of the foregoing and the 16-methylene derivatives corre5 sponding to the foregoing.
Isolate and purify each of the resulting products in a manner similar to that described in Example IB to obtain, respectively, • the 21-acetate, 21-n-butyrate, 21-isobutyrate, 21-vale2Q rate, 21-caprylate, 21-(l'-adamantyl)-carboxylate, 21(1'-adamanty 1)-acetate, 21-benzoate and 21-£-methoxybenzoate esters of 7ot-chloro-l6a-methyl-l,4-pregnadiene17a,21-diol-3,11,20-trione 17-propionate; the 21-acetate, 21-n-butyrate, 21-isobutyrate, 21-vale15 rate, 21-caprylate, 21-(l'-adamantyl)-carboxylate, 21(1'-adamantyl)-acetate, 21-benzoate and 21-g-methoxybenzoate esters of 7«-chloro-l6a-methyl-l,4-pregnadiene17 a,21-diol-3,11,20-trione 17-n-butyrate; the 21-acetate, 21-n-butyrate, 21-isobutyrate, 21-vale20 rate, 21-caprylate, 21-(11-adamantyl)-carboxylate, 21-(1'adamantyl)-acetate, 21-benzoate and 21-p-methoxybenzoate esters of 7a-chloro-l6a-methyl-l,4-pregnadiene-17a,2ldiol-3,11,20-trione 17-benzoate; 7a-chloro-l6a-methyl-l,4-pregnadiene-17a,21-diol-3,11,2025 trione 17,21-diacetate; the 21-acetate, 21-propionate, and 21-valerate esters of 7a-chloro-l6a-methyl-l,4-pregnadiene-17a,21-diol-3,11, 20-trione 17-valerate; a-chloro-l6a-methyl-l,4-pregnadiene-17 a,21-diol-3,11,205 trione 17-isobutyrate 21-acetate; and 7a-chloro-l6a-methyl-l,4-pregnadiene-17a,21-diol-3, 11,20-trione 17-d.odecanoate 21-propionate; and the l6p-epimers and l6-unsubstituted analogs of the foregoing and the 16-methylene derivatives corresponding to the foregoing.
B. 7a-Bromo Derivatives In a manner similar to that described in Examples 2B and 3B, treat each of the starting compounds listed in Example 4A with dry hydrogen bromide in glacial acetic acid. Isolate and purify each of the resultant products in a manner similar to that described in Examples 2B and 3B to obtain, respectively, the 7a-bromo derivatives corresponding to the 7a-chloro products of Example 4A.
Thus the following compounds in particular can be obtained by the method of Example 4(A) or 4(B): 7α-chloro-l,4-pregnadiene-17a,21-diol-3,11,20-trione 2126 acetate m.p. 220-221°C.; [a]_ +113.3° (dimethylforma,Me0H c mide);A 238 nm (C =15,000).
IUcLX - 78 45950 7a-chloro-l6a-methyl-l,4-pregnadiene-17oij21-diol-3Jll,2026 trione 21-acetate [a] +101.6° (dimethylformamide); MeOH U λ 240 nm (£ =15,350). a-chloro-160-methyl-l,4-pregnadiene-17 a,21-diol-3,11,2026 trione 21-acetate m.p. 175-178°C.; [a] +134.3° (dimethylMeOH _ formamide) Xmax 237 nm (C =17,450). 7a-chloro-l60-methyl-1,4-pregnadiene-17a,21-diol-3,11,2026 trione 17-benzoate 21-acetate m.p. 2O9°C. (dec.); [a] n v MeOH e +124.7° (dimethylformamide); λ 233 nm (t =30,000). max a-bromo-1,4-pregnadiene-17 a,21-diol-3,11,20-trione 1726 acetate; m.p. l68°C. (dec.); [α]^ +100.7° (dimethylformamide ). a-bromo-l6a-methyl-l,4-pregnadiene-17 a,21-diol-3,11,20MeOH trione 17,21-dibenzoate m.p. >285°C.; λ 231 nm · r , ITiaX £2b =31,500); +65-8° (dimethylformamide). a-bromo-ΐδβ-methyl-1,4-pregnadiene-17 α,21-diol-3,11,20trione 17-benzoate 21-acetate m.p. l6o°C.(dec.); MeOH [a]n +131.9°(dimethylformamide);Λ 235 nm (C =28,400). u max EXAMPLE 5 7a-CHL0R0- AND 7a-BROMQ-110-HYDROXY-1,4PREGNADIENE-17a,21-DI0L-3,20-DI0NES AND ESTERS THEREOF A· By Reduction of 11-Keto Analogs - 79 48980 In a manner similar to that described in Examples 1C, 2C and 3C, treat each of the 7a-chloro- and 7a-bromo-ll-oxo1.4- pregnadienes prepared in Example '4 with sodium borohydride in tetrahydrofuran and methanol at 0°C. under an atmosphere of nitrogen, then isolate and purify each of the resultant products in a manner similar to that described to obtain: the 7«-chloro- and the 7a-bromo-derivatives of each of the 21-acetate, 21-n-butyrate, 21-isobutyrate, 21-valerate, 21-caprylate, 21-(l’-adamantyl)-carboxylate, 21-(l'-adamantyl)-acetate, 21-benzoate and 21-p-methoxybenzoate esters of 16α-methyl-l,4-pregnadiene-110,17a,21-triol-3,20-dione 17-propionate, of l6a-methyl-l,4-pregnadiene-110,17a,21triol-3,20-dione 17-n-butyrate, and of l6a-methyl-l,4-pregnadiene-110,17a,21-triol-3,20-dione 17-benzoate; the 7a-chloro- and the 7“-hromo- derivatives of I6a-methyl1.4- pregnadiene-HP,17a,21-triol-3,20-dione 17,21-diacetate; the 7a-chloro- and the 7a-bromo derivatives of each of the 21-acetate, 21-propionate, and 21-valerate esters of I6a-methyl-1,4-pregnadiene-110,17a,21-triol-3,20-dione 17-valerate; the 7a-ehloro- and the 7a-bromo- derivatives of l6a-methyl1.4- pregnadiene-110,17a,21-triol-3,2O-dione 17-isobutyrate 21-acetate; and the 7a-chloro- and the 7a-bromo-derivatives of l6a-methy1-1,4-pregnadiene-lip,17a,21-triol-3,20-dione 17-dodecanoate 21-propionate; - 80 45950 and the 16(3-epimers and 16-unsubstituted analogs of the foregoing and the 16-methylene derivatives corresponding to the foregoing.
B. Alternatively, the compounds of this example are prepa5 red by treating the corresponding 110-hydroxy-7-unsubstituted 1,4,6-pregnatriene, e.g. the 21-acetate, 21-pivalate and 21-benzoate of l6a-methyl-l,4-pregnadiene-110,17«,21tr iol-3,20-dione, with hydrogen chloride or hydrogen bromide in the manner described in Examples 1A, IB and 1C and isolating and purifying each of the resultant products in the described manner to obtain the corresponding 7achloro- and 7a-bromo-l,4-pregnadiene.
Thus the following compounds in particular can be obtained by the method of Example 5(A) or 5(B): 7a-ehloro-l6a-methyl-l,4-pregnadiene~ll|3,17a,21-triol26 3,20-dione 21-acetate, m.p. 197-203°C; [a] +49-9° (diMeOII c methylformamide); λ„,„ 242 (fc =14,300). lilaX 7a-chloro-l,4-pregnadiene-llf5,17 a,21-triol-3,20-dione 26 21-acetate,m.p. 23O-233°C; [a]n +60.8° (dimethylformaMeOH c mide); λ 243 nm (C =11,600). max 7a-bromo-l6a-methyl-l,4-pregnadiene-110,17 a,21-triolMeOH 3,20-dione 17,21-dibenzoate, m.p. 23O-234°C.; λ max C 26 232 nm ( C =39,800); [a] +30.5° (dimethylformamide).
D - 81 45950 <- 7 a-chloro-l6a-methyl-l,4-pregnadiene-ΙΙβ ,17 a,21-triol3,20-dione 21-benzoate, [M] + 514, 512. 7a-chloro-l6a-methyl-l,4-pregnadiene-llp,17a,21-triol3,20-dione 17-n-butyrate 21-propionate; m.p. 155-l6O°C.; W+ 536, 534. a-chloro-l6a-methyl-l,4-pregnadiene-llp,17 a,21-triol3,20-dione 17,21-di-n-butyrate [Ml+ 550, 548; m.p.
MeOH 26 145-147°C.; λ 240 nm (C =16,500); [a]n +40.2° ΪΗ3.Χ U (dimethylformamide). 7 a-chloro-ΐδβ-methyl-1,4-pregnadiene-llj3,17 a,21-triol3,20-dione 17-benzoate 21-acetate m.p. 195-198°C.; MeOH [a]p +69.3°(dimethylformamide); A max 235 nm (£ =27,000). α-chloro-l,4-pregnadiene-llf3,17a,21-triol-3,20-dione o 26 17,21-dipropionate m.p. 125-13O°C.; [a]_ +31.3°(dimethylMeOH formamide); λ 240 nm (C =16,000).
IHcxX a-chloro-l6a-methyl-l,4-pregnadiene-ll(3,17 a,21-triol3,20-dione 17-propionate 21-isobutyrate; [Ml+ 536, 534; nrar (dmso-dg) S’ 0.84, 1.04, 1.44, 4.69, 5-99, 6.24, 7.37. 7a-chloro-l6/3-methyl-1,4-pregnadiene-ll/3,17 a, 21-triol-3,20 dione 17-propionate 21-n-butyrate nmr (dmso-dg) S 0.92, 1.25, 1.44, 4.62, 4.72, 4.44, 6.00, 6.25, 7-39· a-chloro-l6a-methyl-l,4-pregnadiene-110,17 a,21-triol3,20-dione 17-propionate 21-valerate; m.p. 134-137°C.; - 82 45850 _ MeOH [a]D +37.5°(dimethylformamide); X max 240 nm =13,700). 7a-chloro-l6a-methyl-l,4-pregnadiene-UP,17a,21-triol3,20-dione 17-isobutyrate 21-acetate; [M] + 522, 520. 7+ 556, 554; nmr (dmso-dg) ? 0.88, 1.12, 1.46, 4.73, 6.02, 6.26, 7-40, 7.50-8.00. a-chloro-l6-methylene-l,4-pregnadiene-110,17 a,21-triol10 3,20-dione 17,21-dipropionate; nmr (dmso-dg) ? 0.98; 1.44, 4.45, 4.73, 4.88, 5.50, 6.00, 6.26, 7.38. 7a-chloro-l6a-methyl-l,4-pregnadi ene-110,17a,21-triol3,20-dione 17-propionate 21-acetate;[M]+ 508, 506; nmr (dmso-dg) ? 0.84, 1.01, 1.42, 4.84, 4.67, 4.40, 5.99, 6.24, 7.37. 7a-chloro-l6a-methyl-l,4-pregnadiene-ll(3,l'7a,21-triol3,20-dione 17-propionate 21-n-butyrate; [M] + 536, 534; nmr (dmso-dg) ? Ο.85, 1.02, 1.44, 4.69, 5.99, 6.25, 7-37. 7a-chloro-l6a-methyl-l,4-pregnadiene-110,17a,21-triol20 3,20-dione 17-valerate 21-acetate; [M]+ 536, 534. 7a-chloro-l6a-methyl-l,4-pregnadiene-110,17a,21-triol-3,20dione 17-n-butyrate 21-acetate; [M]+ 522, 520. 7a-chloro-l6a-methyl-l,4-pregnadiene-110,17a,21-triolMeOH 3,20-dione 21-pivalate; m.p. 227-23O°C.; λ 243 nm ΙΠ 3.x - 83 45950 (£ =13,900); [M] + 494, 492. 7a-chloro-l6g-methyl-l,4-pregnadiene-llg,17α,21-triol26 3,20-dione 21-acetate m.p. 228°C. (dec.); [a] +78.3° MeOH c (dimethylformamide); λ 241 nm (C =15,500). rnax 7a-chloro-l6g-methyl-l,4-pregnadiene-llg,17a,21-triol3,20-dione 17,21-dipropionate; m.p. 125°C.(dec.); \ Me0H [a]„ +74.4°(dimethylformamide); λ 241 nm U ΠΙαΧ (£ =15,200). a-bromo-l6g-methyl-1,4-pregnadiene-llg,17 a,21-triol-3,20dione 17-benzoate 21-acetate; [M]+600, 59θ; m.p. 170°C.
MeOH (dec.); [a]D +72.8°; Amax 235 nm (t =26,500). a-bromo-l6a-methyl-l,4-pregnadiene-llg,17a,21-triol3,20-dione 17-n-butyrate 21-propionate m.p. l47°C.(dec.); . MeOH [a]n +30.8° (dimethylformamide); λ 243 nm JJ ΓΩ3.Χ (£ =15,600). a-bromo-l6a-methyl-l,4-pregnadiene-llg,17 a s 21-triol3,20-dione 17,21-di-n-butyrate m.p, l43-l46°C.; MeOH [a]n +31.8°(dimethylformamide); 243 nm U ΠΙαΧ (£ =15,600). a-bromo-l6a-methyl-l,4-pregnadiene-llg,17 a,21-triol3,20-dione 17-benzoate 21-propionate m.p. l63-17O°C.; MeOH [a] +27.1° (dimethylformamide); λ 233 nm ΓΠ3.Χ (8 =27,900). 7a-bromo-l6a-methyl-l,4-pregnadiene-llg,17a,21-triol3,20-dione 17-benzoate 21-n-butyrate m.p. 138-l44°C.; 459S0 MeOH [α]η +24.2° (dimethylformamide); Λ 234 nm jj max (£ =27,100). α-bromo-l,4-pregnadiene-110,17 a,21-triol-3,20-dione 26 Q 17,21-dipropionate [ab +29.8 (dimethylformamide); . MeOH c A 242 nm (C =15,700). max 7a-bromo-l6a-methyl-l,4-pregnadiene-HP,17a,21-triol. MeOH c 3,20-dione 21-acetate /1 v 244 nm (0=13,700); [M] max 496, 494. a-bromo-160-methyl-1,4-pregnadiene-ll&,17 a,21-triol26 3,20-dione 21-acetate m.p. 165°C.(dec.); [aL· +64.6°; MeOH A 242 nm (C =15,600). mo -v· ' ' max a-bromo-160-methyl-1,4-pregnadiene-110,17 a,21-triol26 3,20-dione 17,21-dipropionate, m.p, 135-137 C.; [a] MeOH +66.4°(dimethylformamide); 242 nm (C =15,500). max 7 a-bromo-l6a-methyl-l, 4-pregnadiene-110,17 a,21-triol3,20-dione 17-propionate 21-acetate [M]+ 552, 550. 7a-bromo-16a-methyl-l,4-pregnadiene-110,17a,21-triol3,20-dione 17-propionate 21-n-butyrate; (M]+ 5θ0, 578; MeOH m.p. 153-155°C.; [a]D +34.7°(dimethylformamide); Afflax 20 241 nm ( £ =15,800). 7a-bromo-16α-methyl-l,4-pregnadiene-118,17«,21-triol-3,20dione 17-n-butyrate 21-acetate. a-bromo-l6a-methyl-l,4-pregnadiene-110,17 a,21-triol-3,20dione 17-valerate 21-acetate; [M]+ 580, 578. - 85 45950 a-bromo-16 a-methyl-1, 4-pregnadiene-lip,17 a,21-triol3,20-dione 17-valerate. 7a-bromo-l6a-methyl-l,4-pregnadiene-llp,17a,21-triol-3520dione 17-propionate 21-isobutyrate m.p. l68-172°C.;[M] + MeOH 580, 578;[α]π +36.3°(dimethylformamide); λ 240 nm JJ IuelX (£ =15,500). a-bromo-l6p-methyl-1,4-pregnadiene-lip,17a,21-triol-3,20dione 17-propionate 21-acetate; [M]+ 552, 550; nmr (dmso-dg) £0.90, 1.44, 4.89, 5-96, 6.25, 7-38. 7a-bromo-l6p-methyl-1,4-pregnadiene-lip,17a,21-triol3,20-dione 17-propionate 21-butyrate m.p. l45°C.; [M]+ 580, 578; nmr (dmso-dg) £ 0.94, 1.28, 1.44, 4.90, 4.61, 4.45, 5.98, 6.28, 7.39.
EXAMPLE 6 7a,9a,llP-TRIHALO-l,4-PREGNADIENE-17a,21DIOL-3·, 20-DIONE 17,21-DIHYDROCARBONCARBOXYLATES A. 7 a-Chloro-l6a-methyl-l,4,9(11)-pregnatriene-17 a,21diol-3,20-dione 17,21-dipropionate (1) To 7a-chloro-l6a-methyl-l,4-pregnadiene-liP,17a,2120 triol-3,20-dione 17,21-dipropionate (0.37 gm.) in dimethyl formamide (11.1 ml.) and collidine (Ο.67 ml.) add a 3-5$ i by weight solution of sulfur dioxide in methanesulfonyl chloride (0.22 ml.). Stir the reaction mixture at 0°C. - 86 45950 for 1/2 hour, then at room temperature for 1/2 hour. Add aqueous IN hydrochloric acid, extract the reaction mixture with ethyl acetate, wash the combined organic extracts with water, dry them over magnesium sulfate and evaporate them in vacuo to a residue comprising 7a-chloro-l6ft-methyl1,4,9(11)-pregnatriene-17a,21-diol-3,20-dione 17,21-dipropionate. Purify the residue by trituration with ether and filtration of the resultant precipitate; m.p. 19826 s MeOH 201°C.; t«lD +26.3° (dimethylformamide); A max 238 nm 10 ( £ =16,500). (2) In similar manner, treat each of 7a-bromo-l6a-methyll,4-pregnadiene-110,17a,2l-triol-3,20-dione 17,21-dipropionate and 7a-bromo-l6a-methyl-l,4-pregnadiene-110,17a, 21-triol-3,20-dione 17-benzoate 21-acetate in dimethyl15 formamide and collidine with a 5-57° by weight solution of sulfur dioxide in methanesulfonyl chloride to obtain, respectively, 7a-bromo-l6a-methyl-l,4,9(ll)-pregnatriene17a,21-diol-3,20-dione 17,21-dipropionate and 7a-bromo-l6amethyl-1,4,9(11)-pregnatriene-17a,2l-diol-3,20-dione 2o 17-benzoate 21-acetate.
B. 7a,9a,110-Trichloro-l6a-methyl-l,4-pregnadiene-17a,21diol-3,20-dione 17,21-dipropionate (1) To a solution of 7a-ehloro-l6a-methyl~l,4,9(11)pregnatriene-17a,21-diol-3,20-dione 17,21-dipropionate (0.18 gm.) in chloroform (5 ml.) and pyridine (0.9 ml.), - 87 45950 add a solution of dry chlorine gas (28 mg., 1.1 equivalents) in chloroform (4 ml.) and let the mixture stand at room temperature for 3 hours. Add methylene chloride (300 ml.), trash the reaction mixture sequentially with 10% aqueous sodium thiosulfate solution, IN hydrochloric acid, and water, dry it over magnesium sulfate and evaporate it. Purify the resultant residue on silica gel by thick layer chromatography using as developing solvent chloroform:ethyl acetate (9:1). Remove the least polar band as shown by ultraviolet light and elute with ethyl acetate. Evaporate the combined ethyl acetate eluates to a residue comprising 7a,9a,110-trichloro-l6a-methyl-l,4-pregnadiene-17a,21-diol-3,20dione 17,21-dipropionate. Further purify by trituration with acetone, and filtering off the triturated MeOH precipitate; m.p. 225-228°C.; λ 236 nm (£=15,600).
IHaX (2) In similar manner treat the 7α-bromo-l,4,9(11)pregnatrienesprepared in Example 6A(2) with chlorine to obtain, respectively, 7a-bromo-9a,110-dichloro-l6a-methyl· l,4-pregnadiene-17a,21-diol~3,20-dione 17,21-dipropionate and 7a-bromo-9a(L10-dichloro-l6a-methyl-l,4-pregnadiene17a,21-diol-3,20-dione 17-benzoate 21-acetate.
C. 7a,9a-Dichloro-110-fluoro-l6a-methyl-l,4-pregnadiene 25 17a,21-diol-3,20-dione 17,21-dipropionate (1) To a solution of 7a-chloro-l6a-methyl-l,4,9(11)- 88 45950 pregnatriene-17a,21-diol~3,20-dione 17,21-dipropionate (0.5 gms.) in chloroform (10 ml.) and pyridine (1 ml.), add a solution of hydrogen fluoride (5 gms.) in tetrahydrofuran (5 ml.) followed by N-chlorosuccinimide (128 mg.). Dilute the reaction mixture with sufficient methylene chloride to form a solution, and stir the reaction mixture for 48 hours at room temperature. Pour the reaction mixture into aqueous sodium carbonate, extract the aqueous mixture with methylene chloride, wash the combined organic extracts successively with water, dilute hydrochloric acid and finally with water. Dry over magnesium sulfate, filter and evaporate to a residue comprising 7a,9a-dichloro-110-fluoro-l6a-methyl-l,4-pregnadiene17a,21-diol-3,20-dione 17,21-dipropionate. Purify the residue by trituration with ether, filtration and recrystallization from acetone:hexane. (2) In similar manner, treat the 7a-bromo-l,4,9(11)-pregnatrienes prepared in Example όΑ(2) in chloroform with hydrogen fluoride and N-chlorosuccinimide in the presence of pyridine and isolate the resultant products to obtain, respectively, 7a-bromo-9a-chloro-110-fluoro-l6a-methyl1,4-pregnadiene-17 a,21-diol-3,20-dione 17,21-dipropionate and 7a-bromo-9a-chloro-110-fluoro-l6a-methyl-l,4-pregnadiene-17a,21-diol-3,20-dione 17-benzoate 21-acetate.
D. 7a-Chloro-9a-bromo-llg-fluoro-l6a-methyl-l,4-pregnadiene-17a,21-diol-3,20-dione 17,21-dipropionate - 89 45950 (1) To a solution of 7a-chloro-l6a-methyl-l,4,9(ll)-pregnatriene-17a,21-diol-3,20-dione 17,21-dipropionate (0.5 gm.) in chloroform (10 ml.) and pyridine (1 ml.) add a solution of hydrogen fluoride (5 gms.) in tetrahydrofuran (5 ml.) followed by N-bromoacetamide (130 mg.). Dilute the reaction mixture with sufficient methylene chloride to form a solution and stir for 48 hours at room temperature. Pour the reaction mixture into aqueous sodium carbonate, extract the aqueous mixture with methylene chloride, and wash the combined organic extracts successively with water, dilute hydrochloric acid and water. Dry the solution over magnesium sulfate, filter and evaporate. Dissolve the resultant residue in aeetone.’ether and filter through a column of Plorisil and eiute with ether. Combine the eluates and evaporate in vacuo to a residue comprising 7a-chloro-9a-bromo-llg-fluoro-l6a-methyl-l,4-pregnadiene17 a,2l-diol-3,20-dione 17,21-dipropionate. (2) In the foregoing procedure by using as starting compounds the 7a-bromo-l,4,9(ll)-pregnatrienes prepared in Example 6A(2), 7a,9a-dibromo-llg-fluoro-l6a-methyl1,4-pregnadiene-17a,21-diol-3,20-dione 17,21-dipropionate and 7a,9a-dibromo-llg-fluoro-l6a-methyl-l,4-pregnadiene17a,21-diol-3,20-dione 17-benzoate 21-acetate respectively are obtained.
E. 7a,llg-Dichloro-9a-bromo-l6a~methyl-l,4-pregnadiene17a,21-diol-3,20-dione 17,21-dipropionate - 90 45950 (1) To a stirred solution of 7a-chloro-l6a-methyl-l,4,9 (11)-pregnatriene-17a,21-diol-3,20-dione 17,21-dipropionate (0.5 gm.) in chloroform (10 ml.) and pyridine (1 ml.) at -20°C. add N-bromoacetamide (130 mg.) and a solution of hydrogen chloride (100 mg.) in tetrahydrofuran (5 ml.). Continue stirring at -20°C. for 15 minutes, then allow the reaction mixture to attain room temperature and stand at room temperature an additional 15 minutes. Add methylene chloride to the reaction mixture and wash the reaction mixture with thiosulfate solution, water, 10% aqueous sodium bicarbonate and finally with water. Dry over magnesium sulfate, filter and evaporate in vacuo. Recrystallize the resultant residue from acetone:hexane to give 7a,110-dichloro-9a-bromo-l6a-methyl-l,4-pregnadiene-17a,21-diol-3,20 dione 17,21-dipropionate. (2) In the foregoing procedure, by using as starting compound the 7a-bromo-l,4,9(ll)-pregnatrienes prepared in Example 6A(2), 7a,9a-dibromo-110-chloro-l6a-methyl1.4- pregnadiene-17 a,21-diol-3,20-dione 17,21-dipropionat e and 7 a,9a-dibromo-110-chloro-16 a-methyl-1,4-pregnadiene17a,21-diol-3,20-dione 17-benzoate 21-acetate respectively are obtained.
F. Treat each of the 7a-ehloro- and 7a-bromo-110-hydroxy1.4- pregnadiene-17a,21-diol-3,20-diones prepared in Example 5 in a manner similar to that described in Example 6A followed by reaction of the resulting 7a-chloro- and - 91 48990 7α-bromo-l,4,9(11)-pregnatriene-17 α,21-diol-3,20-diones with chlorine in the manner described in Example 6b or with a mixture of halogenating reagents in a manner similar to that described in Example 6C-6E to obtain the corre '5 sponding 7a-chloro- and 7a-bromo-9a,110-dihalo-l,4-pregnadiene-17a,21-diol-3,20-diones, e.g. 7a,9a,lip-trichlorol,4-pregnadiene-17a,21-diol-3,20-dione 21-acetate, m.p. x MeOH 299-301°C.; [a] +71.1° (dimethylformamide); A max 239 nm (£ =14,500).
EXAMPLE 7 α-CHLORO-9 a-HALO-1,4-PREGNADIEHE17 a,21-DI0L-3,20-DIONES A. 7 tx-Chloro-9a-fluoro-l6a-methyl-l,4-pregnadiene-llg,17 a 21-triol-3,20-dione 21-acetate To 9a-fluoro-l6a-methyl-l,4-pregnadiene-7P,HP,17a,21tetrol-3,20-dione 21-acetate (0.5 gm.) in methylene chloride (100 ml.) at 0°C. under an atmosphere of nitrogen add N,N —diethyl-1,2,2-trichlorovinylamine (1.67 ml.). Stir at 0°C. for 7 hours, evaporate in vacuo, place the resul20 tant residue on a silica gel column (50 gms.) and elute with chloroform:ethyl acetate (3:1). Combine like fractions containing the desired compound as determined by thin layer chromatography and evaporate. Further purify the resultant residue on thin layer silica gel plates, developing with chloroform:ethyl acetate (3:1). Remove - 92 45950 the band containing the desired product as visualized under ultraviolet light and elute with ethyl acetate. Evaporate the eluate to a residue comprising 7a-chloro9a-fluoro-l6a-methyl-l,4-pregnadiene-lip,ίγα,21-triol-3,20dione 21-acetate. Further purify by recrystallization from acetone:hexane; [M]+ 470, 468; NMR (dmso-dg) S 0.82, 0.90, 1.50, 4.17, 4.55, 4.95, 6.09, 6.27, 7-32.
B. In the procedure of Example 7A, by starting with each of the 9a-ehloro- and 9a-bromo-analogs of the 9a-fluoro70-hydroxy-l,4-pregnadiene starting compound, the corresponding 7a-ehloro derivatives are obtained, i.e. fa,9adichloro-l6a-methyl-l,4-pregnadiene-110,17a,21-triol-3,20dione 21-acetate and 7a-chloro-9a-bromo~l6a-methyl-l,4pregnadiene-110,17a,21-triol-3,20-dione 21-acetate, respectively.
C. Similarly, using as starting materials the 70-hydroxy derivatives prepared in Preparation 11 in the procedure of Example 7A, 7a-chloro-9a-fluoro-l6a-methyl-l,4-pregnadiene-110,17a,21-triol-3,20-dione 17,21-dipropionate, 7a-chloro-9a-fluoro-l6a-methyl-l,4-pregnadiene-110,17a, 21-triol-3,20-dione 17-benzoate 21-propionate, 7a-chloro9a-fluoro-l6a-methyl-l,4-pregnadiene-110,17a,21-triol3,20-dione 17-n-butyrate 21-propionate, their 9a-bromoand 9a-chloro-analogs, their l60-methyl epimers and 16unsubstituted analogs and 16-methylene derivatives cor- 93 . responding thereto are obtained.
EXAMPLE 8 7a-ELU0R0-l,4-PREGNADIENE-3,20-DI0NES A. 7a-Fluoro-l6a-methyl-l, 4-pregnadiene-110,17a, 21-triol5 3,20-dione 21-acetate To l6a-methyl-l,4-pregnadiene-70,110,17a,21-tetrol-3,20dione 21-acetate (0.13 gm.) in methylene chloride (15 ml.) at 0°C. under an atmosphere of nitrogen, add N-(2-chloro1,1,2-trifluoroethyl)-diethylamine (fluoramine) (0.286 ml.). Stir at 0°C. for 18 hours, then evaporate in vacuo and purify the resultant residue by thin layer chromatography, developing with chloroform:ethyl acetate (5:2) to obtain a mixture comprising 7a-fluoro-l6a-methyll,4-pregnadiene-110,17a,21-triol-3,20-dione 21-acetate and l6a-methyl-l,4,6-pregnatriene-110,17a,21-triol-3,20dione 21-acetate. Treat the foregoing mixture (55 mg.) in dioxan (0.58 ml.) and pyridine (3 drops) with osmium tetroxide (10 mg.) at room temperature for 5 days. Saturate the reaction mixture with hydrogen sulfide, filter the reaction mixture, evaporate the filtrate in vacuo at room temperature, and purify the resultant residue by thin layer chromatography on silica gel, developing with chloroform:ethyl acetate (2:1). Evaporate the combined eluates containing the desired product and triturate the resultant residue with ether:hexane to obtain 7a-fluoro- 94 45950 16α-methy1-1,4-pregnadiene-110,17α,21-triol-3,20-dione 21-acetate; [M] + 434; nmr (dmso-dg) £ 0.80, 0.91, 1.42, 4.36, 4.89, 4.92, 5.99, 6.21, 7-37.
B. 7«,9a-Difluoro-l6a- methyl-1,4-pregnadiene-110,17«. 21-triol-3,20-dione 21-acetate To 9a-fluoro-l6a-methyl-l,4-pregnadiene-70,110,17a,21tetrol-3,20-dione 21-acetate (0.35 gm.) in methylene chloride (350 ml.) at 0°C. under an atmosphere of nitrogen add fluoramine (0.76 ml.). Stir at 0°C. for 24 hours, and evaporate the reaction mixture in vacuo. Chromatograph the resultant residue on silica gel by thin layer chromatography, developing with chloroform:ethyl acetate (2:1) and eluting with ethyl acetate the band containing the desired product as visualized under ultraviolet light. Evaporate the combined eluates to a residue of 7a,9a-difluoro-16 a-methyl-1,4-pregnadiene-110,17 a,21-triol-5,20dione 21-acetate. Further purify by recrystallization 26 from acetone:methanol:hexane; m.p. 234-237°C.; [a]^ +45.4° (dimethylformamide).
C. Similarly, by treating the 70-hydroxy-1,4-pregnadienes prepared as described in Preparation 11 with fluoramine according to the procedures of Examples 8A and 8B, there is obtained the corresponding 7a-fluoro-l,4-pregnadiene, e.g. 7a-fluoro-l,4-pregnadiene-110,17a,21-triol26 3,20-dione 21-acetate; m.p. 243~246°C.; [a]p +62.7°. - 95 48980 EXAMPLE 9 7a-IODO-9a-UNSTOSTITUTED-l,4-PREGNADTENE-5,2Q-DI0NES A. 7a-lodo-l6a-methyl-l,4-pregnadiene-110,17a,21-triol5,20-dione 21-acetate Add l6a-methyl-l,4,6-pregnatriene-110,17a,21-triol-3,2Odione 21-acetate (0.1 gm.) to a solution of dry hydrogen iodide (0.512 gm.) in glacial acetic acid (2 ml.) and stir the reaction mixture at room temperature for 50 minutes. Pour into ice water, filter off the precipitate and dry it; triturate it with ether, filter off the solid, dissolve it in methylene chloride, wash the methylene chloride solution with aqueous 0.1N sodium thiosulfate solution and with water, dry it over magnesium sulfate and evaporate it in vacuo. Triturate the resultant re15 sidue with hexane and filter to obtain 7a-iodo-l6a-methyl1,4-pregnadiene-ll|3,17a,21-triol-3,20-dione 21-acetate (8 mg.); [M]+ 542.
B. In similar manner, treat each of the 9-unsubstituted l,4,6-pregnatriene-3,20-diones prepared in Preparations 1-10 with hydrogen iodide in acetic acid according to the procedure of Example 9A to obtain the corresponding a-iodo-9-unsubstituted-l,4-pregnadiene-3,20-dione, e.g. 7a-iodo-l6a-methyl-l,4-pregnadiene-110,17a,21-triolo 26 3,20-dione 17,21-dipropionate, m.p. 150 C. (dec.), [ot]n MeOH cu +22.0° (dimethylformamide), Λ 241 nm ( fc =14,500); o MeOH its Ιδβ-analog, [a]p +52.0° (dimethylformamide), λ max 241 nm (.£ =14,500); and - 96 45950 7a-iodo-l6a-methyl-l,4-pregnadiene-110,17a,21-triol-3,2O26 dione 17-benzoate 21-acetate,[a]_ +34.3° (dimethylformaMeOH c mide); X max 233 nm (C =24,400).
EXAMPLE 10 7a-BR0M0-9a-HAL0-l,4-PREGNADIENE-3,20-DIONES A. 7a-Bromo-9a-fluoro-l6a-methyl-l,4-pregnadiene-llg, 17a,21-triol-3,20-dione 21-acetate To a solution of 70-hydroxy-9«-fluoro-l6a-methyl-l,4pregnadiene-110,17a,21-triol-3,20-dione 21-acetate (0.1 gm.) and lithium bromide (0.1 gm.) in methylene chloride (100 ml.) cooled to 0°C. add fluoramine (0.23 ml.). Stir at 0°C. for 24 hours and then evaporate in vacuo. Dissolve the resultant residue in chloroform, wash the chloroform solution with water, dry it over magnesium sulfate and evaporate. Purify by thin layer chromatography using as developing solvent chloroform:ethyl acetate (2:1). Remove the band containing the desired product as visualized under ultraviolet light and elute with ethyl acetate. Evaporate the combined ethyl acetate eluates in vacuo to a residue comprising 7a-bromo-9afluoro-l6a-methyl-l,4-pregnadiene-ΙΙβ,17a,21-triol-3,20dione 21-acetate.
B. In the procedure of Example 10A, by starting with - 97 48950 each of the 9a-ehloro and 9a-bromo analogs of the 9afluoro-70-hydroxy-1,4-pregnadiene starting compound, the corresponding 7a-bromo derivative is obtained i.e. a-bromo-9a-chloro-l6a-methyl-l,4-pregnadiene-llg,17a» 215 triol-3,20-dione 21-acetate and 7a,9a-dibromo-l6a-methyl1,4-pregnadiene-llg,17a,21-triol-3,20-dione 21-acetate, respectively.
C. Similarly, by treating any of the 70-hydroxy-1,4pregnadienes prepared in Preparation 11 with fluoramine and lithium bromide according to the procedure of Example 10A, the corresponding 7a-bromo-l,4-pregnadiene derivative is obtained.
D. In the procedure of Example 10A, by substituting for lithium bromide an equivalent quantity of lithium chlo15 ride and by using tetrahydrofuran as solvent instead of methylene chloride, the corresponding 7a-chloro compound, i.e. 7a-chloro-9a-fluoro-l6a-methyl-l,4-pregnadiene-llg, 17a,21-triol-3,20-dione 21-acetate, is obtained.
EXAMPLE 11 7 a-HALO-21-DESOXY-l, 4-PREGNADIEME3,20-DIQNES AND CERTAIN 21-ESTER DERIVATIVES A. 7a-Chloro-21-desoxy-l,4-pregnadiene-3,20-diones - 98 4 3830 (1) 7a-Chloro-l,4-pregnadien-17a-ol-3,20-dione and its 17-acetate To 17a-hydroxy-l,4,6-pregnatriene-3,20-dione (0.5 gm.) add glacial acetic acid (20 ml.) saturated with dry hydro5 gen chloride gas, and lithium chloride (2 gms.). Stir at room temperature for 45 minutes, then pour into an aqueous sodium carbonate solution and extract the aqueous mixture with ether. Wash the combined organic extracts with water, dry over magnesium sulfate and evaporate to a residue comprising 7a-chloro-l,4-pregnadiene-17a-ol3,20-dione. Purify by recrystallization from methanol; m.p. 229-231°C.; (α]β +50.7° (dioxan). ’ 7a-Chloro-17a-acetoxy-l,4-pregnadiene-3,20-dione (m.p. 2OO-2O6°C·;[a]n +4.8° (dimethylformamide); MeOH λ 242 nm (C =16,100)) can be prepared similarly max from 17a-acetoxy-l,4,6-pregnatriene-3,20-dione. (2) In the above procedure, by using as starting compounds the 17-propionate, 17-n-butyrate, 17-valerate and 17-benzoate of 1,4,6-pregnatriene-110,17a-diol-3,2020 dione, the corresponding 7a-chloro derivatives, i.e. the 17-propionate, 17-n-butyrate, 17-valerate and 17-benzoate of 7a-chloro-l,4-pregnadiene-110,17a-diol-3,20dione, respectively, are obtained.
B, 7a-Bromo-21-desoxy-l,4-pregnadiene-3,20-diones - 99 45950 (1) In the procedure of Example 11A(1), by using as reagents an equivalent quantity of dry hydrogen bromide instead of dry hydrogen chloride and an equivalent quantity of lithium bromide instead of lithium chloride, the corresponding 7a-hromo derivative, I.e. 7a-hromol,4-pregnadien-17a-ol-3,20-dione, is obtained. 7a-Bromo-17g-acetoxy-l,4-pregnadiene-3,20-dione - MeOH ([a] +5-7° (dimethylformamide); λ 242 nm U TnaX (£ =14,000)) may be prepared similarly from 17ft-acetoxy10 1,4,6-pregnatriene-3,20-dione. (2) Treat each of the starting compounds of Example 11A(2) with dry hydrogen bromide and lithium bromide in glacial acetic acid in the manner of Example 11B(1) to obtain, respectively, the 17-propionate, 17-n-butyrate, 17-vale15 rate and 17-benzoate of 7a-bromo-l,4-pregnadiene-lip,17adiol-3,20-dione.
C. 7ct-Fluoro-21-desoxy-l,4-pregnadiene-3,20-diones and certain 21-ester derivatives In a manner similar to that described in Example 8A, treat each of l,4-pregnadiene-7P,17a-diol-3,20-dione and the 17-propionate, 17-n-butyrate, 17-valerate and 17-benzoate of l,4-pregnadiene-7P,lip,17a-triol-3,20-dione with fluoramine in methylene chloride under an atmosphere of nitrogen. Isolate and purify each of the resultant - 100 products in a manner similar to that described to obtain, respectively, 7a-fluoro-l,4-pregnadiene-17a-ol-3,20-dione and the 17-propionate, 17-n-butyrate, 17-valerate and 17-benzoate of 7a-fluoro-l,4-pregnadiene-110,17a-diol-3,2O5 dione. 7a-Fluoro-17a-acetoxy-l,4-pregnadiene-3,20-dione (m.p. 262 - 265°C.) and 7a-fluoro-l6a-methyl-l, 4-pregnadiene11(3,17a, 21-triol-3,20-dione 17,21-dipropionate (m.p. 157-l6l°C.; [a] +32.9° (dimethylformamide); MeOH e λ max 240 nm (C =15,900)) can be prepared similarly from l,4-pregnadiene-70,17a-diol-3,20-dione 17-acetate and l6a-methyl-l,4- pregnadiene ~ 73,np,17a,21-tetrol3,20-dione 17,21-dipropionate.
D. 7a-Iodo-21-desoxy-l,4-pregnadiene-3,20-diones In a manner similar to that described in Example 9A, treat each of the pregnatriene starting compounds of Example 11A(1) and 11A(2) with hydrogen iodide in glacial acetic acid and isolate each of the resultant products in the described manner to obtain, respectively, 7a-iodo20 1,4-pregnadien—17a-ol-3,20-dione, and the 17-propionate, 17-n-butyrate, 17-valerate and 17-benzoate of 7a-iodo1,4-pregnadiene-110,17 a-diol-3,20-dione. a-Iodo-17 a-acetoxy-1,4-pregnadiene-3,20-dione (m.p. 144°C.(dec.); [a)D -3.5° (dimethylformamide); 101 MeOH ς Λ 242 nm (& =15,100)) may be prepared similarly nictX from 17a-acetoxy-l,4,6-pregnatriene-3,20-dione.
EXAMPLE 12 7a,21-DIHAL0-1,4-PREGNADIEME-3,20-D10NES A. 7a-Chloro-21-halo derivatives (1) 7a,21-Diehloro-l6a-niethyl~l,4-pregnadIene-ll/3,17adiol-3,20-dione 17-propionate is prepared by reaction of l6a-methyl-21-chloro-l,4,6pregnatriene-110,17a-diol-3,20-dione 17-propionate with IQ dry hydrogen chloride gas in dioxan by the method of Example 1A; [M]+ 458, 456, 454. (2) By using as starting compound the 21-fluoro and 21-bromo analogs of the 21-chloro starting compound of Example 12A(1), the corresponding 21-fluoro and 21-bromo derivatives are obtained, i.e. 7a-chloro-21-fluoro-l,4pregnadiene-lip,17a-diol-3,20-dione 17-propionate and 7a-chloro-21-bromo-l,4-pregnadiene-110,17a-diol-3,20-dione 17-propionate. (3) In the procedure of Example 12A, by using starting compounds having different esters at C-17, e.g. the 17-n-butyrate and the 17-benzoate corresponding to the 17-propionate ester named therein, the corresponding - 1024S950 7a-chloro-21-halo derivative is obtained, i.e. the 17-n-buyrate and 17-benzoate of 7a,21-dichloro-l6amethyl-l,4-pregnadiene-110,17a-diol-3,20-dione, of 7achloro-21-fluoro-1,4-pregnadiene-lip,17 a-diol-3,205 dione and of 7a-chloro-21-bromo-l,4-pregnadiene-110,17adiol-3,20-dione. (4) By using as starting compounds the 160-methyl epimers or the 16-unsubstituted or 16-methylene derivatives of l6a-methyl starting compounds of Examples l2A(l)-(3), the corresponding 160-methyl, 16-unsubstituted or 16methylene derivatives of the 7a,21-dihalo products named therein can be obtained, e.g. 7a,21-dichloro-l,4-pregnadiene-110,17a-diol-3,20-dione 17-propionate; [M]+ 472, 470, 468; nmr (dmso-dg)S 0.87, 0.97, 1.41, 2.32, 4.4l, 4.75, 5.95, 6.36, 7.35.
B. 7«-Bromo- and 7a-iodo-21-halo derivatives Treat each of the 1,4,6-pregnatriene starting compounds of Example 12A(l)-(4) with dry hydrogen bromide in acetic acid in a manner similar to that described in Example 2A and B or with dry hydrogen iodide in acetic acid according to the procedure of Example 9A to obtain each of the 7a-bromo- and 7a-iodo-analogs corresponding to the 7achloro derivatives of Example 12A, e.g. 7a-bromo-21-chloro1,4-pregnadiene-110,17a-diol-3,20-dione 17-propionate; nmr (dmso-dg) S’ 0.90, 1.00, 1.45, 2-33, 4.43, 4.85, 5-93, - 103 45950 6.21, 7.36.
C. 7a-Pluoro-21-halo derivatives (1) 7a-Pluoro-21-chloro-l6a-methyl-1.4-pregnadiene-110. a-diol-3,20-dione 17-propionate is prepared by reaction of l6a-methyl-21-chloro-l,4-pregnadiene-70,110,17a-triol-3,20-dione 17-propionate with fluoramine in methylene chloride under an atmosphere of nitrogen by the method of Example 8A. (2) By using as starting compounds the 21-fluoro- and 10 21-bromo- analogs of the 21-chloro starting compound of Example 120(1), the corresponding 21-fluoro- and 21bromo- derivatives are obtained i.e. 7«-fluoro-21-bromoI6a-methyl-l,4-pregnadiene-110,17a-diol-3,20-dione 17-propionate and 7a,21-difluoro-l6a-methyl-l,4-pregnadiene15 110,17a-diol-3,20-dione 17-propionate. (3) By using the 9a-fluoro- and 9a-chloro-derivatives of the starting compounds of Example 120(1) and 120(2), the corresponding 9a-fluoro- and 9«-chloro- derivatives of the 7a-fluoro-l,4-pregnadienes obtained therein are produced. - 104 45950 EXAMPLE 13 OTHER 7«-HALO-9-UNSUBSTITHTED-l,4PREGNADIENE-3,20-DIONES A. 9a-Unsubstituted-l,4,6-pregnatriene-3,20-diones (1) In a manner similar to that described in Preparation 1A treat each of the following l,4-pregnadiene-3,20-diones with dry hydrogen chloride gas in dioxan and DDQ: 1) l6a,17a-isopropylidenedioxy-l,4-pregnadiene-110,21diol-3,20-dione 21-acetate, 2) 14a ,17n-butylideredi oxy-1,4-pregnad.i ene-110,21-diol3,20-dione 21-acetate, 3) 2’,2'-dimethyl-1,4-pregnadiene [17,l6a-d]-l',3'-oxathiolane-3 ,11,20-trione, 4) 110-hydroxy-2',2'-dimethyl-1,4-pregnadieno [17,l6a-d] -1',3'-oxathiolane-3,20-dione, ) D-homo-1,4-pregnadiene-17aa,21-diol-3,11,20-trione 17¾ 21-dipropionate, 6) D-homo-1,4-pregnadiene-110J7a«,21-triol-3,20-dione 174,21-di-n-butyrate, 7) n-butyl 110-hydroxy-3,2O-dioxo-l6a-methyl~l,4-pregnadien-21-oate, - 105 45980 8) propyl 2-chloro-110-hydroxy-3,2O-dioxo-l6a-methyl1,4-pregnadien — 21-oate, 9) l60-methyl-2O-chloromethoxy-21-nor-l,4-pregnadiene110,17a-diol-3,20-dione 17-propionate, ) l60-methyl-2O-fluoromethoxy-21-nor-l,4-pregnadiene110,17a-diol-3,20-dione 17-propionate, 11) l6-methylene-20-ehloromethoxy-21-nor-l,4-pregnadiene 110,17 a-diol-3,20-dione 17-propionate, 12) l6-methylene-20-fluoromethoxy-21-nor-l,4-pregnadiene 110,17a-diol-3,20-dione 17-propionate, 13) l6-fluoromethylene-l,4-pregnadiene-110,17a,21-triol3,20-dione 17,21-dipropionate, 14) l6-chloromethylene-l,4-pregnadiene-17a,21-diol-3,ll, 20-trione 17-benzoate 21-propionate, ) 16-butylidene-l,4-pregnadien-17a-ol-3,20-dione 17propionate, 16) 16-ethylidene-l,4-pregnadiene-17 a,21-diol-3,11,20trione 17,21-dipropionate, 17) l6a,17a-cyclopentylidenedioxy-l,4-pregnadiene-110, 21-diol-3,20-dione 21-acetate, 18) l60-methyl~2O-methoxy-21-nor-l,4-pregnadiene-110, 17a-diol-3,20-dione 17-propionate, and - 106 19) Ιβα-methyl-l,4-pregnadiene-lip,21-diol-3,20-dione 21-pivalate.
Isolate and purify each of the resultant products in a manner similar to that described in Preparation 1A to obtain the 6-dehydro derivative of each of the starting compounds. (2) Treat each of the following compounds with dry hydrogen chloride in dioxan followed by DDQ in the manner described in Preparation 1A: 1) ΐ4α,17α-(2'- butyl idenedioxy) - 1,4-pregnadiene-liP, 21diol-3,20-dione 21-isonicotinate, and 2) lip,21-dihydroxy-2'-methyl-5'PH-1,4-pregnadieno [17,l6a-d]oxazole-3,20-dione 21-acetate.
After stirring the reaction mixture at room temperature for 24 hours, filter and evaporate the filtrate at 40°C. in vacuo. Dissolve the resultant residue in water, neutralize with sodium hydroxide and extract with chloroform. Wash the organic solution with water, dry over magnesium sulfate and filter through a column of neutral alumina, washing the column with chloroform:ethyl acetate. Evaporate each of the eluates to a residue comprising the 6-dehydro derivative of each of the starting compounds. - 107 45950 B. 7a-Chloro-9-unsubstituted-l,4-pregnadienes (1) In a manner similar to that described in Example 1A, treat each of the l,4,6-pregnatriene-3,20-diones prepared in Example 13A(1) with dry hydrogen chloride in dioxan, and isolate and purify each of the resultant products in a manner similar to that described to obtain the 7 achloro derivative of.each of the starting compounds of Example 15A(1), e.g. 7a-ehloro-l6a,17ct-isopropylidenedioxy-l,4-pregnadiene-110,21-diol-3,20-dione; m.p. 255~257°C·; 26 , MeOH Q [a]n +104.9° (dimethylformamide); A 242 (v =15,600).
U IticLX (2) Treat ΐ4α,17α-(2'-' butylidenediojy) - 1,4,6-pregnatriene-110,21-diol-3,20-dione 21-isonicotinate with hydrogen chloride gas in dioxan for 16 hours at room temperature in a manner similar to that described in Example 1A. Pour the reaction mixture into ice water, neutralize the aqueous solution with sodium hydroxide, then filter off the resultant precipitate, wash it with water and dry it in air. Separate the components of the foregoing precipitate in a manner similar to that described in Example 1 to obtain 7 achloro-l4a,l7a-(2'-’ butyl tdenedioxy) — 1,4-pregnadiene110,21-diol-3,20-dione 21-isonicotinate. 110,21-Dihydroxy-2'-methyl-510H-1,4,6-pregnadieno[17,l6a-d]oxazole3,20-dione 21-acetate is similarly transformed into 7achloro-110,21-dihydroxy-2'-methyl-5'0H-1,4-pregnadieno [17,l6a-d]oxazole-3,20-dione 21-acetate. - 108 4593ο C. 7a-Bromo-9-unsubstituted-l,4-pregnadienes (1) In a manner similar to that described in Example 2 treat each of the l,4,6-pregnatriene-3,20-diones prepared in Example 13A(1) with dry hydrogen bromide in acetic acid. Isolate and purify each of the resultant products to obtain the corresponding 7a-bromo derivative of each of the starting compounds of Example 13A(1), e.g. 7a-bromol6a,17a-isopropylidenedioxy-l,4-pregnadiene-llB,21-diol26 3,20-dione 21-acetate; m.p. 197-2OO°C.; [a] +91-9° MeOH c (dimethylformamide); λ__„ 242 ( v =15,000). (2) Treat each of the 1,4,6-pregnatriene-3,20-dione derivatives prepared in Example 13A(2) with dry hydrogen bromide in acetic acid in a manner similar to that described in Example 2A. After stirring the reaction mixture at 0°C. for 1 hour, pour it into water, neutralize with sodium hydroxide, filter off the resultant precipitate, wash it with water and dry it; purify it in a manner similar to that described in Example 2A. The 7a-bromo derivatives of each of the starting compounds of Example 13A(2) are thereby obtained.
D. 7o-Iodo-9-uh5Ubstituted-l,4-pregnadienes (1) In a manner similar to that described in Example 9A, treat each of the 1,4,6-pregnatriene-3,20-dione derivatives prepared in Example 13A(1) with dry hydrogen iodide - 109 45950 V__ in glacial acetic acid. Isolate and purify each of the resultant products in a manner similar to that described to obtain the 7«-iodo derivative of each of the l,4-pregnadiene-3,20-dione starting compounds of Example 13A(1). (2) Treat each of the 1,4,6-pregnatriene-3,20-dione compounds of Example 13A(2) with dry hydrogen iodide in acetic acid in the manner described in Example 9A. After stirring the reaction mixture at room temperature for minutes, pour it into ice water, neutralize with sodium hydroxide, filter off the resultant precipitate, and purify it in a manner similar to that described in Example 9A. The 7a-iodo derivatives of the 1,4-pregnadiene-3,20dione starting compounds of Example 13A(2) are thereby obtained.
E. 7«-Fluoro-9-unsubstituted-l,4-pregnadienes (1) 70-Hydroxy-l,4-pregnadiene-3,20-diones Subject the following 1,4,6-pregnatriene-3,20-diones to a sequence of reactions similar to those described in Preparat ion 11A(1)-(4). 1) 16 a,17 α-isopropylidenedioxy-l,4,6-pregnatriene-110,21diol-3,20-dione 21-acetate, - 110 45950 2) 14 α,17 α-n-butylidenedioxy-1,4,6-pregnatriene-110,21diol-3,20-dione 21-acetate, 3) D-homo-1,4,6-pregnatriene-l 7aa,21-diol-3,11,20-trione 17¾ 21-dipropionate, 4) D-homo-1,4,6-pregnatriene-liP ,17a a, 21-triol-3,20-dione 17a,21 di-n-butyrate, ) ΐ6β-methyl-20-chloromethoxy-21-nor-l,4,6-pregnatriene110,17a-diol-3,20-dione 17-propionate, 6) l60-methyl-2O~fluoromethoxy-21-nor-l,4,6-pregnatriene10 11(3,17a-diol-3,20-dione 17-propionate, and 7) l6a,17a-cyclopentylidenedioxy-l,4,6~pregnatriene-110, 21-diol-3,20-dione 21-acetate.
Isolate and purify each of the respective products in a manner similar to that described in Preparation 11A(4) to obtain, respectively, 1) 16a,17a-isopropylidenedioxy-l,4-pregnadiene-7 0,110, 21-triol-3,20-dione 21-acetate, 2) l4a,17a-n-butylidenedioxy-l,4-pregnadiene-70,110,21triol-3,20-dione 21-acetate, 3) D-homo-1,4-pregnadiene-7P ,17aa,21-triol-3,11,20-trione 17a,21-dipropionate, 4) D-homo-1,4-pregnadiene-76,116,17aa,21-tetrol-3,20-dione 111 17¾ 21-di-n-butyrate, ) l60-methyl-2O-chloromethoxy-21-nor-l,4-pregnadiene7β,110 , 17α-triol-3,20-dione 17-propionate, 6) l60-methyl-2O-fluoromethoxy-21-nor-l,4-pregnadiene5 73,110,17a-triol-3,20-dione 17-propionate, and 7) l6a,17a-cyclopentylidenedioxy-l,4-pregnadiene-70,110, 21-triol-3,20-dione 21-acetate. (2) In a manner similar to that described in Example 8A, treat each of the 70-hydroxy derivatives of Example 13E(1) with fluoramine in methylene chloride at 0°C. under an atmosphere of nitrogen. Isolate and purify each of the resultant products in a manner similar to that described to obtain, respectively, 1) 7 a-fluoro-l6a,17 a-isopropylidenedioxy-1,4-pregnadiene15 110,21-diol-3,20-dione 21-acetate, 2) 7α-fluoro-14 a,17a-n-butylidenedioxy-1,4-pregnadiene110,21-diol-3,20-dione 21-acetate, 3) 7a-fluoro-D-homo-1,4-pregnadiene-17 a,21-diol-3,11,20trione 17,21-dipropionate, 4) 7a-fluoro-D-homo-l,4-pregnadiene-110,17a,21-triol3,20-dione 17,21-di-n-butyrate, ) 7 α-fluoro-l60-methyl-2O-ehloromethoxy~21-nor-l,4-pregnadiene-110,17a-diol~3,20-dione 17-propionate, - 112 4S9S0 6) 7a-fluoro-l60-methyl-2O-fluoromethoxy-21-nor-l,4-pregnadiene-110,17a-diol-3,20-dione 17-propionate, and 7) 7a-fluoro-l6a,17a-oyclopentylidenedioxy-l,4-pregnadiene-110,21-diol-3,20-dione 21-acetate.
EXAMPLE 14 OTHER 7«,9«-DIHALO-110-HYDROXY-l,4PREGNADIENE-3,2O-DIOHES A. 70-Hydroxy-9a-halo-l, 4-pregnadiene-3,20-diones (1) Treat each of the following 6,7-unsubstituted-9a-halo10 l,4-pregnadiene-3,20-diones with dry hydrogen chloride gas and DDQ in dioxan in a manner similar to that described in Preparation 1A, and then subject each of the resulting 9a-halo-l,4,6-pregnatriene-3,20-diones to a sequence of reactions similar to those described in Pre15 paration 11A(1)—(4): 1) 9a-fluoro-110,21-dihydroxy-2'-methyl-5'BH-l,4-pregnadieno[17,l6a-d]oxazole-3,20-dione 21-acetate, 2) 9a-fluoro-l6a,17a-cyclopentylidenedioxy-l,4-pregnadiene-ΙΙβ,21-diol-3,20-dione 21-acetate, 3) 9a-fluoro-lip-hydroxy-2',2'-dimethyl-1,4-pregnadieno [17,l6a-d]l',3'-oxathiolane-3,20-dione, - 113 45850 4) 9a-chloro-110-hydroxy-21,21-di methoxy -1,4-pregnadieno [17,l6a-d]-1’,3’-oxathiolane-3,20-dione, ) 9a-fluoro-l6a~methyl-21,21 -diacetoxy-l,4-pregnadiene 110,17 a-diol-3,20-dione 17-propionate, 6) 9a-fluoro-l6a-methyl-l,4-pregnadien-110-ol-3j2O,21trione 21,21-dimethylacetal, 7) 9a-fluoro-l6a-methyl-l,4-pregnadien-110-ol“3,2O,21trione 21-ethyleneketal, 8) 2-chloro-9a-fluoro-l6a-methyl-l,4-pregnadiene-110,17 diol-3,20,21-trione, 9) 2-chloro-9a-fluoro-l6a-methyl-l,4-pregnadiene-110,17 diol-3,20,21-trione 21-methylhemiacetal, ) 9a-fluoro-l60-methyl-2O-fluoromethoxy-21-nor-l,415 pregnadiene-110,17a-diol-3,20-dione 17-propionate, 11) 9a-fluoro-l60-methyl-2O-chloromethoxy-21-nor-l,4pregnadiene-110,17a-diol-3,20-dione 17-propionate, and 12) 9a-fluoro-16a-methyl-l,4-pregnadiene-110,21-diol3,20-dione 21-acetate.
Isolate and purify each of the resultant products in a manner similar to that described in Preparation 11A(4) to obtain the corresponding 70-hydroxy derivatives of the foregoing starting compounds. - 114 4595ο (2) In a manner similar to that described in Example 1A treat each of the following 6,7-unsubstituted-9a-fluorol,4-pregnadiene-3,20-diones with dry hydrogen chloride and DDQ in dioxan followed by treatment of the resulting 9a-fluoro-l,4,6-pregnatriene-3,20-dione in a manner similar to that described in Preparation 11D: 1) 9a-fluoro-l6-methylene-20-fluoromethoxy-21-nor-l,4pregnadiene-110,17 a-diol-3,20-dione 17-propionate, 2) 9a-fluoro-l6-methylene-20-chloromethoxy-21-nor-l,410 pregnadiene-110,17«-diol-3,20-dione 17-propionate, and 3) 9a-fluoro-l6-fluoromethylene-l,4-pregnadiene-110,17a, 21-triol-3,20-dione 21-acetate.
Isolate and purify each of the resultant products in a manner similar to that described in Preparation 11D(3) to obtain the corresponding 70-hydroxy derivative, i.e. 1) 9a-fluoro-l6-rnethylene-20-fluoromethoxy-21-nor-l,4pregnadiene-70,110,17 a-triol-3,20-dione 17-propionate, 2) 9a-fluoro-l6-methylene-20-chloromethoxy-21-nor-l,4pregnadiene-70,110,17a-triol-3,20-dione 17-propionate, and 3) 9a-fluoro-l6-fluoromethylene-l,4-pregnadiene-70,110, 17a,21-tetrol-3,20-dione 21-acetate. (3) (a) Treat n-butyl 9a-fluoro-110-hydroxy-l6a,17a-isopropylidenedioxy-3,20-dioxo-l,4-pregnadien-21-oate with - 115 4 8080 dry hydrogen chloride and DDQ in dioxan according to the procedure of Example 1A followed by treatment of the resulting 1,4,6-pregnatriene in a manner similar to that described in Preparation 11A(1), (2) and (3) to obtain n-butyl 60-propionyloxy-7P,110-dihydroxy-9a-fluoro-l6a, a-isopropylidenedioxy-3,20-dioxo-l,4-pregnadien-21oate. (3)(b) Treat n-butyl 60-propionyloxy-70,110-dihydroxy9ct-fluoro-l6a , 17a-isopropylidenedioxy-3,20-dioxo-l,4-pre10 gnadien-21-oate (1 gm.) with zinc (1 gm.) and acetic acid (10 ml.) at room temperature for 1 hour. Filter the reaction mixture, pour the filtrate into water, filter off the resultant precipitate and dry it in air to obtain n-butyl 70,110-dihydroxy-9a-fluoro-l6a,17a-isopropylidene15 dioxy-3,20-dioxo-l,4-pregnadien-21-oate.
B. 7«-Fluoro-9a-halo-l,4-pregnadiene-3,20-diones In a manner similar to that described in Example 8A, treat each of the 70-hydroxy-l,4-pregnadienes prepared in Example 14A with fluoramine in methylene chloride at 0°C. under an atmosphere of nitrogen. Isolate and purify each of the resultant products in a manner similar to that described to obtain the 7 C. 7 a-Bromo-9a-halo-l,4-pregnadiene~3,20-diones - 116 45950 In a manner similar to that described in Example 10Α, treat each of the 70-hydroxy-1,4-pregnadiene-3,20-diones prepared in Example 14a with fluoramine and lithium bromide in methylene chloride and isolate and purify each of the resultant products in the described manner to obtain the 7a-bromo derivative of each of the starting compounds listed In Examples 14a(1), 14A(2) and l4A(3).
D. 7 a-Chloro-9°-halo-l,4-pregnadiene-3,20-diones In a manner similar to that described in Example 10D, treat each of the 70-hydroxy-1,4-pregnadiene-3,20-diones prepared in Example 14a with fluoramine and lithium chloride in methylene chloride and isolate and purify each of the resultant products in a manner similar to that described to obtain, respectively, the 7a--chloro derivative of each of the starting compounds listed in Examples 14A(1), 14A(2) and 14A(3).
E. 7a,9«,17a-Trihalo-l,4-pregnadiene-3,20-diones (1) 7 α,9a-Difluoro-17 ot-chloro-l6a-methyl-l,4-pregnadiene110,21-diol-3,20-dione 21-acetate and the correspon20 ding 17ot-bromo derivative At -78°C. add anhydrous hydrogen fluoride (15 ml.) to a mixture of 7a,9a-difluoro-l6a-methyl-l,4-pregnadiene-110, - 117 21-diol-3,20-dione 21-acetate (5 gms.) and N-chlorosuccinimide (2 gms.) in tetramethylene sulfone (5 ml.). Allow the reaction mixture to stand at 3°C. for 7 days, then pour with stirring into a mixture of equal parts of water, ice and 25% aqueous ammonium hydroxide (300 ml.).
Filter off the resultant precipitate, wash it with water and dissolve it in methylene chloride. Wash the organic solution with 10% aqueous sodium sulfite and water, dry it over sodium sulfate and evaporate it in vacuo. Chro10 matograph the resultant residue on silica gel eluting with chloroform‘.ethyl acetate (2:1). Combine like eluates containing the desired compound as determined by thin layer chromatography and evaporate t;hem in vacuo to a residue comprising 7a,9a-difluoro-17a-chloro-l6a15 methyl-1,4-pregnadiene-110,21-d'iol-3,20-dione 21-acetate.
In the above procedure, by substituting for N-chloro-succinimide an equivalent quantity of N-bromosuceinimide, there is obtained the corresponding 17a-bromo compound, i.e. 7a, 9a-difluoro-17a-bromo-l6a-methyl-l,4-pregnadiene20 110,21-diol-3,20-dione 21-acetate. (2) In similar manner, treat 7a,9a-difluoro-l6a-methyll,4-pregnadien-110-ol-3,2O,21-trione 21-ethylene ketal with either N-chlorosuccinimide or N-bromosuccinimide - 118 45950 and hydrogen fluoride in tetramethylene sulfone in a manner similar to that described in Example l4E(l) to obtain either 7a,9a-difluoro-17a-chloro-l6a-methyl-l,4pregnadien-lip-ol-3,20,21-trione or 7a,9a-difluoro-17abromo-l6a-methyl-l,4-pregnadien-llP-ol-3,20,21-trione, respectively. (3) In the procedures of Examples 14e(1) and l4E(2), by starting with the 7a-chloro or 7a-bromo analog corresponding to the 7a-fluoro-l,4-pregnadiene starting compound named therein, there is obtained either the 7a-chloro-17ahalo or 7a-bromo-17a-halo derivative corresponding to the 7a-fluoro-17a-halo products named therein, i.e. 7a,17a-dichloro-9a-fluoro-l6a-methyl-l,4-pregnadiene-lip, 21-diol-3,20-dione 21-acetate, 7a-bromo-9a-fluoro-17achloro~l6a-methyl-1, 4-pregnadiene-HP,21-diol-3,20-dione 21-acetate, 7a-chloro~9a-fluoro-17a-bromo-l6a-methyll,4-pregnadiene-llP,21-diol-3,20-dione 21-acetate, 7a, 17a-dibromo-9a-fluoro-l6a-methy1-1,4-pregnadiene-llp,21diol-3,20-dione 21-acetate, 7a,17a-dichloro-9a-fluorol6a-methyl-l,4-pregnadien-HP-ol-3,20,21-trione, 7 achloro-9a-fluoro-17 a-bromo-l6a-methyl-l,4-pregnadien-liPol-3,20,21-trione, 7a-bromo-9a-fluoro-17a-chloro-l6amethyl-l,4-pregnadiene-lip-ol-3,20,21-trione, and 7a,17adibromo-9a-fluoro-16α-methyl-l,4-pregnadien-lip-ol-3,20,21trione. - 119 x. 45950 EXAMPLE 15 OTHER 7a,9a,HB-TRIHALO-l,4-PREGNADIENE3,20-DIQNES A. 7a,9a,llg-Trichloro-21-fluoro-l6-methylene-l,4-pre5 gnadien-17a-ol-3,20-dione 17-propionate (1) 7a-0hloro-21-fluoro-l6-methylene-l,4,9(11)-pregnatrien-I7a-ol-3,20-dione 17-propionate is prepared by reaction of 7a-chloro-21-fluoro-l6-methylene-1,4-pregnadiene-llg,17 a-diol-3,20-dione 17-propionate with methanesulfonyl chloride and sulfur dioxide in dimethylformamide and collidine by the method of Example 6A(1). (2) 7α,9α,llg-Trichloro-21-fluoro-l6-methylene-l,4-pregnadien-17a-ol-3,20-dione 17-propionate is prepared by re15 action of the 7a-chloro-21-fluoro-l,4,9(U)-pregnatriene of Example 15A(1) with chlorine in chloroform and pyridine by the method of Example 6B(1). Β. 7 α,9a,17 a-Trichloro-llg-fluoro-l6a-methyl-l,4-pregnadien-21-ol-3,20-dione 21-pivalate (l) 7 a-Chloro-l6a-methyl-l,4,9(11)-pregnatrien-21-ol3,20-dione 21-pivalate 120 45950 is prepared by reaction of 7a-chloro-l6a-methyl-l,4pregnadiene-ΙΙβ,21-diol-3,20-dione 21-pivalate with methanesulfonyl chloride and sulfur dioxide in dimethylformamide and collidine by the method of Example 6a(1). (2) 7a,9a,17a-Trichloro-llg-fluoro-l6a-methyl-l,4-pregnadien-21-ol-3,20-dione 21-pivalate is prepared by reaction cf 7a-chloro-16α-methyl-l,4,9(11)pregnatrien-21-ol-3,20-dione 21-pivalate with anhydrous hydrogen fluoride and N-chlorosuccinimide in tetramethylene sulfone by the method of Example 14E(1).
C. Treat each of the following 7-unsubstituted-l,4-pregnadiene-3,20-diones with DDQ and hydrogen chloride in a manner similar to that described in Preparation 1A, then react the resulting 1,4,6~pregnatriene-3,20-dione according to the procedures described in Preparation 11A followed by treatment of the resulting 70-hydroxy derivative thereby obtained with fluoramine according to the procedure of Example 8A or fluoramine together with lithium chloride according to the procedure of Example 10D or with fluoramine together with lithium bromide according to the procedure of Example 10A to obtain the corresponding 7afluoro- or 7a-chloro- or 7a-bromo- derivative of the following starting compounds: n-butyl 9a-chloro-ll(3fluoro-14 a,17 a-ethylidenedioxy-3,20-dioxo-l,4-pregnadien21-oate, methyl 9a,llB-dichloro-l6a-methyl-17a-acetoxy3,20-dioxo-l,4-pregnadien-21-oate, n-butyl 110-fluoro121 43950 9a-chloro-l4a,17a-ethylidene-dioxy-3,20-dioxo-l,4-pregnadien-21-oate, n-butyl 9a-chloro-110-fluoro-l4a,17a-ethylidenedioxy -3,20-dioxo-l,4-pregnadien-21-oate, n-butyl9a-chloro-110-fluoro-l4a,17a-ethylidenedioxy-3,2O-dioxo5 l,4-pregnadien-21-oate, methyl 9a,110-dichloro-l6a-methyl17a-acetoxy-3,20-dioxo-l,4-pregnadien-21-oate, methyl 9a,110-dichloro-l6a-methyl-17 a-acetoxy-3,20-dioxo-l,4-pregnadien-21-oate and methyl 9a,110-dichloro-l6a-methyl17a-acetoxy-3,20-dioxo-l,4-pregnadien-21-oate.
EXAMPLE 16 PREPARATION OF 17a-M0N0ESTERS / A. Using malt diastase (1) 7 «-Bromo-l6a-methyl-l,4-pregnadiene-110,17 a,21-triol3,20-dione 17-valerate To a suspension of diastase enzyme of malt (1.67 gm.) in ethanol (33·5 ml.) and water (167.5 ml.) add 7a-bromol6a-methyl-l,4-pregnadiene-110,17 a,21-triol-3,20-dione 17-valerate 21-acetate (33-5 mg.). Stir the reaction mixture at room temperature for 3 days, then evaporate in vacuo at room temperature. Dissolve the resultant residue in ethyl acetate and water and filter the solution through a Celite pad, washing with ethyl acetate.
Separate the organic and aqueous layers, then extract the aqueous layer with ethyl acetate. Wash the combined - 122 4595ο organic extracts with water, dry them over magnesium sulfate and evaporate them in vacuo Purify the resultant residue by thin layer chromatography using as developing solvent chloroform:ethyl acetate (3:1). Remove the band containing the desired product as visualized under ultraviolet light. Elute with ethyl acetate and evaporate to a residue comprising 7a-bromo-l6a-methyl-l,4-pregnadiene-110,17a,21-triol-3,20-dione 17-valerate. Purify by triturating with ether:hexane. (2) In similar manner, treat each of 7a-ehloro-l6a-methyl1,4-pregnadiene-110,17a,21-triol-3,20-dione 17-valerate 21-acetate and 7a-chloro-l6a-methyl-l,4-pregnadiene-110, 17a,21-triol-3,20-dione 17,21-dipropionate with diastase enzyme of malt in aqueous ethanol according to the procedure of Example l6A(l) to obtain, respectively, 7achloro-l6a~methy 1-1,4-pregnadiene-lliS,17 a,21-triol-3,20dione 17-valerate and 7a-chloro-l6a-methyl-l,4-pregnadiene-110,17a,21-triol-3,20-dione 17-propionate. (3) In similar manner, by treating any of the 7a-halo-21-acyloxy-l,4-pregnadienes of Examples 1-15 with diastase enzyme of malt in aqueous ethanol in a manner similar to that described in Example l6A(l), the corresponding 21-hydroxy derivative is obtained.
B. By acid hydrolysis 7a-Bromo-l,A-pregnadiene-llg,17 a,21-triol-3,20-dione 17-benzoate and its l6a-methyl derivative - 123 “ 45980 To 7a-bromo-l,4-pregnadiene-110,17α,21-triol-3,20-dione 17benzoate 21-acetate (0.44 gm.) in methanol (69 ml.) add 70% aqueous perchloric acid (1.76 ml.) and stir the reaction mixture for 4 hours. Bring the reaction mixture to neutra5 lity with saturated aqueous sodium bicarbonate and remove the methanol by evaporation in vacuo. Cool the aqueous reaction mixture and filter off the resultant precipitate comprising a mixture of 7a-bromo-l,4-pregnadiene-110,17a, 21-triol-3,20-dione and the 17-monobenzoate and 21-mono10 benzoate esters thereof. Separate by thin layer chromatography on silica gel developing with ethyl acetate: chloroform (1:1), remove the band containing the desired 17benzoate ester as visualized under ultraviolet light, elute with ethyl acetate and evaporate to a residue of 7a-bromo15 l,4-pregnadiene-110,17«,21-triol-3,20-dione 17-benzoate. a-Bromo-l6a-methyl-l,4-pregnadiene-110,17 a,21-triol-3,20MeOH dione 17-benzoate, m.p. 144-144.5°C., λ max 233 nm (£ =24,700), may be similarly prepared by hydrolysis of 7 a-bromo-l6a-methyl-l,4-pregnadiene-110,17a,21-triol-3,2020 dione 17,21-dibenzoate.
C. 7a-Halo-9a-fluoro-1,4-pregnadiene-110,l6a,17a,21tetrol-3,20-dione 17-hydrocarboncarboxylates (1) 7a-Chloro- and 7a-bromo-9a-fluoro-l,4-pregnadiene-110, 16a,I7a,21-tetrol~3,20-dione 17-propionate and 17-n-butyrate (a) 9a-Fluoro-l,4,6-pregnatriene-l6a,17 a,21-triol3,11,20-trione 16,21-diacetate 17-propionate and 17-nbutyrate are prepared by reaction of 9a-fluoro-1,4,6-preg- 124 4595 natriene-l6a,17α,21-triol-3,11,20-trione 16,21-diacetate with trifluoroacetic anhydride, toluene-p-sulfonic acid monohydrate and either propionic acid or n-butyric acid by the method of Preparation 5D. (b) 9a-Fluoro-l,4-pregnadiene-70>l6a,17«,21-tetrol3,11,20-trione 16,21-diacetate 17-propionate and 17-nbutyrate are prepared by subjecting 9a-fluoro-l,4,6-preg natriene-16 a,17 a,21-triol-3,11,20-trione 16,21-diacetate 17-propionate and 17-n-butyrate to a sequence of reac10 tions similar to that described in Preparation 11A(1~4). (c) 7a,9a-Difluoro-l,4-pregnadiene-l6a,17a,21-triol3,11,20-trione 16,21-diacetate 17-propionate and 17-nbutyrate are prepared by reaction of 7a,9a-difluoro-l,4pregnadiene-l6a,17a,21-triol-3,11,20-trione 16,21-di15 acetate 17-propionate and 17-n-butyrate with fluoramine in methylene chloride by the method of Example 8a.
The 17-propionate and 17-n-butyrate of ?a-bromo-9afluoro-l,4-pregnadiene-l6a,17a,21-triol-3,11,20-trione 16,21-diacetate and of 7a-chloro-9a-fluoro-l,420 pregnadiene-l6a,17a,21-triol-3,11,20-trione 16,21-diacetate can be obtained by the methods of Examples 10A and IOC by reaction of the 70-hydroxy pregnadienes of Example l6C(l)(b) with lithium bromide and fluoramine or with lithium chloride - 125 45950 and fluoramine in methylene chloride. (d) 7a-Halo-9a-fluoro-1,4-pregnadiene-llg,16α,17a,21-tetrol-3,20-dione 16,21-diacetate 17-propionates and 17-n-butyrates In a manner similar to that described in Example 1C and 2C, treat all six products of Example l6C(l)(c) with sodium borohydride in tetrahydrofuran and methanol under an atmosphere of nitrogen, and isolate each of the resultant products in a manner similar to that described to obtain, respectively, the 17-propionate and 17-n-butyrate of 7a,9a-difluoro-l,4-pregnadiene-llg,16a,17a,21tetrol-3,20-dione 16,21-diacetate, the 17-propionate and the 17-n-butyrate of 7a-chloro-9a-fluoro-l,4-pregnadieneIlg5l6a,17a,21-tetrol-3j20-dione 16,21-diacetate, and the 17-propionate and 17-n-butyrate of 7a-bromo-9a-fluoro-l,4 pregnadiene-llg,16a,17a,21-tetrol-3,20-dione 16,21-diacetate. (e) 7 a-Halo-9a-fluoro-1,4-pregnadiene-llg,16α,17 a,21tetrol-3,20-dione 17-propionates and 17-n-butyrates In a manner similar to that described in Example 16A, treat all six products of Example l6C(l)(d) with diastase enzyme of malt in aqueous ethanol and isolate and puri fy each of the resultant products in a manner similar to that described to obtain, respectively, the 17-propionate and the 17-n-butyrate of 7a,9 110,ΐδα,17α,21-tetrol-3,20-dione, the 17-propionate and 17-n-butyrate of 7a-chloro-9a-fluoro-l,4-pregnadiene110,l6a,17a,21-tetrol-3,20-dione, and the 17-propionate and 17-n-butyrate of 7a-bromo-9a-fluoro-l,4-pregnadiene~ 110,16a,17a,21-tetrol-3,20-dione. (2) 7a-Chloro and 7a-brotno-9a-fluoro-l,4-pregnadiene110,l6a,17a,21-tetrol-3,20-dione 17-benzoate (a) 9«-Fluoro-l,4,6-pregnatriene-110,l6a,17ot,21-tetrol3,20-dione 16,17-methylorthobenzoate 21-acetate is prepared by reaction of 9a-fluoro-l,4,6-pregnatriene110,16a,17a,21-tetrol-3,20-dione 21-acetate with trimethylorthobenzoate and pyridinium toluene-p-sulfonate in dioxan and benzene by the method of Preparation 2C(1). (b) 7a-Chloro- and 7a-bromo-9a-fluoro-l,4-pregnadiene110,l6a,17a,21-tetrol-3,20-dione 16,17-methylorthobenzoate 21-acetate are prepared from 9a-fluoro-l,4,6-pregnatriene-110,16a, 17a,21-tetrol~3,20-dione 16,17-methylorthobenzoate 21acetate by reaction with hydrogen chloride in tetrahydrofuran and with hydrogen bromide in glacial acetic acid respectively by the methods of Examples IB and 2B. (c) 7a-Chloro- and 7a-bromo-9a-fluoro-l,4-pregnadiene110,16a,17a,21-tetrol-3,20-dione 17-benzoate 21acetate - 127 are prepared from 7a-chloro- and 7a-bromo-9a-fluoro-l,4pregnadiene-110,16 a,17 a,21-t etrol-3,20-dione 16,17-methylorthobenzoate 21-acetate respectively by hydrolysis with aqueous acetic acid by the method of Preparation 2A(2). (d) 7a-Chloro- and 7a-bromo-9a-fluoro-l,4-pregnadienellg,l6ct,17 EXAMPLE 17 7a-HAL0-l,4-PREGNADIENE-17a,21-DIOL3,20-DIONE 17-HYDROCARBONCARBOXYLATE 21-RETINOATES A. 7 a-Chloro-16 a-methyl-1,4-pregnadiene-110,17a,21-triol3,20-dione 17-propionate 21-retinoate To a suspension of 7a-chloro-l6a-methyl-l,4-pregnadiene110,17a,21-triol-3,20-dione 17-propionate (464 mg., 1 mmol), in methylene chloride (50 ml.) under nitrogen and in the dark, add retinoic acid (300 mg., 1 mmol) and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-£-toluenesulfonate (424 mg., 1 mmol). Stir at room temperature for 17 hours, then.add an additional mmol of retinoic - 128 45950 acid and an additional mmol of the diimide, and continue stirring the reaction mixture for an additional 24 hours. Extract the reaction mixture sequentially with 2% hydrochloric acid, water, 5% aqueous sodium bicarbonate and again with water. Dry over sodium sulfate and evaporate in vacuo. Chromatograph the resultant residue on silica gel GP thick layer plates, eluting with ethyl acetate: chloroform (1:2). Remove the steroidal retinoate band from the thick layer plate, extract with ethyl acetate and evaporate in vacuo to a residue comprising 7a-chlorol6a-methyl-l,4-pregnadiene-lip,17 a,21-triol-3,20-dione 17-propionate 21-retinoate. Further purify by recrystallization from ether .-petroleum ether.
B. Similarly, by treating any 21-hydroxy-7a-halo-l,4pregnadiene-3,20-dione of this invention by the method of Example 17A, its 21-retinoate is obtained.
EXAMPLE 18 7a-Chloro-l6a-methyl-l,4-pregnadiene-110, 17u,21-triol-3,20-dione To a solution of 7a-chloro-l6a-methyl-l,4-pregnadiene110,17a,21-triol-3,20-dione 17,21-dipropionate (3-5 gms.) in methanol (300 ml.) add saturated aqueous sodium bicarbonate solution (30 ml.) and allow to stand at room temperature for 18 hours. Pour into water, filter off the resultant precipitate, wash it with water until neu- 129 45850 tral, then dry it in air. Recrystallize the dried precipitate from acetone/hexane to give 7a-chloro-l6a-methyll, 4-pregnadiene-110,17a,21-triol-3,20-dione, yield 1.3 gm., „ MeOH m. p. 176-179°C·,[a]n +47.5°(dimethylformamide); λ V ΓΠ&Χ 242 nm (£ =15,500).
EXAMPLE 19 α-Bromo-l,4-pregnadiene-110,17 a,21-triol~5,20-dione and its 21-acetate To a solution of l,4,6-pregnatriene-110,17a,21-triol10 3,20-dione 21-acetate (5 gms.) in glacial acetic acid (62 ml.) add dry hydrogen bromide (37.5 gms.) and allow the reaction mixture to stand at 0~5°C. for 45 minutes.
Pour the reaction mixture into water, filter off the resultant precipitate, wash it with water and dry it in air to obtain 7a-bromo-l,4-pregnadiene-110,17a,21-triol3,20-dione 21-aeetate.
Dissolve the foregoing product in methanol (525 ml.), add 70% aqueous perchloric acid (13-2 ml.) and stir the reaction mixture at room temperature for 18 hours. Add water, then saturated aqueous sodium bicarbonate until the solution is neutral, and evaporate the reaction mixture until the methanol is removed. Extract the aqueous reaction mixture with ethyl acetate, wash the combined ethyl acetate extracts with water, dry them over sodium sulfate and evaporate them. Recrystallize the resultant - 130 4S9S0 residue from acetone to obtain 7a-bromo-l,4-pregnadiene110,17a,21-triol-3,20-dione, yield 0.3 gm., m.p.
. MeOH >320°C.,[a]n +48.2° (dimethylformamide), Λ JJ ΙΠ&Λ 241 nm ( £ =15,100). 7a-Chloro-l6a-methyl-l,4-pregnadiene~110,17a,21-triol26 3,20-dione, m.p. 176-179°C., [a]R +47.5° (dimethylforma. MeOH mide), λ 242 nm ( C -15,500), may be prepared simiHIcLX larly.
EXAMPLE 20 7a-CHL0R0-4-PREGNENE-17a,21-DIOL-3,11,20-TRIONE 17,21-DIPROPIONATE AND ITS l6a-METHYL AND 160-METHYL DERIVATIVES A. At 10°C. dissolve 4,6-pregnadiene-17a,21-diol~3,11,20trione 17,21-dipropionate (911 mg.) in a freshly prepared solution of hydrogen chloride in tetrahydrofuran and water (10 ml.) comprising 38.2% by weight of hydrogen chloride and 3.7% by weight of water. Stir the reaction mixture for 15 minutes at 0-2°C., then pour into ice water (100 ml.). Filter off the resultant precipitate, wash it with water, and dry it, partially under a blanket of nitrogen and then at room temperature in vacuo for 17 hours to obtain a mixture of 7a-chloro-4-pregnene-17a,21-diol~3,11,20-trione 17,21-dipropionate and 4,6-pregnadiene-17a,21-diol-3,11,20trione 17,21-dipropionate. Separate the components of this mixture by thick layer chromatography on silica gel, developing with hexane:dimethoxyethane (2:1), and elute with - 131 45950 ethyl acetate the band containing 7a-chloro-4-pregnene17a,21-diol-3,11,20-trione 17,21-dipropionate as shown by ultraviolet spectrum. Evaporate the ethyl acetate eluate at room temperature and recrystallize the resultant residue from acetone:hexane at room temperature to obtain 7 a-chloro-4-pregnene-17 a,21-diol-3,11,20-trione 17,21-dipropionate. Store in an open vessel at room temperature in vacuo.
B. 7 a-Chloro-l6a-methyl-4-pregnene-17a,2l-diol-3,11,20trione 17,21-dipropionate and 7«-ohloro-l6g-methyl-4pregnene-17 a,21-diol-3,11,20-trione 17,21-dipropionate are prepared by reaction of l6a-methyl-4,6-pregnadiene17a,21-diol-3,11,20-trione 17,21-dipropionate and ΐ6βmethyl-4,6-pregnadiene-17a,21-diol-3,11,20-trione 17,21dipropionate with hydrogen chloride in aqueous tetrahydrofuran by the method of Example 20A.
EXAMPLE 21 7a-BROMO-4-PREGNENE-17 a,21-DIOL-3,11,20TRIONE-17>21-DIPROPIONATE AND ITS l6a-METHYL AND Ι6βMETHYL DERIVATIVES ' A. Dissolve at room temperature 4,6-pregnadiene-17a,21diol-3,11,20-trione 17,21-dipropionate (235 mg.) in a freshly prepared solution of hydrogen bromide in acetic acid (44%, 2.5 ml.). Stir at room temperature for 30 minutes, then add the reaction mixture to water - 132 4 58 5ο (100 ml.), filter off the resultant precipitate, wash with water and dry it under a blanket of nitrogen to obtain a mixture of 7a-bromo-4-pregnene-17a,21-diol-3,11,20-trione 17,21-dipropionate and 4,6-pregnadiene-17a,21-diol-3,11,20trione 17,21-dipropionate. Isolate 7a-bromo-4-pregnene17a,21-diol-3,11,20-trione 17,21-dipropionate from this mixture by the method of Example 20A, and store it in an open vessel at room temperature in vacuo.
B. 7 a-Bromo-l6a-methyl-4-pregnene-17a,21-diol-3,11,20trione 17,21-dipropionate and 7a-bromo-l6g-methyl-4-pregnene -17a,21-diol-3,11,20-trione 17,21-dipropionate are prepared by reaction of l6a-methyl-4,6-pregnadiene-17a,21-diol3,11,20-trione 17,21-dipropionate and l6g-methyl-4,6-pregnadiene-17a,21-diol-3,11,20-trione 17,21-dipropionate with hydrogen bromide in acetic acid by the method of Example 21A.
EXAMPLE 22 7a-HALO-4-PREGNENE-llg,17«,21-TRI0L-3,20-DIONE 17,21-DIPROPIONATE AND ITS l6a-METHYL AND ΐόβ-METHYL DERIVATIVES A. 7 a-Chloro-4-pregnene-llg,17 a,21-triol~3,20-dione 17,21dipropionate and its l6a-methyl and l6g-methyl derivatives (1) At room temperature dissolve 7a-chloro-4-pregnene17a,21-diol-3,11,20-trione 17,21-dipropionate (3-1 g.) in methanol (375 ml.) and add water (30 ml.). To this so- 133 45950 lution at 0°-2°C. under an atmosphere of nitrogen add sodium borohydride (2.38 gms.). After 30 minutes, cautiously add the reaction solution to 4.2 liters of water containing 80 ml. of N hydrochloric acid. Filter off the resulting precipitate and chromatograph it on silica gel, eluting with chloroform:ethyl acetate (3:1). Evaporate the combined eluates in vacuo To 152 mg. of the resultant residue, add a suspension of manganese dioxide (600 mg.) in benzene (7 ml.), stir for 5 hours, filter, and chroma10 tograph the filtrate on silica gel by thin layer chromatography, developing with chloroform:ethyl acetate (3:1) and eluting with ethyl acetate the band containing the desired product as determined by ultraviolet spectrum. Evaporate the ethyl acetate solution in vacuo to a residue comprising 7a-chloro-4-pregnene-110,17a,21-triol-3,20-dione 17,21-dipropionate. Further purify by recrystallization methanol from ether:hexane at room temperature: λ 237 nm max (6 =15,500). (2) 7 a-Chloro-l6a-methyl-4-pregnene-ΙΙβ,17 a,21-triol-3,2020 dione 17,21-dipropionate and 7a-chloro-l60-methyl-4-pregnene-llg,17a,2l-triol-3,20-dione 17,21-dipropionate are prepared by reaction of 7a-chloro-l6a-methyl-4-pregnene-17a, 21-diol-3,11,20-trione 17,21-dipropionate and 7a-chlorol6(3-methyl-4-pregnene-17a,21-diol-3,11,20-trione 17,21-di25 propionate with sodium borohydride in aqueous methanol and reaction of the product therefrom with manganese dioxide in benzene by the method of Example 22A(1). - 134 B. 7a-Bromo-4-pregnene-110,17α,21-triol-5,20-dione 17,21dipropionate and its l6«-methyl and 160-methyI derivatives are prepared by the method of Example 22A from the 7a-bromo analogs of the 7a-chloro starting compounds named therein.
EXAMPLE 25 OTHER 7«-HAL0-ll-0XYGENATED-4-PREGNBNE-17a,21-DIQL5,20-DIQNES AND ESTER DERIVATIVES THEREOF Esters of 4,6-pregnadiene~3,ll,20-trione-17a,21-diols (prepared as described in Preparation 12) may similarly be used as starting materials in Examples 20 and 21, and the resulting esters of 7a-chloro- and 7a-bromo-4-pregr.ene-3, ll,20-dione-17a,21-diols may be treated according to the procedure of Example 22 to yield esters of 7a-chloro- and 7a-bromo-4-pregnene-3,2O-dione-110,17a,21-trxols.
EXAMPLE 24 7a-IODO-9a-FLUORO-l60-METHYL-l,4-PREGNADIENE110,17a,21-TRI0L-5,20-DIONE 17,21-DIPROPIONATE (A) To a solution of dry hydrogen iodide (0.4 gm.) in glacial acetic acid (1.5 ml.) at room temperature, protected from light, add a solution of 9a-fluoro-l60-methyl-l,4, 6-pregnatriene-110,17a,21-triol~3,20-dione 17,21-dipropionate (0.05 gm.) In glacial acetic acid (0.5 ml.). Stir the reaction mixture (protected from light) at room temperature for 30 minutes and then add 5% sodium thiosulfate solution (20 ml.). Extract the mixture with methylene - 135 48850 chloride (two 50 ml. portions), wash the combined organic extracts twice with water, dry them over anhydrous sodium sulfate’ and evaporate them at room temperature in vacuo. Purify the resultant residue on silica gel by thick layer chromatography, developing with ethyl acetate/chloroform (1:9). Scrape off the more polar band as shown under ultraviolet light, wash the silica gel with ethyl acetate, evaporate the combined ethyl acetate washings in vacuo and recrystallize the resultant residue from ether to obtain 7a-iodo-9a-fluoro-160-methyl-1,4-pregnadiene-110,17a, 21-triol~3,20-dione 17,21-dipropionate, yield 16 mg. (39%); m.p. l45°C. (decomp.); nmr (dmso-dg) ? 0.95, 1.28, 1.55, 4.20, 4.59, 4.70, 5-99, 6.20, 7-25Alternatively, the compound of this example is prepared according to Examples 24(B) and 24(C) below.
(B) 7a-lodo-9g-fluoro-l60-methyl-l,4-pregnadiene-17a,21diol-3,11,20-trione 17,21-dipropionate is prepared in a manner similar to that described in Example 24(A) from 9a-fluoro-l6p-methyl-1,4,6-pregnatriene-17 a,21-diol-3,11, - trione 17,21-dipropionate (100 mg.) and dry hydrogen iodide (0.8 gm .) in glacial acetic acid (4 ml.); yield=80 mg., (64% theory). It is further purified by recrystallization from ether, m.p. 106°C. (decomp.).
(C) 7 a-Iodo-9«-fluoro-160-methyl-1,4-pregnadiene-110,17«, 21- triol-3,20-dione 17,21-dipropionate is prepared in a manner similar to that described in Example 3C(1) from - 136 45950 7a-iodo-9a-fluoro-ΐδβ-methyl-1,4-pregnadiene-17a,21-diol3,11,20-trione 17,21-dipropionate by reduction with sodium borohydride at 0°C. in tetrahydrofuran and methanol under nitrogen.
EXAMPLE 25 7a-I0D0-9a-CHL0R0-l63-METHYL-l,4PREGNADIENE-113,17a,21-TRIOL-3,20-DIONE 17,21DIPROPIONATE (A) 7a-Iodo-9a-chloro-l6g-methyl-l ,4 -pregnadiene-Π β, 17a,21-triol-3,20-dione 17,21-dipropionate is prepared in a manner similar to that described in Example 24(A) from 9a-chloro-l60-methyl-1,4,6-pregnatriene-110,17a,21-triol3,20-dione 17,21-dipropionate and hydrogen iodide in glacial acetic acid; yield=15%.
(B) Alternatively, the compound of this example is made by treating 9a-chloro-l6p-methy1-1,4,6-pregnatriene-17a,21diol-3,11,20-trione 17,21-dipropionate with hydrogen iodide in acetic acid according to Example 24(A) followed by reduction of the resulting 7a-iodo-9a-chloro-l6i3-methyl-l,42o pregnadiene-17a,21-diol-3,11,20-trione 17,21-dipropionate with sodium borohydride in methanol/tetrahydrofuran according to Example 30(1). - 137 4S9S0 EXAMPLE 26 7a-IODO-9a-BROMO-l6g-METHYL-l,4PREBNADIENE-ΙΙβ,17a,21-TRIOL-3,20-DIONE 17,21DIPROPIONATE Treat 9a-bromo-l6P-methyl-l,4,6-pregnatriene-17a,21-diol3,11,20-trione 17,21-dipropionate with hydrogen iodide in glacial acetic acid according to Example 24(B), followed by reduction of the resulting 7a-iodo-9a-bromo-l6|3-methyl1,4-pregnadiene-17a,21-diol-3,11,20-trione 17 j 21-dipropionate with sodium borohydride in methanol/tetrahydrofuran according to the procedure of Example 24(C) to obtain 7 a-iodo-9 a-bromo-ΐδβ -methyl-1,4-pregnadiene-lip,17a,21triol-3,20-dione 17,21-dipropionate.
EXAMPLE 27 7a-BR0M0-9«-PLU0R0-l63-METHYL-1,4-PREGNADIENE11β,17a,21-TRI0L-5,20-DIONE 17,21-DIPROPIONATE (A) 7 a-BroiTio-9a-fluoro-l60-methyl-1,4-pregnadiene-17a, 21diol-3,11,20-trione 17,21-dipropionate To a solution of 9a-fluoro-l6B-methyl-l,4,6-pregnatriene-17a,21-diol-3,11,20-trione 17,21-dipropionate (0.5 gm.) in glacial acetic acid (1 ml.) add a solution of dry hydrogen bromide in glacial acetic acid (48% w/w; 5 ml.). Stir at 5°C. for one hour, then pour into ice water (300 ml.). Filter off the resultant precipitate, wash it thoroughly with water and dry it in air at room temperature. Purify the precipitate on thick layer silica gel plates, develop- 138 4595 ing with ethyl acetate/chloroform (1:5). Scrape off the band containing the desired compound as shown under ultraviolet light and extract the compound from the silica gel with ethyl acetate. Evaporate the ethyl acetate solution to a residue comprising 7a-bromo-9a-fluoro-l60methyl-1,4-pregnadiene-17 a,21-diol-3,11,20-trione 17,21dipropionate, yield=60% theory, m.p. 115°C. (decomp.).
(B) In a manner similar to that described in Example 30(1) reduce the product of Example 27(A) with sodium borohydride in methanol/tetrahydrofuran to obtain 7a-bromo-9a-fluoro 160-methyl-1,4-pregnadiene-17a,21-diol-3,11,20-trione 17, 21-dipropionate.
EXAMPLE 28 a-BR0M0-9 q-CHLORO-l60-METHYL-1,4-PREGNADIENE15 110,17a,21-TRI0I.-3,20-DIONE 17,21-DIPROPIONATE Treat 9a-chloro-l60-methyl-l,4,6-pregnatriene-17a,21-diol3,11,20-trione 17,21-dipropionate with hydrogen bromide in acetic acid in a manner similar to that described in Example 27(A) followed by reduction of the resulting fa20 bromo-9a-chloro-l60-methyl-1,4-pregnadiene-17a,21-diol3,11,20-trione 17,21-dipropionate with sodium borohydride in methanol and tetrahydrofuran according to Example 30(1) to obtain 7a-bromo-9a-chloro-l60-methyl-l,4-pregnadiene110,17a,21-triol-3,20-dione 17,21-dipropionate. - 139 45950 EXAMPLE 29 (A) 7a-Iodo-9a-fluoro-l6a-methyl-l,4-pregnadiene-17«,21diol-5,11,20-trione 17,21-dipropionate is prepared by reaction of 9a-fluoro-l6a-rnethyl-l,4,6-pregnatriene-17a,21diol-3,11,20-trione 17,21-dipropionate with hydrogen iodide in glacial acetic acid in the dark by the method of Example 24(A).
(B) 7a-Iodo-9a-fluoro-i6a-methyl-l,4-pregnadiene-llg,17a, 2l-triol-3,20-dione 17,21-dipropioriate is prepared by reduction of the compound of part (A) with sodium borohydride by the method of Example 3C(1).
EXAMPLE 30 (A) 7a-Bromo-9a-fluoro-l6a-methyl-l,4-pregnadiene-17a,21diol-3,11,20-trione 17,21-dipropionate is prepared by reaction of 9a-fluoro-l6a-methyl-l,4,6-pregnatriene-17a,21diol-3,11,20-trione 17,21-dipropionate with hydrogen bromide in glacial acetic acid in the dark by the method of Example-24(A).
(B) 7 g-Bromo-9a-fluoro-l6a-methyl-l,4-pregnadiene-llg,17«, 21-triol-5,20-dione 17,21-dipropionate is prepared by reduction of the compound of part(A) with sodium borohydride by the method of Example 3C(1).
EXAMPLE 31 (A) 7 a-Iodo-9a-chloro-l6q-methyl-l,4-pregnadiene-17 a,21diol-3,11,20-trione 17,21-dipropionate is prepared by re- 140 45850 action of 9a-chloro-l6a-methyl-l,4,6-pregnatriene-17«,21diol-3,11,20-trione 17,21-dipropionate with hydrogen iodide in glacial acetic acid in the dark by the method of Example 24(A).
(B) 7a-Iodo-9a-chloro-l6a-methyl-l,4-pregnadiene-llg,17a, 2i-triol-g,20-dione '17,21-dipropionate is prepared by reduction of the compound of part (A) with sodium borohydride by the method of Example 3C(1).
EXAMPLE 32 (A) 7a-Bromo-9«-chloro-l6a-methyl-l,4-pregnadiene-17a,21diol-3,11,20-trione 17,21-dipropionate is prepared by reaction of 9a-chloro-l6a-methyl-l,4,6-pregnatriene-17a, 21-diol-3,11,20-trione 17,21-dipropionate with hydrogen bromide in glacial acetic acid in the dark by the method of Example 24(A).
(B) 7a-Bromo-9«-chloro-l6a-methyl-l,4-pregnadiene-llg,17«, 21-triol-3,20-dione 17,21-dipropionate is prepared by reduction of the compound of part (A) with sodium borohydride by the method of Example 3C(1).
EXAMPLE 33 (A) 7a-Iodo-9a-fluoro-l6ct,17a-isopropylidenedioxy-l,4pregnadien-21-ol-3,11,20-trione 21-acetate is prepared by reaction of 9a-fluoro-l6a,17a-isopropylidenedioxy-l,4,6pregnatrien-21-ol-3,11,20-trione 21-acetate with hydrogen iodide in glacial acetic acid in the dark by the method - 141 45950 of Example 24(A).
(B) 7q-Ioao-9a-fluoro-l6a 317 ct-isopropylidenedioxy-1,4pregnadiene-llg,21-diol-3,20-dione 21-acetate is prepared by reduction of the compound of part (A) with sodium borohydride by the method of Example 3C(1).
EXAMPLE 34 (A) 7a-Bromo-9a-fluoro-l6a,17a-isopropylidenedioxy-l,4pregnadien-21-ol-3,11,20-trione 21-acetate is prepared by reaction of 9a-fluoro-l6a,17a-isopropylidenedioxy-l,4,6pregnatrien-21-01-3,11,20-trione 21-acetate with hydrogen bromide in glacial acetic acid in the dark by the method of Example 24(A).
(B) 7a-Bromo-9a-fluoro-l6a,17a-isopropylidenedioxy-1,4pregnadiene-ΙΙβ,21-diol~3,20-dione 21-acetate is prepared by reduction of the compound of part(A) with sodium borohydride by the method of Example 30(1).
The invention further provides pharmaceutical compositions suitable especially for the treatment of inflammatory conditions in animals and humans and comprising at least one compound of the formula 1 defined above, together with a compatible pharmaceutical carrier or excipient.
The compositions may take the form of dosage units, for example tablets, pellets, capsules, dragees, suppositories or injectable preparations in ampoules. Dosage units preferably contain from 0,05 to 10 mg. of active - 142 ingredient. The compositions may also be formulated as sprays, powders, drops, aerosols, retention enemas, suspensions, syrups, elixirs, emulsions, ointments, lotions or creams; such compositions preferably contain from 0.0001% to 5% by weight, preferably from 0.001 to 0.5%, especially from 0.01 to 0.25% of active ingredient of the formula I hereinabove defined.
The compositions may be administered orally for inflammatory disorders, particularly arthritis and rheumatism; intravenously in aqueous solution as the 21-hemisuccinate or 21-phosphate ester for the treatment of shock; intramuscularly for long-term systemic activity or intraartieularly for long-term local activity with low systemic effects in the treatment of rheumatoid arthritis, tennis elbow, bursitis, gout and similar conditions by administration In aqueous suspension as the 17,21-dihydrocarboncarboxylates, e.g. 17,21-di-propionate, 17,21di-butyrate and 17-benzoate 21-acetate; topically in creams, lotions or ointments as the 17-mono lower alkanoate or benzoate in the treatment of contact and allergic dermatitis and psoriasis and of corticosteroid-responsive conditions such as alopecia areata and alopecia totalis; in the form of ophthalmic suspensions or nasal sprays; or as inhalation aerosols in the treatment of asthma and allergic rhinitis. Such pharmaceutical forms are prepared according to procedures well known in the art and may contain other active ingredients, such as antibacterials, e.g. neomycin sulfate in creams for to- 143 45950 pical use.
The following examples illustrate topical formulations according to this invention. In each, a preferred active ingredient is 7a-chloro-l6a-methyl-l,4-pregnadiene 110,17a,21-triol-3,20-dione 17,21-dipropionate; however, this compound may be replaced by equivalent quantities of other active compounds of this invention, e.g. by the 17,21-dipropionate or the 17-benzoate 21-propionate of 7 a-bromo-16a-methyl-l,4-pregnadiene-110,17 a,21-triol-3,20 dione. The formulations are prepared by standard methods.
FORMULATION EXAMPLES 1. Ointment mg/g Active ingredient 0.1-5.0 Mineral oil 20.0 White petrolatum to make 1.00 g 2« Glycol Ointment Active ingredient 0.1-0.5 Hexylene glycol 100.0 Propylene glycol monostearate 20.0 White wax . 60.0 White petrolatum to make 1.00 g 3. Lotion ms/g Active ingredient 0.1-5.0 Ethyl alcohol 400.0 Polyethylene glycol 400 300.0 Hydroxypropyl cellulose 5.0 Propylene glycol to make 1.0 g - 144 45950 4. Gel mg/g Active ingredient 0.1-5.( Ethyl alcohol 400.0 Polyethylene glycol 400 300.0 *Carbopol 940 (Goodrich Chemical Co.) 15.0 Potassium hydroxide 5.0 Propylene glycol co make 1.00 g 5. Cream mg/g Active ingredient 0.1-5.( Isopropyl palmitate 100.0 Glyceryl stearate 80.0 Promulgen-type D (Robinson, Wagner 50.0 Co.) White wax 50.0 Propylene glycol 100.0 Purified water to make 1.00 g 6. Topical Aerosol mg/can Active ingredient 6.4 Mineral oil 1,250.0 Neobee M-5 (Caprylic/capric glyceride) (PVO International, Inc.) 3,743.6 DIchlorodifluoromethane 17,200.0 Trichloromonofluoromethane 68,800.0 91,000.0 *Carbopol is a Trade Mark - 145 45950 7. Inhalation Aerosol Active ingredient Oleic acid Trichloromonofluoromethane Dichlorodifluoromethane 8. Intra-Articular Injection Active ingredient Sodium phosphate, dibasic, anhydrous R Sodium chloride, USP Disodium edetate, USP Polysorbate 80, USP Benzyl alcohol, R Methyl p-hydroxybenzoate, USP Propyl p-hydroxybenzoate, USP Sodium carboxymethylcellulose Polyethylene glycol 4000, USP HC1 IN qs pH 7.1 Water for injection qs ad 9. Solution Active ingredient Kt-Methylpyrrolidone Isopropyl myristate Isopropyl alcohol qs to mg/can 12.60 1.26 ,686.14 14,700.00 ,400.00 mg/ml 0.1-5.0 2.00 .00 0.10 0.50 9.00 1.80 0.20 .00 .00 1.00 ml mg/ml 0.1-5.0 200 1.0 ml - 146 45950

Claims (15)

1. A 3,20-dioxo-7a-halo-4-pregnene or -1,4-pregnadiene of the formula 5 wherein the dotted line it the 1/’-positions indicates a 1,2-single bond or a 1,2-double bond; W is a group (Η,Η), (H, lower alkyl), (Η,α-OV 1 ) or =CHT, wherein is a hydrogen atom or an acyl radical of retinoic acid or of a carboxylic acid having up to 12 10 carbon atoms, and T is a hydrogen, fluorine or chlorine atom or a lower alkyl group; Q is a chlorine or bromine atom or a group OV wherein V is a hydrogen atom or an acyl radical of a carboxylic acid having up to 12 carbon atoms, or, provided that W 15 is a group (Η,Η) or (H, lower alkyl), Q can also be a hydrogen atom; - 147 45950 or Q and W taken together are a l6a,17a-lower-alkylidenedioxy, -cyeloalkylidenedioxy or -aralkylidenedioxy group together with a 160-hydrogen atom or a grouping —N> S> C _ R 1 or / wherein R is a <ς--0 R ^--0 lower alkyl group and R 1 is a lower alkyl or phenyl group B is a hydrogen atom or, together with Q, is a Ι4α,17αlower alkylidenedioxy group; M is a group -CHO or such a group in the form of an acetal, hemiacetal or acylal, -CH^, -C00r\ -CHgHal or
2
3 10 -CH 2 0V , wherein R is a hydrocarbyl group having up to 12 carbon atoms, Hal is a halogen atom having an 2 atomic weight of less than 100, and V is a hydrogen atom or an acyl radical of retinoic acid, of a carboxylic acid having up to 12 carbon atoms or of 15 phosphoric acid, which may be in the form of a mono- or 2 di-alkali or alkaline earth metal salt; or OV together with Q is an alkylidenedioxy, cyeloalkylidenedioxy, aralkylidenedioxy, alkylorthoalkanoate or alkylorthoarylcarboxylate group; or, provided that Q is an Ο-Acyl group 2 2 . 20 M can also be a group -OR wherein R is a lower alkyl or halolower alkyl group; X is a hydrogen atom or a halogen atom having an atomic weight of less than 100; - 148 45950 Y is an oxygen atom or a group (Η,β-ΟΗ) or ι'Η,ρ-OCOH), or, provided that X is chlorine or bromine, Y can also be a group (Η,β-halogen), said halogen having an atomic weight of less than 100 and being at least as electrone5 gative as X, or, provided that X is hydrogen, Y can also be a group (H,H); A, which is in the α-position in the
4. -pregnenes, is a hydrogen atom or, provided that Y is (Η,β-ΟΗ), A can also be a chlorine or fluorine atom or a methyl group; 10 and Z is a fluorine, chlorine, bromine or iodine atom; and, when W is (H,H), the D-homo analogs thereof. 2. A compound as claimed in claim 1 wherein the dotted line indicates a 1,2-double bond. 15 3. A Compound as claimed in claim 2 wherein X, Y and Z are as defined in claim 1; W is a group (Η,Η), (H, lower alkyl), (Η,α-OV ) or =CHT, wherein V^ is a hydrogen atom or an acyl radical of isonicotinic acid, of benzoic acid substituted ^y a h a ]_ o gen 20 atom or by a methoxy group, of retinoic acid or of a hydrocarboncarboxylic acid having up to 12 carbon atoms, and T is a hydrogen, fluorine or chlorine atom or a lower alkyl group; - 149 45980 Q is a chlorine or bromine atom or a group OV wherein V is a hydrogen atom or an acyl radical of a hydrocarboncarboxylic acid having up to 12 carbon atoms or of benzoic acid substituted by a halogen atom or by a metho5 xy group, or, provided that W is a group (H,H) or (H, lower alkyl), Q can also be a hydrogen atom; or Q and W taken together are a l6a,17a-lower-alkylidenedioxy or l6a,17a-cycloalkylidenedioxy group; A and B are hydrogen atoms; and 10 M is a group -CHO or such a group in the form of an acetal, hemiacetal or acylal, -CH-j, -C00r\ -CHpHal or 2 3 . -CHgOV , wherein R is a hydrocarbyl group having up to 12 carbon atoms, Hal is a halogen atom having an 2 . atomic weight of less than 100, and V is a hydrogen 15 atom or an acyl radical of retinoic acid, of isonieotinic acid, of benzoic acid substituted by a halogen atom or by a methoxy group, of a hydrocarboncarboxylic acid having up to 12 carbon atoms or of phosphoric acid, which may be in the form of a mono- or di-alkali or alkaline p 20 earth metal salt; or OV together with Q is an alkylidenedioxy, alkylorthoalkanoate or alkylorthoarylcarboxylate group; or, provided that Q is an Ο-Acyl group, M can 2 2 also be a group -OR wherein R is a lower alkyl or halolower alkyl group. 25 4. A compound as claimed in claim 3 wherein Z is a chlorine or bromine atom.
5. A compound as claimed in claim 3 or claim 4 wherein X is a hydrogen atom. - 150 45950
6. A Compound as claimed in any of claims 3 to 5 wherein V is a methylene group or the group (H,CH^).
7. A compound as claimed in any of claims 3 to 6 wherein Y is an oxygen atom or the group (Η,β-ΟΗ). 5
8. A compound as claimed in any of claims 3 to 7 wherein Z is a chlorine or bromine atom, W is a methylene group or the group (H,CH^), 10 Y is an oxygen atom or the group (Η,β-ΟΗ), p and V and V , which may be the same or different, are hydrogen atoms or acyl radicals of hydrocarbon carboxylic acids having up to 12 carbon atoms. p
9. A compound as claimed in claim 8 wherein V and V , 15 which may be the same or different, are acyl radicals of hydrocarboncarboxylic acids having up to 8 carbon atoms.
10. A compound as claimed in claim 8 or claim 9 wherein W is (Η,ά-ΟΗ^). 20
11. A compound as claimed in any of claims 8 to 10 wherein V is a propionyl, n-butyryl or benzoyl group.
12. A compound us claimed in claim 10 wherein Y is the group (Η,β-ΟΗ), V is a benzoyl or propionyl group, and - 151 45930 V 2 is a lower alkanoyl group having up to 8 carbon atoms. 1J. 7a-Chloro-l6a-methyl-l,4-pregnadiene-llg,17«,21triol-3,20-dione 17,21-dipropionate. 14. 7a-Bromo-l6a-methyl-l,4-pregnadiene-llg,17a,21 5 triol-3,20-dione 17,21-dipropionate. 15. 7 a-Bromo-l6a-methyl-l,4-pregnadiene-llg,17 a,21triol-3,20-dione 17-benzoate 21-acetate. 16. 7 a-Chloro-l6-methylene-l,4-pregnadiene-llg,17 α,21triol-3,20-dione 17,21-dipropionate. 10 17. 7d,9a,llg-Trichloro-l6a-methyl- i l,4-pregnadiene-17a, 21-diol-3,20-dione 17,21-dipropionate. 18. A 3,20-dioxo-7a-halo-4-pregnene having the formula wherein Z is a chlorine, bromine or iodine atom, 15 y is an oxygen atom or the group (H,g-OH), W is a methylene group or the group (H,CH X ) or (H,H), 2 . . and V and V , which may be the same or different, are hydrogen atoms or acyl radicals of hydrocarboncarboxylic acids having up to 12 carbon atoms. 20 19· 7a-Chloro-4-pregnene-llg,17a,21-triol-3,20-dione 17,21-dipropionate, 7a-bromo-l6a,17a-isopropylidenedioxy-1,4-pregnadiene-llg,21-diol-3,20-dione 21-acetate or 7a-fluoro-l6a-methyl-l,4-pregnadiene-llg,17a,21-triol 3,20-dione 17-benzoate 21-acetate. - 152 45950 20. A process for the preparation of a compound as claimed in claim 1 wherein Z is a chlorine, bromine or iodine atom, with the proviso that Z is not a chlorine atom when X is a halogen ~ atom, which comprises the addition, of a hydrogen halide selected from hydrogen chloride,hydrogen bromide and hydrogen iodide to the 6,7-double bond of a compound of the formula M' wherein the dotted line, A, B, X and Y are as defined in claim 1 and W', Q' and M* are W, Q and M as defined in claim 1, or V and Q’ taken together are a l6a,17a-alkylorthoalkanoate or l6a,17a-alkylorthoarylcarboxylate group together with a Ιδβ-hydrogen atom, or M' is the group -CHgOV^, and 0V^ and Q' together with the oxygen atom of the Ο^θ carbonyl group are a 17a, 20; 20,2l-bis-methylenedloxy group. in the presence of an inert solvent; with the provisos that (i) when the hydrogen halide is hydrogen chloride, then X is a hydrogen atom; - 153 45950 (ii) when Y is the group (H,0-OH) and the hydrogen halide is hydrogen bromide, then X is a hydrogen atom; and (iii) when Y is the group (Η, 0-OH) and the hydrogen halide is hydrogen iodide, then X is a hydrogen, chlorine or fluorine atom; whereafter, when W and Q’ taken together are a I6a,17a-alkylorthoalkanoate or l6a,17a-alkylorthoarylcarboxylate group together with a 160-hydrogen atom, the product is hydrolysed to yield a compound wherein Q is a hydroxy group and W is the group (H, a-OH), or, when OV 3 and Q' together with the oxygen atom of the Cg Q carbonyl group are a 17a,2O;2O,21-bis-methylenedioxy group, the product is hydrolysed to yield a compound wherein OV 3 and Q are hydroxy groups; and/or, when Y is an oxygen atom and either (i) Z is a bromine atom and X is a halogen atom, or (ii) Z is an iodine atom and X is a bromine atom, and a compound wherein Y is the group (Η, 0-OH) is required, this compound is prepared by reduction of a corresponding product wherein Y is an oxygen atom; and/or, when X is a hydrogen atom, Y is the group (Η, 0-OH), and Z is a chlorine or bromine atom, a 9(11)double bond is introduced by dehydration and the product is subjected to addition of halogen to the 9(11)double bond or to addition of a 9a-chlorine or bromine atom and of an 110-hydroxy group to the 9(ll)-double bond; and a compound claimed in claim 1 is then isolated. 21. A process for the preparation of a compound as - 154 459 50 claimed in claim 1 wherein Z is a chlorine, bromine or iodine atom, with the proviso that Z is not a chlorine atom when X is a halogen atom, which comprises the addition of a hydrogen halide selected from hydrogen chloride, 5 hydrogen bromide and hydrogen iodide to the 6,7-double bond of a compound of the formula IV defined in claim 20 in the presence of an inert organic solvent; with the provisos that (i) when the hydrogen halide is hydrogen chloride, IQ then X is a hydrogen atom; (ii) when Y is the group (Η, β-ΟΗ) and the hydrogen halide is hydrogen bromide, then X is a hydrogen atom; and (iii) when Y is the group (Η, β-ΟΗ) and the hydrogen halide is hydrogen iodide, then X is a hydrogen, chlorine 15 or fluorine atom; subjecting the resulting product, if desired or necessary, to one or more of the following finishing steps in any appropriate order, and then isolating a compound claimed in claim 1: 20 a) Hydrolysis of an esterifying group or groups at the 16α-, 17α- and/or 21-position to hydroxy; b) Hydrolysis of a 17a,20;20,21-bis-methylenedioxy group to 20-oxo-17a,21-dihydroxy groups, or of a 21-ethylene ketal to 21-oxo, or of a 17a,21-alkylidenedioxy, 25 -cycloalkylidenedioxy or -aralkylidenedioxy group to 17a, 21-dihydroxy groups; c) Esterification of a hydroxy group at the 16α-, 17α- and/or 21-position; - 155 45950 d) Reduction of an 11-oxo group to an Ιΐβ-hydroxy group; e) 9(11)-Dehydration of a 9-unsubstituted-llB-ol to a 4,9(11)-pregnadiene or to a 1,4,9(11)-pregnatriene, 5 except when Z is an iodine atom, followed by addition of halogen to the 9(ll)-double bond; or followed by addition of a chlorine or bromine atom and a hydroxy group to the 9(11)-double bond with the formation of a 9a-chloro- or 9a-bromo-ΙΙβ-hydroxy steroid; 10 f) 17a-Chlorination or bromination. 22. A process as claimed in claim 20 or claim 21 viherein the compound of the formula IV has a 1,2-double bond and the inert organic solvent is anhydrous. 23. A process as claimed in claim 22 wherein the solvent 15 is an ether, a chlorinated hydrocarbon, an organic acid, a tertiary amide or dimethyl sulfoxide. 24. A process as claimed in claim 22 wherein the solvent is dioxan, acetic acid or tetrahydrofuran. 25. A process as claimed in any of claims 22 to 24 2Q wherein the compound of the formula IV is reacted with hydrogen chloride in tetrahydrofuran. 26. A process as claimed in any of claims 22 to 24 wherein the compound of the formula IV is reacted with hydrogen bromide or hydrogen iodide in glacial acetic 25 acid. 27. A process as claimed in any of claims 22 to 26 wherein the reaction is effected at a temperature from 0°C. up to ambient temperature. 28. A process as claimed in any of claims 22 to 27 - 156 45050 wherein the hydrogen halide is present in at least a 5 molar excess. 29· A process as claimed in claim 28 wherein the hydrogen halide is present in a 10 to 50 molar excess. 5 30. A process as claimed in any of claims 22 to 29 wherein the resulting 7a-halo-steroid is separated at temperatures no higher than about 25°C. in a state substantially free of acid and base by freeing it of excess acid and solvent without subjecting it to a substantially IQ basic medium. 31. A process as claimed in any of claims 20 to 30 wherein a steroid claimed in claim 1 wherein Y is the group (Η, 0-OH) is prepared from a steroid of the formula IV defined in claim 20 wherein Y is an oxygen atom by reaction 15 with hydrogen chloride, hydrogen bromide or hydrogen iodide in an inert organic solvent, followed by reduction at the 11-position. 32. A process as claimed in claim 31 wherein the reduction is effected with sodium, potassium or lithium 20 borohydride, tetra-n-butyl-ammonium borohydride or lithium tri-t-butoxy-aluminium hydride, in an inert organic solvent. 33· A process as claimed in claim 31 wherein the reduction is effected with sodium borohydride in an inert orga25 nic solvent comprising methanol or dimethylformamide. 34. A process as claimed in claim 20 or claim 21 wherein the compound of formula IV has a 1,2-single bond, the reaction with hydrogen chloride, hydrogen bromide or hydrogen - 157 48980 iodide is effected at a temperature no higher than 30°C., and the resulting 7a-halo-steroid is isolated at temperatures no higher than 25°C. in a state substantially free of acid and base by freeing it of excess acid and solvent without subjecting it to a substantially basic medium. 35. A process as claimed in claim 34 having the features of any of claims 23 to 29. 36. A process as claimed in claim 34 or claim 35 wherein the inert organic solvent is not anhydrous and the hydrogen halide is hydrogen chloride. 37. A process as claimed in any of claims 34 to 36 having the features of claim 32 and/or claim 33. 38. A process as claimed in claim 37 wherein the product of the reduction is oxidised with an oxidising agent capable of oxidising an allylic hydroxy group to an oxo group under substantially non-basic conditions. 39. A process as claimed in claim 38 wherein the oxidising agent is neutral active manganese dioxide in an inert organic solvent at room temperature. 40. A process as claimed in claim 38 wherein the oxidising agent is pyridinium chlorochromate in an inert organic solvent, or a carbodiinride with dimethylsulfoxide and a weak acid. 41. A process as claimed in any of claims 20 to 40 wherein X in the compound of formula IV is a hydrogen atom. 42. A process for the preparation of a compound claimed in claim 1 wherein Z is a fluorine, chlorine or bromine atom, with the proviso that Z is a fluorine atom when a 1,2-single bond is present, which comprises reacting a compound of the - 158 45950 formula Μ wherein the dotted line, A and B are as defined in claim 1, Q' is as defined in claim 20, M and W are respecti5 vely M' and W' defined in claim 20 with the proviso that M is not a hydroxymethyl group and W is not the group (H, α-OH), and the grouping H \ c ^ I represents |; or | X wherein Y and X are as defined in claim 1, TO with a halogenating agent capable of replacing the 7P-hydroxy group with a 7a-halogen atom selected from fluorine, chlorine and bromine, in the presence of an inert, organic solvent, with the proviso that a 7a-chlorine or 7a-bromine atom is introduced only when a 1,2-double bond 15 is present; whereafter, when W and Q' taken together are a l6a,17a-alkylorthoalkanoate or l6a,17a-alkylorthoarylcarboxylate group together with a 160-hydrogen atom, the product is hydrolysed to yield a compound wherein Q is a 20 hydroxy group and W is the group (H, a-OH), or, when 0V^ and Q' together with the oxygen atom of the C 20 carbonyl group are a 17u,2O;20,21-bis-methyl- 159 45950 enedioxy group, the product is hydrolysed to yield a com3 pound wherein OV and Q are hydroxy groups, and/or, when the grouping 0^ represents halogen is added to the 9,11-double bond or a chlorine 5 or bromineatom and a hydroxy group are added to the 9,11double bond with the formation of a 9a-chloro- or 9a-bromo110-hydroxy steroid. 43, A process for the preparation of a compound as claimed in claim 1 wherein Z is a fluorine, chlorine or bromine atom, 10 with the proviso ‘that Z is a fluorine atom when a 1,2-single bond is present, which comprises reacting a compound of the formula V defined in claim 42 with a halogenating agent capable of replacing the 70-hydroxy group with a 7a-halogen atom selected from fluorine, chlorine and bromine, in 15 the presence of an inert organic solvent, with the proviso that a 7a-ehlorine or 7a-bromine atom is introduced only when a 1,2-double bond is present; and then the resulting product is subjected, if desired or necessary, to one or more of the following 20 finishing steps in any appropriate order: a) Hydrolysis of an esterifying group or groups at the 16α-, 17α- and/or 21-position to hydroxy; b) Hydrolysis of a 17a,20;20,21-bis-methylenedioxy group to 20-oxo-17a,21-dihydroxy groups, or of a 21-ethyl25 ene ketal to 21-oxo, or of a 17a,21-alkylidenedioxy, -cyeloalkylidenedioxy or -aralkylidenedioxy group to 17a, 21-dihydroxy groups; c) Esterification of a hydroxy group at the 16α-, 17α- and/or 21-position; d) Reduction of an 11-oxo group to an 110-hydroxy group; - 160 459 50 e) Addition to the 9,11-double bond of halogen or of a 9a-chlorine or bromine atom and of an Ιΐβ-hydroxy II such a 9(ll)-double bond has been introduced by 9(11)dehydration of a 9-unsubstituted-llB-ol; f) 17a-Chlorination or bromination. 44. A process as claimed in claim 42 or claim 43 wherein the halogenating agent is either a tertiary amine having an N-(2-chloro-l,l,2-trifluoroethyl) group, said amine being used alone for the preparation of a 7«-fluoro steroid but in the presence of a metal chloride or bromide that is soluble in the reaction mixture for the preparation of a 7ot-ehloro or 7a-bromo steroid respectively, or a tertiary amine having an N-trichlorovinyl group for the preparation of a 7a-chloro steroid. 45. A process as claimed in claim 44 wherein the halogenating agent is N-(2-chloro-l,l,2-trifluoroethyl)diethylamine and the reaction is effected at moderately low temperatures under an inert atmosphere. 46. A process as claimed in claim 45 wherein the reaction is effected at about 0°C. under anhydrous conditions. 47. A process as claimed in claim 45 or claim 46 wherein the molar ratio of N-(2-chloro-l,l,2-trifluoroethyl)diethylamine to steroid is about 6 to 1. 48. A process as claimed in any of claims 44 to 47 wherein the reaction mixture is free of metal chloride and bromide, the solvent is a halohydrocarbon, and the product - l6l 45850 is a 7a-fluoro steroid. 49. A process as claimed in any of claims 44 to 47 wherein the reaction mixture contains lithium bromide as metal bromide, the solvent is a halohydrocarbon, and 5 the product is a 7a-bromosteroid. 50. A process as claimed in any of claims 44 to 47 wherein the reaction mixture contains lithium chloride as metal chloride, the solvent is an ether, and the product is a 7a-chloro steroid. 10 51. A process as claimed in claim 49 or 50 wherein the molar ratio of lithium chloride or lithium bromide to steroid is about 12 to 1. 52. A process as claimed in any of claims 48 to 51 wherein the halohydrocarbon is methylene chloride and the 15 ether is tetrahydrofuran. 53. A process as claimed in claim 44 wherein the halogenating agent is N,N-diethyl-l,2,2-trichlorovinylamine in a halohydrocarbon as solvent. 54. A process as claimed in claim 53 wherein the halo20 hydrocarbon is methylene chloride and the reaction is effected at moderately low temperatures. 55. A process as claimed in claim 54 wherein the reaction is effected at about 0°C. under an inert atmosphere. 56. A process as claimed in any of claims 53 to 55 25 wherein the molar ratio of N,N-diethyl-l,2,2-trichlorovinylamine to steroid is about 6 to 1. 57. A process as claimed in any of claims 42 to 56 wherein the compound of the formula V has a 1,2-double bond. - 162 45950 58. A process as claimed in any of claims 21 to 41 and 45 to 57 wherein the hydrolysis of an esterifying group at the ΐ6α-, 17α- or 21-position is effected by means of mild base. 59. A process as claimed in any of claims 21 to 41 and 43 to 57 wherein the hydrolysis of an esterifying group at the 16-, 17- or 21-position is effected by means of a strong mineral acid. 60. A process as claimed in any of claims 21 to 4l and 43 to 57 wherein the hydrolysis of a 17a,21-orthoester the 21-position to yield a 17-ester is effected under mildly acidic conditions. 61. A process as claimed in any of claims 20 to 57 wherein the hydrolysis of a l6a,17a-orthoester at the l6a~position to yield a 17-ester is effected under mildly acidic conditions. 62. A process as claimed in any of claims 21 to 41 and 43 to 57 wherein the hydrolysis of a 16- or 21-hydrocarboncarboxylate is effected by means of malt diastase. 63. A process as claimed in any of claims 21 to 4l and 43 to 57 wherein the hydrolysis of a 21-ethylene ketal or of a 17aj21-alkylidenedioxy, -cycloalkylidenedioxy or -aralkylidenedioxy group is effected by means of mild acid. 64. A process as claimed in any of claims 20 to 57 wherein the hydrolysis of a 17a,2O;2O,21-bis-methylenedioxy group is effected by means of mild acid or under - 163 4S9S0 substantially neutral conditions by means of triphenylcarbenium tetrafluoroborate. 65. A process as claimed in any of claims 21 to 41 and 43 to 57 wherein the esterification of a hydroxy group 5 at the 16a- and/or 21-position and/or, in the absence of an 11β-hydroxy group, at the 17a-position, is effected by means of a carboxylic acid having up to 12 carbon atoms or retinoic acid together with an esterifying agent or by means of a reactive derivative of said acid. 10 66. A process as claimed in any of claims 21 to 41 and 43 to 57 wherein the esterification of a resulting steroid having 11β- and 17a-hydroxy groups is effected at the 17-position by conversion of the Ιΐβ-hydroxy group into Ιΐβ-trifluoroacetate with trifluoroacetic anhydride, 15 esterification at the 17-position with the required acid, trifluoroacetic anhydride and a strong acid catalyst, and hydrolysis of the Ιΐβ-trifluoroacetate group with mild base. 67. A process as claimed in any of claims 21 to 4l and 20 43 to 57 wherein the esterification of a 21-ol is effected by means of pyrophosphoryl chloride to yield a 21-phosphate; which if desired is converted into a mono- or di-alkali metal or alkaline earth metal salt. 68. A process as claimed in claim 67 wherein the metal 25 salt is prepared by partial or complete neutralisation of the 21-phosphate with an alkali metal methoxide or an alkaline earth metal methoxide. 69. A process as claimed in any of claims 21 to 4l and - 164 45950 43 to 57 wherein the esterification of a 17a-hydroxy group in a 17«,21-diol or Ilf! ,17a,21-triol is effected by formation of a 17a,21-orthoester followed by hydrolysis at the 21-position. 70. A process as claimed in any of claims 20 to 30, 34 to 36 and 42 to 57 wherein the reduction of an 11keto group is effected by means of sodium, potassium or lithium borohydride, tetra-n-butylammonium borohydride or lithium tri-t-butoxy-aluminium hydride, in an inert organic solvent. 71. A process as claimed in any of claims 20 to 41 and 43 to 57 wherein the 9(11)-dehydration is effected by means of mesyl chloride, a tertiary amine, a dialkylamide and sulfur dioxide. 72. A process as claimed in any of claims 20 to 57 and 71 wherein there is introduced a 9a-chlorine or 9a-bromine atom together with an llg-hydroxy group by means of an N-chloro-amide or N-bromo-amide and a strong mineral acid in an inert organic solvent. 73. A process as claimed in any of claims 20 to 57 and 71 wherein the introduction of 9«- and 110-halogen atoms is effected by means of molecular chlorine in chloroform and pyridine, by means of hydrogen fluoride and an N-chloro-amide or N-bromo-amide in an inert organic solvent, or by means of hydrogen chloride and an N-bromo-amide in an inert organic solvent. 74. A process as claimed in any of claims 21 to 41 and 43 to 57 wherein the introduction of a 17a-chlorine or - 165 4S950 17a-bromine atom is effected by means of an N-chloro-amide or N-bromo-amide in an inert solvent at reduced temperature, 75. A process as claimed in claim 73 or claim 74 wherein 5 the N-chloro-amide or N-bromo-amide is N-chloro-succinimide or N-bromosuccinimide. 76. A process for the preparation of a compound as claimed in any of claims 1 to 19 substantially as herein described. 10 77. A process for the preparation of a compound as claimed in any of claims 1 to 19 substantially as herein described in any Of Examples 1 to 34. 78. Compounds as claimed in claim 1 whenever prepared by a process as claimed in any of claims 15 20 to 77. 79· Pharmaceutical compositions comprising as active ingredient at least one compound as claimed in any of claims 1 to 19 and 78, together with a pharmaceutical carrier or excipient. 20 80. Compositions as claimed in claim 79 in the form of dosage units. 81. Compositions as claimed in claim 80 in the form of tablets, pellets, capsules, dragees, suppositories or injectable preparations in ampoules. 25 82. Compositions as claimed in claim 80 or claim SI containing from 0.05 to 10 mg. of active ingredient per dosage unit. - 166 45950 84. 83. Compositions as claimed in claim 79 in the form of sprays, powders, drops, aerosols, suspensions, syrups, elixirs, emulsions, ointments, lotions, creams, or retention enemas. 84. Compositions as claimed in claim 83 containing from 5 0.001 to 0.5% by weight of active ingredient. 85. Compositions as claimed in any of claims 79 to 84 wherein the active ingredient is a compound as claimed in any of claims
13. To 17. 86. Pharmaceutical compositions as claimed in claim 79 substantially 10 as herein described. 87. Pharmaceutical compositions as claimed in claim 79 substantially as herein described in any of the Formulation Examples. 88. A process for the preparation of a composition as claimed in claim 80 which comprises bringing a compound as claimed in
14. 15 any of claims 1 to 19 and 78 into a form suitable for therapeutic administration, by admixing it with a pharmaceutical carrier or excipient. 89. A method for eliciting a corticoid effect in non-human animal which comprises administering to said animal an effective
15. 20 amount of a compound as claimed in any of claims 1 to 19 and 78.
IE2576/77A 1976-12-22 1977-12-19 Novel 7-halo-3,20-dioxo-1,4-pregnadienes and-4-pregnenes and their preparation IE45950B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75325676A 1976-12-22 1976-12-22
US05/753,257 US4076708A (en) 1976-12-22 1976-12-22 Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby

Publications (2)

Publication Number Publication Date
IE45950L IE45950L (en) 1978-06-22
IE45950B1 true IE45950B1 (en) 1983-01-12

Family

ID=27115720

Family Applications (1)

Application Number Title Priority Date Filing Date
IE2576/77A IE45950B1 (en) 1976-12-22 1977-12-19 Novel 7-halo-3,20-dioxo-1,4-pregnadienes and-4-pregnenes and their preparation

Country Status (20)

Country Link
JP (1) JPS604198B2 (en)
AR (1) AR226806A1 (en)
AT (2) AT373269B (en)
BE (1) BE862089A (en)
DE (1) DE2756550C2 (en)
DK (1) DK153494C (en)
FI (1) FI63947C (en)
FR (1) FR2384793A1 (en)
GB (1) GB1575983A (en)
HK (1) HK584A (en)
HU (1) HU179784B (en)
IE (1) IE45950B1 (en)
IL (1) IL53636A (en)
MY (1) MY8500082A (en)
NL (1) NL180479C (en)
NO (1) NO151826C (en)
NZ (1) NZ186031A (en)
PT (1) PT67432B (en)
SE (1) SE429865B (en)
SG (1) SG58683G (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109680036A (en) 2017-10-02 2019-04-26 爱科来株式会社 The measurement of glycated proteins

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3429926A (en) * 1964-05-25 1969-02-25 Squibb & Sons Inc 7-halo and 6-halo,6-dehydro a-norprogesterones

Also Published As

Publication number Publication date
HU179784B (en) 1982-12-28
JPS604198B2 (en) 1985-02-01
AT373269B (en) 1984-01-10
FR2384793B1 (en) 1981-11-13
JPS5379850A (en) 1978-07-14
FI773825A (en) 1978-06-23
DK569977A (en) 1978-09-28
MY8500082A (en) 1985-12-31
IL53636A0 (en) 1978-03-10
BE862089A (en) 1978-06-20
FI63947C (en) 1983-09-12
NO151826C (en) 1985-06-12
SE7714538L (en) 1978-06-23
SG58683G (en) 1985-01-11
NL180479C (en) 1987-03-02
NZ186031A (en) 1984-07-31
NL7714056A (en) 1978-06-26
NL180479B (en) 1986-10-01
PT67432A (en) 1978-01-01
IE45950L (en) 1978-06-22
DK153494C (en) 1989-02-20
IL53636A (en) 1983-05-15
ATA909477A (en) 1983-05-15
DE2756550A1 (en) 1978-07-06
NO774359L (en) 1978-06-23
FR2384793A1 (en) 1978-10-20
DK153494B (en) 1988-07-18
SE429865B (en) 1983-10-03
DE2756550C2 (en) 1986-10-16
GB1575983A (en) 1980-10-01
AR226806A1 (en) 1982-08-31
AT377566B (en) 1985-04-10
FI63947B (en) 1983-05-31
NO151826B (en) 1985-03-04
ATA575980A (en) 1982-04-15
PT67432B (en) 1979-05-23
HK584A (en) 1984-01-13

Similar Documents

Publication Publication Date Title
US4124707A (en) 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor
CA1099254A (en) PROCESS FOR THE PREPARATION OF 7 .alpha.-HALOGENO-3-OXO-4- DEHYDRO STEROIDS AND NOVEL 7.alpha.-HALOGENO DERIVATIVES PRODUCED THEREBY
EP0057401B1 (en) Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4267173A (en) Use of 6β-fluoro-7α-halogenocorticoids as topical anti-inflammatories and pharmaceutical formulations useful therefor
EP0004773B1 (en) 17-beta-thiocarboxylic acid esters of 4-halo-3-oxoandrost-4-enes, their pharmaceutical use and processes for their preparation
FI80888C (en) Process for the preparation of therapeutically effective steroid carboxylic acid esters
US4172132A (en) 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
US4619921A (en) Polyhalogeno-steroids
US4336200A (en) 17α-Acyloxy-5β-corticoids
CA1162532A (en) 6.alpha.-FLUORO-PREDNISOLONE 17,21 DIESTERS
US4318853A (en) 9β,11β-Epoxy-5β-corticoids
US4201778A (en) 6-Acyloxy-1,4,6-pregnatrienes, their use as anti-inflammatory agents, methods for their manufacture, and 6-oxo-1,4-pregnadiene intermediates
GB1563638A (en) 21-halogenopregnane compounds
US4427591A (en) Reduced A ring-Δ9(11) -corticoids
IE45950B1 (en) Novel 7-halo-3,20-dioxo-1,4-pregnadienes and-4-pregnenes and their preparation
US4185101A (en) 1,3,5(10),6,8-19-Nor-pregnapentaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
KR810000311B1 (en) Process for the preparation of 7-halogeno-3,20-dioxo-1,4-pregnadienes and 4-pregnen
US3931167A (en) Process for the manufacture of 3-keto-6-azido-4,6-bis-dehydro-steroids and intermediates useful therein
US3980680A (en) Process for the preparation of 21-desoxy-17-acyloxy-4-pregnenes and of 21-iodo-21-desoxy-17-acyl oxy-4-pregnene intermediates useful therein
EP0000609B1 (en) Novel 19-nor-pregnahexaenes, process for the preparation thereof, and pharmaceutical compositions containing them
Ayer et al. Reduced A ring-Δ 9 (11)-corticoids
KR840000155B1 (en) Method of preparing 6 -9 -fluour-16-methyl-17,21-diesters prednisolone
CH637406A5 (en) Novel steroids of the pregnane series, process for their preparation and pharmaceutical products containing them
US3029259A (en) 9alpha-halo-4-pregnene-3, 20 diones and derivatives thereof
NO791143L (en) 4,6-DIHALOGENSTEROIDS AND PROCEDURES FOR THEIR PREPARATION

Legal Events

Date Code Title Description
MK9A Patent expired